Methods of using a bispecific antibody that recognizes coagulation factor ix and / or activated coagulation factor ix and coagulation factor x and / or activated coagulation factor x

Abstract

An objective of the present disclosure is to provide effective pharmaceutical compositions and dosage regimens for preventing and / or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors found that categorized flat dosing (CFD) of emicizumab can provide therapeutic effects and safety that are comparable with those of per-kg dosing (PKD), as well as more simplified, less wasteful regimens and enables administration with injectable device such as an autoinjector or syringe.

Description

METHODS OF USING A BISPECIFIC ANTIBODY THAT RECOGNIZES COAGULATION FACTOR IX AND / OR ACTIVATED COAGULATION FACTOR IX AND COAGULATION FACTOR X AND / OR ACTIVATED COAGULATION FACTOR XThe present disclosure relates generally to the field of therapeutics for bleeding disorders.Hemophilia is a hemorrhagic disease caused by a congenital deficiency or dysfunction of coagulation factor VIII (FVIII) or coagulation factor IX (FIX). The former is called hemophilia A and the latter is called hemophilia B. Genes for both factors are located on the X chromosome, and since genetic defects take the X-chromosome-linked recessive hereditary form, 99% or more of the patients who develop the disease are men. It is known that the prevalence rate is approximately one in 10,000 live male births, and the ratio between hemophilia A and hemophilia B is approximately 5:1.The severity of hemophilia A is defined by the FVIII activity in blood. Patients with an activity of less than 1% are classified as severe, patients with an activity of 1% to 5% are classified as moderate, and patients with an activity of more than 5% and less than 40% are classified as mild. Severe patients who account for approximately half of hemophilia A patients exhibit bleeding symptoms several times a month, and this frequency is markedly high as compared to those of moderate and mild patients.For bleeding in hemophilia A patients, FVIII formulations are generally administered on demand (on-demand therapy). In recent years, FVIII formulations are also administered prophylactically to prevent bleeding events (regular replacement therapy; NPLs 1 and 2). FVIII formulations are mainly administered at home, but since they are administered intravenously, the difficulty of securing a blood vessel is a problem. Therefore, there has been a strong need for pharmaceutical agents with a lesser burden regarding their administration as compared to FVIII formulations.Occasionally, antibodies against FVIII (inhibitors) develop in hemophilia A patients. Such inhibitors counteract the effects of the FVIII formulations. For bleeding in patients who have developed inhibitors (inhibitor patients), bypassing agents are administered. Their mechanisms of action are not dependent on FVIII function, that is, on the function of catalyzing the activation of blood coagulation factor X (FX) by activated blood coagulation factor IX (FIXa). Therefore, in some cases, bypassing agents cannot sufficiently stop the bleeding. Recently, results suggesting the effectiveness of regular administration therapy of bypassing agents have been obtained, but this has not yielded a sufficient effect to suppress bleeding as compared to FVIII formulations. Accordingly, there has been a strong need for therapeutic agents that can be administered subcutaneously, as well as long-acting therapeutic agents that can be administered less frequently, regardless of the presence of inhibitors.Recently, as a means for solving the problem, an antibody that functionally substitutes for FVIII, emicizumab (trade names: Hemlibra / ACE910 / RO5534262) and its use were disclosed (PTLs 1, 2, 3, 4, and 5, NPLs 3, 4, 5, and 6).Emicizumab is a recombinant humanized bispecific antibody that binds to (a1) FIX and / or FIXa and (a2) FX and / or activated blood coagulation factor FX (FXa), and substitutes for the cofactor function of FVIII. Emicizumab has been approved in more than 100 nations including the United States and Japan as a recombinant drug that suppresses the bleeding tendency in patients with hemophilia A. This product is a long-acting subcutaneous preparation that allows low frequency administration-subcutaneous administration at 3 mg / kg (body weight) per time, four times at weekly intervals, and thereafter, at any of the dosage and administration regimens of 1.5 mg / kg (body weight) per time at weekly intervals, 3 mg / kg (body weight) per time at 2-week intervals, or 6 mg / kg (body weight) per time at 4-week intervals. Dosage regimens of emicizumab have been described (PTLs 6 and 7).Meanwhile, to reduce a wasted volume that remains in a vial of emicizumab, some reports have assessed the possibility of increasing / decreasing the weight-equivalent doses (e.g., per-kg dosing) and administration intervals of emicizumab (NPLs 7-11). However, no dedicated research to justify the clinical application of fixed doses of emicizumab based on body weight ranges (interchangeably termed "categorized flat dosing" or "CFD" herein) from the efficacy and safety perspectives have been reported.[PTL 1] WO 2005 / 035754[PTL 2] WO 2005 / 035756[PTL 3] WO 2006 / 109592[PTL 4] WO 2012 / 067176[PTL 5] WO 2015 / 194233[PTL 6] WO 2018 / 047813[PTL 7] WO 2021 / 070885Non-Patent Literature[NPL 1] Blood 58, 1-13 (1981)[NPL 2] Nature 312, 330-337 (1984)[NPL 3] Nature Medicine 18, 1570-1574(2012)[NPL 4] PLOS ONE 8, 1-13(2013)[NPL 5] J Thromb Haemost. 12, 206-213(2014)[NPL 6] Blood 127(13), 1633-1641(2016)[NPL 7] United Kingdom Haemophilia Centres Doctors' Organisation (UKHCDO), Maintenance Dose table for Emicizumab (Hemlibra) for Haemophilia A in patients without an inhibitor (last updated: August 2019), http: / / www.ukhcdo.org / ukhcdo-emi-dose-table-final / [NPL 8] Research and Practice in Thrombosis and Haemostasis Volume 7, Issue 2, 100074 (2023)[NPL 9] Thrombosis and Haemostasis Volume 122, Issue 02, 208-215 (2022)[NPL 10] Journal of Managed Care & Specialty Pharmacy Volume 29, Number 1, 47-57 (2022)[NPL 11] Haemophilia Volume 27, Issue 3, 358-365 (2021)An objective of the present disclosure is to provide fixed doses of emicizumab based on categorized body weight ranges.As a result of dedicated research, the present inventors found that categorized flat dosing (CFD) of emicizumab, e.g., according to Table 1, can provide therapeutic effects and safety that are comparable with those of per-kg dosing (PKD), as well as more simplified, less wasteful regimens. In some embodiments, a CFD regimen can reduce dosing errors as compared to PKD.Specifically, the present disclosure relates to the following:[1] A pharmaceutical composition comprising a bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein the pharmaceutical compositioncomprises, as a single dose, a maintenance dose of the bispecific antibody selected from the group consisting of (a)-(h) below, and is administered to a patient every two weeks; orcomprises, as a single dose, a maintenance dose of the bispecific antibody selected from the group consisting of (i)-(t) below, and is administered to a patient every four weeks:(a) a maintenance dose of 135 mg for a patient with a body weight of 41 kg or more and less than 50 kg;(b) a maintenance dose of 165 mg for a patient with a body weight of 50 kg or more and less than 60 kg;(c) a maintenance dose of 195 mg for a patient with a body weight of 60 kg or more and less than 70 kg;(d) a maintenance dose of 225 mg for a patient with a body weight of 70 kg or more and less than 83 kg;(e) a maintenance dose of 270 mg for a patient with a body weight of 83 kg or more and less than 100 kg;(f) a maintenance dose of 330 mg for a patient with a body weight of 100 kg or more and less than 120 kg;(g) a maintenance dose of 390 mg for a patient with a body weight of 120 kg or more and less than 140 kg;(h) a maintenance dose of 450 mg for a patient with a body weight of 140 kg or more and less than 165 kg;(i) a maintenance dose of 135 mg for a patient with a body weight of 21 kg or more and less than 25 kg;(j) a maintenance dose of 165 mg for a patient with a body weight of 25 kg or more and less than 30 kg;(k) a maintenance dose of 195 mg for a patient with a body weight of 30 kg or more and less than 35 kg;(l) a maintenance dose of 225 mg for a patient with a body weight of 35 kg or more and less than 41 kg;(m) a maintenance dose of 270 mg for a patient with a body weight of 41 kg or more and less than 50 kg;(n) a maintenance dose of 330 mg for a patient with a body weight of 50 kg or more and less than 60 kg;(o) a maintenance dose of 390 mg for a patient with a body weight of 60 kg or more and less than 70 kg;(p) a maintenance dose of 450 mg for a patient with a body weight of 70 kg or more and less than 83 kg;(q) a maintenance dose of 540 mg for a patient with a body weight of 83 kg or more and less than 100 kg;(r) a maintenance dose of 660 mg for a patient with a body weight of 100 kg or more and less than 120 kg;(s) a maintenance dose of 780 mg for a patient with a body weight of 120 kg or more and less than 140 kg; and(t) a maintenance dose of 900 mg for a patient with a body weight of 140 kg or more and less than 165 kg.[1-1] A pharmaceutical composition comprising a bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein the pharmaceutical compositioncomprises, as a single dose, a maintenance dose of the bispecific antibody selected from the group consisting of (a-1)-(g-1) below, and is administered to a patient every two weeks; orcomprises, as a single dose, a maintenance dose of the bispecific antibody selected from the group consisting of (h-1)-(r-1) below, and is administered to a patient every four weeks:(a-1) a maintenance dose of 135 mg for a patient with a body weight of 48 kg or more and less than 50 kg;(b-1) a maintenance dose of 195 mg for a patient with a body weight of 66 kg or more and less than 70 kg;(c-1) a maintenance dose of 225 mg for a patient with a body weight of 76 kg or more and less than 83 kg;(d-1) a maintenance dose of 270 mg for a patient with a body weight of 99 kg or more and less than 100 kg;(e-1) a maintenance dose of 330 mg for a patient with a body weight of 111 kg or more and less than 120 kg;(f-1) a maintenance dose of 390 mg for a patient with a body weight of 131 kg or more and less than 140 kg;(g-1) a maintenance dose of 450 mg for a patient with a body weight of 151 kg or more and less than 165 kg;(h-1) a maintenance dose of 135 mg for a patient with a body weight of 23 kg or more and less than 25 kg;(i-1) a maintenance dose of 165 mg for a patient with a body weight of 28 kg or more and less than 30 kg;(j-1) a maintenance dose of 195 mg for a patient with a body weight of 33 kg or more and less than 35 kg;(k-1) a maintenance dose of 225 mg for a patient with a body weight of 38 kg or more and less than 41 kg;(l-1) a maintenance dose of 270 mg for a patient with a body weight of 48 kg or more and less than 50 kg;(m-1) a maintenance dose of 390 mg for a patient with a body weight of 66 kg or more and less than 70 kg;(n-1) a maintenance dose of 450 mg for a patient with a body weight of 76 kg or more and less than 83 kg;(o-1) a maintenance dose of 540 mg for a patient with a body weight of 99 kg or more and less than 100 kg;(p-1) a maintenance dose of 660 mg for a patient with a body weight of 111 kg or more and less than 120 kg;(q-1) a maintenance dose of 780 mg for a patient with a body weight of 131 kg or more and less than 140 kg; and(r-1) a maintenance dose of 900 mg for a patient with a body weight of 151 kg or more and less than 165 kg.[1-2] A pharmaceutical composition comprising a bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein the pharmaceutical compositioncomprises, as a single dose, a maintenance dose of the bispecific antibody selected from the group consisting of (a-2)-(h-2) below, and is administered to a patient every two weeks; orcomprises, as a single dose, a maintenance dose of the bispecific antibody selected from the group consisting of (i-2)-(t-2) below, and is administered to a patient every four weeks:(a-2) a maintenance dose of 135 mg for a patient with a body weight of 41 kg or more and less than 45 kg, and more than 45kg and less than 50kg;(b-2) a maintenance dose of 165 mg for a patient with a body weight of 50 kg or more and less than 55kg, and more than 55kg and less than 60 kg;(c-2) a maintenance dose of 195 mg for a patient with a body weight of 60 kg or more and less than 65kg, and more than 65kg and less than 70 kg;(d-2) a maintenance dose of 225 mg for a patient with a body weight of 70 kg or more and less than 75kg, and more than 75kg and less than 83 kg;(e-2) a maintenance dose of 270 mg for a patient with a body weight of 83 kg or more and less than 90kg, and more than 90kg and less than 100 kg;(f-2) a maintenance dose of 330 mg for a patient with a body weight of 100 kg or more and less than 110kg, and more than 110kg and less than 120 kg;(g-2) a maintenance dose of 390 mg for a patient with a body weight of 120 kg or more and less than 130kg, and more than 130kg and less than 140 kg;(h-2) a maintenance dose of 450 mg for a patient with a body weight of 140 kg or more and less than 150kg, and more than 150kg and less than 165 kg;(i-2) a maintenance dose of 135 mg for a patient with a body weight of 21 kg or more and less than 22.5 kg, and more than 22.5 kg and less than 25 kg;(j-2) a maintenance dose of 165 mg for a patient with a body weight of 25 kg or more and less than 27.5 kg, and more than 27.5 kg and less than 30 kg;(k-2) a maintenance dose of 195 mg for a patient with a body weight of 30 kg or more and less than 32.5 kg, and more than 32.5kg and less than 35 kg;(l-2) a maintenance dose of 225 mg for a patient with a body weight of 35 kg or more and less than 37.5 kg, and more than 37.5 kg and less than 41 kg;(m-2) a maintenance dose of 270 mg for a patient with a body weight of 41 kg or more and less than 45 kg, and more than 45kg and less than 50 kg;(n-2) a maintenance dose of 330 mg for a patient with a body weight of 50 kg or more and less than 55 kg, and more than 55kg and less than 60 kg;(o-2) a maintenance dose of 390 mg for a patient with a body weight of 60 kg or more and less than 65 kg, and more than 65kg and less than 70 kg;(p-2) a maintenance dose of 450 mg for a patient with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(q-2) a maintenance dose of 540 mg for a patient with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(r-2) a maintenance dose of 660 mg for a patient with a body weight of 100 kg or more and less than 110 kg, and more than 110 kg and less than 120 kg;(s-2) a maintenance dose of 780 mg for a patient with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than 140 kg; and(t-2) a maintenance dose of 900 mg for a patient with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than 165 kg.[2] A bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein the bispecific antibodyis administered to a patient every two weeks, as a single dose in a pharmaceutical composition, at a maintenance dose of the bispecific antibody selected from the group consisting of (a)-(h) below; oris administered to a patient every four weeks, as a single dose in a pharmaceutical composition, at a maintenance dose of the bispecific antibody selected from the group consisting of (i)-(t) below:(a) a maintenance dose of 135 mg for a patient with a body weight of 41 kg or more and less than 50 kg;(b) a maintenance dose of 165 mg for a patient with a body weight of 50 kg or more and less than 60 kg;(c) a maintenance dose of 195 mg for a patient with a body weight of 60 kg or more and less than 70 kg;(d) a maintenance dose of 225 mg for a patient with a body weight of 70 kg or more and less than 83 kg;(e) a maintenance dose of 270 mg for a patient with a body weight of 83 kg or more and less than 100 kg;(f) a maintenance dose of 330 mg for a patient with a body weight of 100 kg or more and less than 120 kg;(g) a maintenance dose of 390 mg for a patient with a body weight of 120 kg or more and less than 140 kg;(h) a maintenance dose of 450 mg for a patient with a body weight of 140 kg or more and less than 165 kg;(i) a maintenance dose of 135 mg for a patient with a body weight of 21 kg or more and less than 25 kg;(j) a maintenance dose of 165 mg for a patient with a body weight of 25 kg or more and less than 30 kg;(k) a maintenance dose of 195 mg for a patient with a body weight of 30 kg or more and less than 35 kg;(l) a maintenance dose of 225 mg for a patient with a body weight of 35 kg or more and less than 41 kg;(m) a maintenance dose of 270 mg for a patient with a body weight of 41 kg or more and less than 50 kg;(n) a maintenance dose of 330 mg for a patient with a body weight of 50 kg or more and less than 60 kg;(o) a maintenance dose of 390 mg for a patient with a body weight of 60 kg or more and less than 70 kg;(p) a maintenance dose of 450 mg for a patient with a body weight of 70 kg or more and less than 83 kg;(q) a maintenance dose of 540 mg for a patient with a body weight of 83 kg or more and less than 100 kg;(r) a maintenance dose of 660 mg for a patient with a body weight of 100 kg or more and less than 120 kg;(s) a maintenance dose of 780 mg for a patient with a body weight of 120 kg or more and less than 140 kg; and(t) a maintenance dose of 900 mg for a patient with a body weight of 140 kg or more and less than 165 kg.[2-1] A bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein the bispecific antibodyis administered to a patient every two weeks, as a single dose in a pharmaceutical composition, at a maintenance dose of the bispecific antibody selected from the group consisting of (a-1)-(g-1) below; oris administered to a patient every four weeks, as a single dose in a pharmaceutical composition, at a maintenance dose of the bispecific antibody selected from the group consisting of (h-1)-(r-1) below:(a-1) a maintenance dose of 135 mg for a patient with a body weight of 48 kg or more and less than 50 kg;(b-1) a maintenance dose of 195 mg for a patient with a body weight of 66 kg or more and less than 70 kg;(c-1) a maintenance dose of 225 mg for a patient with a body weight of 76 kg or more and less than 83 kg;(d-1) a maintenance dose of 270 mg for a patient with a body weight of 99 kg or more and less than 100 kg;(e-1) a maintenance dose of 330 mg for a patient with a body weight of 111 kg or more and less than 120 kg;(f-1) a maintenance dose of 390 mg for a patient with a body weight of 131 kg or more and less than 140 kg;(g-1) a maintenance dose of 450 mg for a patient with a body weight of 151 kg or more and less than 165 kg;(h-1) a maintenance dose of 135 mg for a patient with a body weight of 23 kg or more and less than 25 kg;(i-1) a maintenance dose of 165 mg for a patient with a body weight of 28 kg or more and less than 30 kg;(j-1) a maintenance dose of 195 mg for a patient with a body weight of 33 kg or more and less than 35 kg;(k-1) a maintenance dose of 225 mg for a patient with a body weight of 38 kg or more and less than 41 kg;(l-1) a maintenance dose of 270 mg for a patient with a body weight of 48 kg or more and less than 50 kg;(m-1) a maintenance dose of 390 mg for a patient with a body weight of 66 kg or more and less than 70 kg;(n-1) a maintenance dose of 450 mg for a patient with a body weight of 76 kg or more and less than 83 kg;(o-1) a maintenance dose of 540 mg for a patient with a body weight of 99 kg or more and less than 100 kg;(p-1) a maintenance dose of 660 mg for a patient with a body weight of 111 kg or more and less than 120 kg;(q-1) a maintenance dose of 780 mg for a patient with a body weight of 131 kg or more and less than 140 kg; and(r-1) a maintenance dose of 900 mg for a patient with a body weight of 151 kg or more and less than 165 kg.[2-2] A bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein the bispecific antibodyis administered to a patient every two weeks, as a single dose in a pharmaceutical composition, at a maintenance dose of the bispecific antibody selected from the group consisting of (a-2)-(h-2) below; oris administered to a patient every four weeks, as a single dose in a pharmaceutical composition, at a maintenance dose of the bispecific antibody selected from the group consisting of (i-2)-(t-2) below:(a-2) a maintenance dose of 135 mg for a patient with a body weight of 41 kg or more and less than 45 kg, and more than 45kg and less than 50kg;(b-2) a maintenance dose of 165 mg for a patient with a body weight of 50 kg or more and less than 55kg, and more than 55kg and less than 60 kg;(c-2) a maintenance dose of 195 mg for a patient with a body weight of 60 kg or more and less than 65kg, and more than 65kg and less than 70 kg;(d-2) a maintenance dose of 225 mg for a patient with a body weight of 70 kg or more and less than 75kg, and more than 75kg and less than 83 kg;(e-2) a maintenance dose of 270 mg for a patient with a body weight of 83 kg or more and less than 90kg, and more than 90kg and less than 100 kg;(f-2) a maintenance dose of 330 mg for a patient with a body weight of 100 kg or more and less than 110kg, and more than 110kg and less than 120 kg;(g-2) a maintenance dose of 390 mg for a patient with a body weight of 120 kg or more and less than 130kg, and more than 130kg and less than 140 kg;(h-2) a maintenance dose of 450 mg for a patient with a body weight of 140 kg or more and less than 150kg, and more than 150kg and less than 165 kg;(i-2) a maintenance dose of 135 mg for a patient with a body weight of 21 kg or more and less than 22.5 kg, and more than 22.5 kg and less than 25 kg;(j-2) a maintenance dose of 165 mg for a patient with a body weight of 25 kg or more and less than 27.5 kg, and more than 27.5 kg and less than 30 kg;(k-2) a maintenance dose of 195 mg for a patient with a body weight of 30 kg or more and less than 32.5 kg, and more than 32.5kg and less than 35 kg;(l-2) a maintenance dose of 225 mg for a patient with a body weight of 35 kg or more and less than 37.5 kg, and more than 37.5 kg and less than 41 kg;(m-2) a maintenance dose of 270 mg for a patient with a body weight of 41 kg or more and less than 45 kg, and more than 45kg and less than 50 kg;(n-2) a maintenance dose of 330 mg for a patient with a body weight of 50 kg or more and less than 55 kg, and more than 55kg and less than 60 kg;(o-2) a maintenance dose of 390 mg for a patient with a body weight of 60 kg or more and less than 65 kg, and more than 65kg and less than 70 kg;(p-2) a maintenance dose of 450 mg for a patient with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(q-2) a maintenance dose of 540 mg for a patient with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(r-2) a maintenance dose of 660 mg for a patient with a body weight of 100 kg or more and less than 110 kg, and more than 110kg and less than 120 kg;(s-2) a maintenance dose of 780 mg for a patient with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than 140 kg; and(t-2) a maintenance dose of 900 mg for a patient with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than 165 kg.[3] A method of treating a disease and / or reducing an incidence of the disease in a subject, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the method comprises administering to the subject a pharmaceutical composition comprising a bispecific antibody,wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein the pharmaceutical compositioncomprises, as a single dose, a maintenance dose of the bispecific antibody selected from the group consisting of (a)-(h) below and is administered every two weeks; orcomprises, as a single dose, a maintenance dose of the bispecific antibody selected from the group consisting of (i)-(t) below and is administered every four weeks:(a) a maintenance dose of 135 mg for a subject with a body weight of 41 kg or more and less than 50 kg;(b) a maintenance dose of 165 mg for a subject with a body weight of 50 kg or more and less than 60 kg;(c) a maintenance dose of 195 mg for a subject with a body weight of 60 kg or more and less than 70 kg;(d) a maintenance dose of 225 mg for a subject with a body weight of 70 kg or more and less than 83 kg;(e) a maintenance dose of 270 mg for a subject with a body weight of 83 kg or more and less than 100 kg;(f) a maintenance dose of 330 mg for a subject with a body weight of 100 kg or more and less than 120 kg;(g) a maintenance dose of 390 mg for a subject with a body weight of 120 kg or more and less than 140 kg;(h) a maintenance dose of 450 mg for a subject with a body weight of 140 kg or more and less than 165 kg;(i) a maintenance dose of 135 mg for a subject with a body weight of 21 kg or more and less than 25 kg;(j) a maintenance dose of 165 mg for a subject with a body weight of 25 kg or more and less than 30 kg;(k) a maintenance dose of 195 mg for a subject with a body weight of 30 kg or more and less than 35 kg;(l) a maintenance dose of 225 mg for a subject with a body weight of 35 kg or more and less than 41 kg;(m) a maintenance dose of 270 mg for a subject with a body weight of 41 kg or more and less than 50 kg;(n) a maintenance dose of 330 mg for a subject with a body weight of 50 kg or more and less than 60 kg;(o) a maintenance dose of 390 mg for a subject with a body weight of 60 kg or more and less than 70 kg;(p) a maintenance dose of 450 mg for a subject with a body weight of 70 kg or more and less than 83 kg;(q) a maintenance dose of 540 mg for a subject with a body weight of 83 kg or more and less than 100 kg;(r) a maintenance dose of 660 mg for a subject with a body weight of 100 kg or more and less than 120 kg;(s) a maintenance dose of 780 mg for a subject with a body weight of 120 kg or more and less than 140 kg; and(t) a maintenance dose of 900 mg for a subject with a body weight of 140 kg or more and less than 165 kg.[3-1] A method of treating a disease and / or reducing an incidence of the disease in a subject, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the method comprises administering to the subject a pharmaceutical composition comprising a bispecific antibody,wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein the pharmaceutical compositioncomprises, as a single dose, a maintenance dose of the bispecific antibody selected from the group consisting of (a-1)-(g-1) below and is administered every two weeks; orcomprises, as a single dose, a maintenance dose of the bispecific antibody selected from the group consisting of (h-1)-(r-1) below and is administered every four weeks:(a-1) a maintenance dose of 135 mg for a subject with a body weight of 48 kg or more and less than 50 kg;(b-1) a maintenance dose of 195 mg for a subject with a body weight of 66 kg or more and less than 70 kg;(c-1) a maintenance dose of 225 mg for a subject with a body weight of 76 kg or more and less than 83 kg;(d-1) a maintenance dose of 270 mg for a subject with a body weight of 99 kg or more and less than 100 kg;(e-1) a maintenance dose of 330 mg for a subject with a body weight of 111 kg or more and less than 120 kg;(f-1) a maintenance dose of 390 mg for a subject with a body weight of 131 kg or more and less than 140 kg;(g-1) a maintenance dose of 450 mg for a subject with a body weight of 151 kg or more and less than 165 kg;(h-1) a maintenance dose of 135 mg for a subject with a body weight of 23 kg or more and less than 25 kg;(i-1) a maintenance dose of 165 mg for a subject with a body weight of 28 kg or more and less than 30 kg;(j-1) a maintenance dose of 195 mg for a subject with a body weight of 33 kg or more and less than 35 kg;(k-1) a maintenance dose of 225 mg for a subject with a body weight of 38 kg or more and less than 41 kg;(l-1) a maintenance dose of 270 mg for a subject with a body weight of 48 kg or more and less than 50 kg;(m-1) a maintenance dose of 390 mg for a subject with a body weight of 66 kg or more and less than 70 kg;(n-1) a maintenance dose of 450 mg for a subject with a body weight of 76 kg or more and less than 83 kg;(o-1) a maintenance dose of 540 mg for a subject with a body weight of 99 kg or more and less than 100 kg;(p-1) a maintenance dose of 660 mg for a subject with a body weight of 111 kg or more and less than 120 kg;(q-1) a maintenance dose of 780 mg for a subject with a body weight of 131 kg or more and less than 140 kg; and(r-1) a maintenance dose of 900 mg for a subject with a body weight of 151 kg or more and less than 165 kg.[3-2] A method of treating a disease and / or reducing an incidence of the disease in a subject, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the method comprises administering to the subject a pharmaceutical composition comprising a bispecific antibody,wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein the pharmaceutical compositioncomprises, as a single dose, a maintenance dose of the bispecific antibody selected from the group consisting of (a-2)-(h-2) below and is administered every two weeks; orcomprises, as a single dose, a maintenance dose of the bispecific antibody selected from the group consisting of (i-2)-(t-2) below and is administered every four weeks:(a-2) a maintenance dose of 135 mg for a subject with a body weight of 41 kg or more and less than 45 kg, and more than 45kg and less than 50kg;(b-2) a maintenance dose of 165 mg for a subject with a body weight of 50 kg or more and less than 55kg, and more than 55kg and less than 60 kg;(c-2) a maintenance dose of 195 mg for a subject with a body weight of 60 kg or more and less than 65kg, and more than 65kg and less than 70 kg;(d-2) a maintenance dose of 225 mg for a subject with a body weight of 70 kg or more and less than 75kg, and more than 75kg and less than 83 kg;(e-2) a maintenance dose of 270 mg for a subject with a body weight of 83 kg or more and less than 90kg, and more than 90kg and less than 100 kg;(f-2) a maintenance dose of 330 mg for a subject with a body weight of 100 kg or more and less than 110kg, and more than 110kg and less than 120 kg;(g-2) a maintenance dose of 390 mg for a subject with a body weight of 120 kg or more and less than 130kg, and more than 130kg and less than 140 kg;(h-2) a maintenance dose of 450 mg for a subject with a body weight of 140 kg or more and less than 150kg, and more than 150kg and less than 165 kg;(i-2) a maintenance dose of 135 mg for a subject with a body weight of 21 kg or more and less than 22.5 kg, and more than 22.5 kg and less than 25 kg;(j-2) a maintenance dose of 165 mg for a subject with a body weight of 25 kg or more and less than 27.5 kg, and more than 27.5 kg and less than 30 kg;(k-2) a maintenance dose of 195 mg for a subject with a body weight of 30 kg or more and less than 32.5 kg, and more than 32.5kg and less than 35 kg;(l-2) a maintenance dose of 225 mg for a subject with a body weight of 35 kg or more and less than 37.5 kg, and more than 37.5 kg and less than 41 kg;(m-2) a maintenance dose of 270 mg for a subject with a body weight of 41 kg or more and less than 45 kg, and more than 45kg and less than 50 kg;(n-2) a maintenance dose of 330 mg for a subject with a body weight of 50 kg or more and less than 55 kg, and more than 55kg and less than 60 kg;(o-2) a maintenance dose of 390 mg for a subject with a body weight of 60 kg or more and less than 65 kg, and more than 65kg and less than 70 kg;(p-2) a maintenance dose of 450 mg for a subject with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(q-2) a maintenance dose of 540 mg for a subject with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(r-2) a maintenance dose of 660 mg for a subject with a body weight of 100 kg or more and less than 110 kg, and more than 110kg and less than 120 kg;(s-2) a maintenance dose of 780 mg for a subject with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than 140 kg; and(t-2) a maintenance dose of 900 mg for a subject with a body weight of 140 kg or more and less than 150kg, and more than 150 kg and less than 165 kg.[4] Use of a bispecific antibody in the manufacture of a pharmaceutical composition for treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein the pharmaceutical compositioncomprises, as a single dose, a maintenance dose of the bispecific antibody selected from the group consisting of (a)-(h) below and is administered to a patient every two weeks; orcomprises, as a single dose, a maintenance dose of the bispecific antibody selected from the group consisting of (i)-(t) below and is administered to a patient every four weeks:(a) a maintenance dose of 135 mg for a patient with a body weight of 41 kg or more and less than 50 kg;(b) a maintenance dose of 165 mg for a patient with a body weight of 50 kg or more and less than 60 kg;(c) a maintenance dose of 195 mg for a patient with a body weight of 60 kg or more and less than 70 kg;(d) a maintenance dose of 225 mg for a patient with a body weight of 70 kg or more and less than 83 kg;(e) a maintenance dose of 270 mg for a patient with a body weight of 83 kg or more and less than 100 kg;(f) a maintenance dose of 330 mg for a patient with a body weight of 100 kg or more and less than 120 kg;(g) a maintenance dose of 390 mg for a patient with a body weight of 120 kg or more and less than 140 kg;(h) a maintenance dose of 450 mg for a patient with a body weight of 140 kg or more and less than 165 kg;(i) a maintenance dose of 135 mg for a patient with a body weight of 21 kg or more and less than 25 kg;(j) a maintenance dose of 165 mg for a patient with a body weight of 25 kg or more and less than 30 kg;(k) a maintenance dose of 195 mg for a patient with a body weight of 30 kg or more and less than 35 kg;(l) a maintenance dose of 225 mg for a patient with a body weight of 35 kg or more and less than 41 kg;(m) a maintenance dose of 270 mg for a patient with a body weight of 41 kg or more and less than 50 kg;(n) a maintenance dose of 330 mg for a patient with a body weight of 50 kg or more and less than 60 kg;(o) a maintenance dose of 390 mg for a patient with a body weight of 60 kg or more and less than 70 kg;(p) a maintenance dose of 450 mg for a patient with a body weight of 70 kg or more and less than 83 kg;(q) a maintenance dose of 540 mg for a patient with a body weight of 83 kg or more and less than 100 kg;(r) a maintenance dose of 660 mg for a patient with a body weight of 100 kg or more and less than 120 kg;(s) a maintenance dose of 780 mg for a patient with a body weight of 120 kg or more and less than 140 kg; and(t) a maintenance dose of 900 mg for a patient with a body weight of 140 kg or more and less than 165 kg.[4-1] Use of a bispecific antibody in the manufacture of a pharmaceutical composition for treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein the pharmaceutical compositioncomprises, as a single dose, a maintenance dose of the bispecific antibody selected from the group consisting of (a-1)-(g-1) below and is administered to a patient every two weeks; orcomprises, as a single dose, a maintenance dose of the bispecific antibody selected from the group consisting of (h-1)-(r-1) below and is administered to a patient every four weeks:(a-1) a maintenance dose of 135 mg for a patient with a body weight of 48 kg or more and less than 50 kg;(b-1) a maintenance dose of 195 mg for a patient with a body weight of 66 kg or more and less than 70 kg;(c-1) a maintenance dose of 225 mg for a patient with a body weight of 76 kg or more and less than 83 kg;(d-1) a maintenance dose of 270 mg for a patient with a body weight of 99 kg or more and less than 100 kg;(e-1) a maintenance dose of 330 mg for a patient with a body weight of 111 kg or more and less than 120 kg;(f-1) a maintenance dose of 390 mg for a patient with a body weight of 131 kg or more and less than 140 kg;(g-1) a maintenance dose of 450 mg for a patient with a body weight of 151 kg or more and less than 165 kg;(h-1) a maintenance dose of 135 mg for a patient with a body weight of 23 kg or more and less than 25 kg;(i-1) a maintenance dose of 165 mg for a patient with a body weight of 28 kg or more and less than 30 kg;(j-1) a maintenance dose of 195 mg for a patient with a body weight of 33 kg or more and less than 35 kg;(k-1) a maintenance dose of 225 mg for a patient with a body weight of 38 kg or more and less than 41 kg;(l-1) a maintenance dose of 270 mg for a patient with a body weight of 48 kg or more and less than 50 kg;(m-1) a maintenance dose of 390 mg for a patient with a body weight of 66 kg or more and less than 70 kg;(n-1) a maintenance dose of 450 mg for a patient with a body weight of 76 kg or more and less than 83 kg;(o-1) a maintenance dose of 540 mg for a patient with a body weight of 99 kg or more and less than 100 kg;(p-1) a maintenance dose of 660 mg for a patient with a body weight of 111 kg or more and less than 120 kg;(q-1) a maintenance dose of 780 mg for a patient with a body weight of 131 kg or more and less than 140 kg; and(r-1) a maintenance dose of 900 mg for a patient with a body weight of 151 kg or more and less than 165 kg.[4-2] Use of a bispecific antibody in the manufacture of a pharmaceutical composition for treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein the pharmaceutical compositioncomprises, as a single dose, a maintenance dose of the bispecific antibody selected from the group consisting of (a-2)-(h-2) below and is administered to a patient every two weeks; orcomprises, as a single dose, a maintenance dose of the bispecific antibody selected from the group consisting of (i-2)-(t-2) below and is administered to a patient every four weeks:(a-2) a maintenance dose of 135 mg for a patient with a body weight of 41 kg or more and less than 45 kg, and more than 45kg and less than 50kg;(b-2) a maintenance dose of 165 mg for a patient with a body weight of 50 kg or more and less than 55kg, and more than 55kg and less than 60 kg;(c-2) a maintenance dose of 195 mg for a patient with a body weight of 60 kg or more and less than 65kg, and more than 65kg and less than 70 kg;(d-2) a maintenance dose of 225 mg for a patient with a body weight of 70 kg or more and less than 75kg, and more than 75kg and less than 83 kg;(e-2) a maintenance dose of 270 mg for a patient with a body weight of 83 kg or more and less than 90kg, and more than 90kg and less than 100 kg;(f-2) a maintenance dose of 330 mg for a patient with a body weight of 100 kg or more and less than 110kg, and more than 110kg and less than 120 kg;(g-2) a maintenance dose of 390 mg for a patient with a body weight of 120 kg or more and less than 130kg, and more than 130kg and less than 140 kg;(h-2) a maintenance dose of 450 mg for a patient with a body weight of 140 kg or more and less than 150kg, and more than 150kg and less than 165 kg;(i-2) a maintenance dose of 135 mg for a patient with a body weight of 21 kg or more and less than 22.5 kg, and more than 22.5 kg and less than 25 kg;(j-2) a maintenance dose of 165 mg for a patient with a body weight of 25 kg or more and less than 27.5 kg, and more than 27.5 kg and less than 30 kg;(k-2) a maintenance dose of 195 mg for a patient with a body weight of 30 kg or more and less than 32.5 kg, and more than 32.5kg and less than 35 kg;(l-2) a maintenance dose of 225 mg for a patient with a body weight of 35 kg or more and less than 37.5 kg, and more than 37.5 kg and less than 41 kg;(m-2) a maintenance dose of 270 mg for a patient with a body weight of 41 kg or more and less than 45 kg, and more than 45kg and less than 50 kg;(n-2) a maintenance dose of 330 mg for a patient with a body weight of 50 kg or more and less than 55 kg, and more than 55kg and less than 60 kg;(o-2) a maintenance dose of 390 mg for a patient with a body weight of 60 kg or more and less than 65 kg, and more than 65kg and less than 70 kg;(p-2) a maintenance dose of 450 mg for a patient with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(q-2) a maintenance dose of 540 mg for a patient with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(r-2) a maintenance dose of 660 mg for a patient with a body weight of 100 kg or more and less than 110 kg, and more than 110kg and less than 120 kg;(s-2) a maintenance dose of 780 mg for a patient with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than 140 kg; and(t-2) a maintenance dose of 900 mg for a patient with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than 165 kg.[5] A kit for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the kit comprises:(1) a container;(2) a pharmaceutical composition comprising a maintenance dose of a bispecific antibody selected from the group consisting of (a)-(h) below, or a maintenance dose the bispecific antibody selected from the group consisting of (i)-(t) below,wherein the bispecific antibody is administered to a patient in accordance with an instruction document which is optionally comprised in the kit; andwherein the instruction document instructs that the bispecific antibodyis administered every two weeks, as a single dose, at a maintenance dose of the bispecific antibody selected from the group consisting of (a)-(h) below, oris administered every four weeks, as a single dose, at a maintenance dose of the bispecific antibody selected from the group consisting of (i)-(t) below,wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively:(a) a maintenance dose of 135 mg for a patient with a body weight of 41 kg or more and less than 50 kg;(b) a maintenance dose of 165 mg for a patient with a body weight of 50 kg or more and less than 60 kg;(c) a maintenance dose of 195 mg for a patient with a body weight of 60 kg or more and less than 70 kg;(d) a maintenance dose of 225 mg for a patient with a body weight of 70 kg or more and less than 83 kg;(e) a maintenance dose of 270 mg for a patient with a body weight of 83 kg or more and less than 100 kg;(f) a maintenance dose of 330 mg for a patient with a body weight of 100 kg or more and less than 120 kg;(g) a maintenance dose of 390 mg for a patient with a body weight of 120 kg or more and less than 140 kg;(h) a maintenance dose of 450 mg for a patient with a body weight of 140 kg or more and less than 165 kg;(i) a maintenance dose of 135 mg for a patient with a body weight of 21 kg or more and less than 25 kg;(j) a maintenance dose of 165 mg for a patient with a body weight of 25 kg or more and less than 30 kg;(k) a maintenance dose of 195 mg for a patient with a body weight of 30 kg or more and less than 35 kg;(l) a maintenance dose of 225 mg for a patient with a body weight of 35 kg or more and less than 41 kg;(m) a maintenance dose of 270 mg for a patient with a body weight of 41 kg or more and less than 50 kg;(n) a maintenance dose of 330 mg for a patient with a body weight of 50 kg or more and less than 60 kg;(o) a maintenance dose of 390 mg for a patient with a body weight of 60 kg or more and less than 70 kg;(p) a maintenance dose of 450 mg for a patient with a body weight of 70 kg or more and less than 83 kg;(q) a maintenance dose of 540 mg for a patient with a body weight of 83 kg or more and less than 100 kg;(r) a maintenance dose of 660 mg for a patient with a body weight of 100 kg or more and less than 120 kg;(s) a maintenance dose of 780 mg for a patient with a body weight of 120 kg or more and less than 140 kg; and(t) a maintenance dose of 900 mg for a patient with a body weight of 140 kg or more and less than 165 kg.[5-1] A kit for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the kit comprises:(1) a container;(2) a pharmaceutical composition comprising a maintenance dose of a bispecific antibody selected from the group consisting of (a-1)-(g-1) below, or a maintenance dose the bispecific antibody selected from the group consisting of (h-1)-(r-1) below,wherein the bispecific antibody is administered to a patient in accordance with an instruction document which is optionally comprised in the kit; andwherein the instruction document instructs that the bispecific antibodyis administered every two weeks, as a single dose, at a maintenance dose of the bispecific antibody selected from the group consisting of (a-1)-(g-1) below, oris administered every four weeks, as a single dose, at a maintenance dose of the bispecific antibody selected from the group consisting of (h-1)-(r-1) below,wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively:(a-1) a maintenance dose of 135 mg for a patient with a body weight of 48 kg or more and less than 50 kg;(b-1) a maintenance dose of 195 mg for a patient with a body weight of 66 kg or more and less than 70 kg;(c-1) a maintenance dose of 225 mg for a patient with a body weight of 76 kg or more and less than 83 kg;(d-1) a maintenance dose of 270 mg for a patient with a body weight of 99 kg or more and less than 100 kg;(e-1) a maintenance dose of 330 mg for a patient with a body weight of 111 kg or more and less than 120 kg;(f-1) a maintenance dose of 390 mg for a patient with a body weight of 131 kg or more and less than 140 kg;(g-1) a maintenance dose of 450 mg for a patient with a body weight of 151 kg or more and less than 165 kg;(h-1) a maintenance dose of 135 mg for a patient with a body weight of 23 kg or more and less than 25 kg;(i-1) a maintenance dose of 165 mg for a patient with a body weight of 28 kg or more and less than 30 kg;(j-1) a maintenance dose of 195 mg for a patient with a body weight of 33 kg or more and less than 35 kg;(k-1) a maintenance dose of 225 mg for a patient with a body weight of 38 kg or more and less than 41 kg;(l-1) a maintenance dose of 270 mg for a patient with a body weight of 48 kg or more and less than 50 kg;(m-1) a maintenance dose of 390 mg for a patient with a body weight of 66 kg or more and less than 70 kg;(n-1) a maintenance dose of 450 mg for a patient with a body weight of 76 kg or more and less than 83 kg;(o-1) a maintenance dose of 540 mg for a patient with a body weight of 99 kg or more and less than 100 kg;(p-1) a maintenance dose of 660 mg for a patient with a body weight of 111 kg or more and less than 120 kg;(q-1) a maintenance dose of 780 mg for a patient with a body weight of 131 kg or more and less than 140 kg; and(r-1) a maintenance dose of 900 mg for a patient with a body weight of 151 kg or more and less than 165 kg.[5-2] A kit for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the kit comprises:(1) a container;(2) a pharmaceutical composition comprising a maintenance dose of a bispecific antibody selected from the group consisting of (a-2)-(h-2) below, or a maintenance dose the bispecific antibody selected from the group consisting of (i-2)-(t-2) below,wherein the bispecific antibody is administered to a patient in accordance with an instruction document which is optionally comprised in the kit; andwherein the instruction document instructs that the bispecific antibodyis administered every two weeks, as a single dose, at a maintenance dose of the bispecific antibody selected from the group consisting of (a-2)-(h-2) below, oris administered every four weeks, as a single dose, at a maintenance dose of the bispecific antibody selected from the group consisting of (i-2)-(t-2) below,wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively:(a-2) a maintenance dose of 135 mg for a patient with a body weight of 41 kg or more and less than 45 kg, and more than 45kg and less than 50kg;(b-2) a maintenance dose of 165 mg for a patient with a body weight of 50 kg or more and less than 55kg, and more than 55kg and less than 60 kg;(c-2) a maintenance dose of 195 mg for a patient with a body weight of 60 kg or more and less than 65kg, and more than 65kg and less than 70 kg;(d-2) a maintenance dose of 225 mg for a patient with a body weight of 70 kg or more and less than 75kg, and more than 75kg and less than 83 kg;(e-2) a maintenance dose of 270 mg for a patient with a body weight of 83 kg or more and less than 90kg, and more than 90kg and less than 100 kg;(f-2) a maintenance dose of 330 mg for a patient with a body weight of 100 kg or more and less than 110kg, and more than 110kg and less than 120 kg;(g-2) a maintenance dose of 390 mg for a patient with a body weight of 120 kg or more and less than 130kg, and more than 130kg and less than 140 kg;(h-2) a maintenance dose of 450 mg for a patient with a body weight of 140 kg or more and less than 150kg, and more than 150kg and less than 165 kg;(i-2) a maintenance dose of 135 mg for a patient with a body weight of 21 kg or more and less than 22.5 kg, and more than 22.5 kg and less than 25 kg;(j-2) a maintenance dose of 165 mg for a patient with a body weight of 25 kg or more and less than 27.5 kg, and more than 27.5 kg and less than 30 kg;(k-2) a maintenance dose of 195 mg for a patient with a body weight of 30 kg or more and less than 32.5 kg, and more than 32.5kg and less than 35 kg;(l-2) a maintenance dose of 225 mg for a patient with a body weight of 35 kg or more and less than 37.5 kg, and more than 37.5 kg and less than 41 kg;(m-2) a maintenance dose of 270 mg for a patient with a body weight of 41 kg or more and less than 45 kg, and more than 45kg and less than 50 kg;(n-2) a maintenance dose of 330 mg for a patient with a body weight of 50 kg or more and less than 55 kg, and more than 55kg and less than 60 kg;(o-2) a maintenance dose of 390 mg for a patient with a body weight of 60 kg or more and less than 65 kg, and more than 65kg and less than 70 kg;(p-2) a maintenance dose of 450 mg for a patient with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(q-2) a maintenance dose of 540 mg for a patient with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(r-2) a maintenance dose of 660 mg for a patient with a body weight of 100 kg or more and less than 110 kg, and more than 110kg and less than 120 kg;(s-2) a maintenance dose of 780 mg for a patient with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than 140 kg; and(t-2) a maintenance dose of 900 mg for a patient with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than 165 kg.[6] A pharmaceutical composition comprising a bispecific antibody,wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively;which is selected from the group consisting of (C1) to (C20) below:(C1) a pharmaceutical composition comprising 135 mg of the bispecific antibody for use in administering once every two weeks to a congenital hemophilia A patient whose body weight is 41 kg or more and less than 50 kg;(C2) a pharmaceutical composition comprising 165 mg of the bispecific antibody for use in administering once every two weeks to a congenital hemophilia A patient whose body weight is 50 kg or more and less than 60 kg;(C3) a pharmaceutical composition comprising 195 mg of the bispecific antibody for use in administering once every two weeks to a congenital hemophilia A patient whose body weight is 60 kg or more and less than 70 kg;(C4) a pharmaceutical composition comprising 225 mg of the bispecific antibody for use in administering once every two weeks to a congenital hemophilia A patient whose body weight is 70 kg or more and less than 83 kg;(C5) a pharmaceutical composition comprising 270 mg of the bispecific antibody for use in administering once every two weeks to a congenital hemophilia A patient whose body weight is 83 kg or more and less than 100 kg;(C6) a pharmaceutical composition comprising 330 mg of the bispecific antibody for use in administering once every two weeks to a congenital hemophilia A patient whose body weight is 100 kg or more and less than 120 kg;(C7) a pharmaceutical composition comprising 390 mg of the bispecific antibody for use in administering once every two weeks to a congenital hemophilia A patient whose body weight is 120 kg or more and less than 140 kg;(C8) a pharmaceutical composition comprising 450 mg of the bispecific antibody for use in administering once every two weeks to a congenital hemophilia A patient whose body weight is 140 kg or more and less than 165 kg;(C9) a pharmaceutical composition comprising 135 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 21 kg or more and less than 25 kg;(C10) a pharmaceutical composition comprising 165 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 25 kg or more and less than 30 kg;(C11) a pharmaceutical composition comprising 195 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 30 kg or more and less than 35 kg;(C12) a pharmaceutical composition comprising 225 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 35 kg or more and less than 41 kg;(C13) a pharmaceutical composition comprising 270 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 41 kg or more and less than 50 kg;(C14) a pharmaceutical composition comprising 330 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 50 kg or more and less than 60 kg;(C15) a pharmaceutical composition comprising 390 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 60 kg or more and less than 70 kg;(C16) a pharmaceutical composition comprising 450 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 70 kg or more and less than 83 kg;(C17) a pharmaceutical composition comprising 540 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 83 kg or more and less than 100 kg;(C18) a pharmaceutical composition comprising 660 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 100 kg or more and less than 120 kg;(C19) a pharmaceutical composition comprising 780 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 120 kg or more and less than 140 kg; and(C20) a pharmaceutical composition comprising 900 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 140 kg or more and less than 165 kg,preferably, wherein the pharmaceutical composition in (C1) to (C20) comprises the bispecific antibody as a single maintenance dose.[7] A pharmaceutical composition comprising a bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein:(A) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 41 kg or more and less than 50 kg;(B) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 50 kg or more and less than 60 kg;(C) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 60 kg or more and less than 70 kg;(D) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 70 kg or more and less than 83 kg;(E) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 83 kg or more and less than 100 kg;(F) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 100 kg or more and less than 120 kg;(G) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 120 kg or more and less than 140 kg; and / or(H) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 140 kg or more and less than 165 kg.[7-1] The pharmaceutical composition of [7], wherein:(A) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 41 kg or more and less than 50 kg;(B) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 50 kg or more and less than 60 kg;(C) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 60 kg or more and less than 70 kg;(D) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 70 kg or more and less than 83 kg;(E) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 83 kg or more and less than 100 kg;(F) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 100 kg or more and less than 120 kg;(G) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 120 kg or more and less than 140 kg; and(H) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 140 kg or more and less than 165 kg.[7-2] A pharmaceutical composition comprising a bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein:(A-1) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 48 kg or more and less than 50 kg;(B-1) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 66 kg or more and less than 70 kg;(C-1) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 76 kg or more and less than 83 kg;(D-1) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 99 kg or more and less than 100 kg;(E-1) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 111 kg or more and less than 120 kg;(F-1) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 131 kg or more and less than 140 kg; and / or(G-1) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 151 kg or more and less than 165 kg.[7-3] A pharmaceutical composition comprising a bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein:(A-2) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(B-2) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 50 kg or more and less than 55 kg, and more than 55 kg and less than 60 kg;(C-2) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(D-2) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 70 kg or more and less than 75kg, and more than 75 kg and less than 83 kg;(E-2) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 83 kg or more and less than 90 kg and more than 90 kg and less than 100 kg;(F-2) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 100 kg or more and less than 110 kg, and more than 110kg and less than 120 kg;(G-2) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than 140 kg; and / or(H-2) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than 165 kg.[8] A bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein:(A) 135 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 41 kg or more and less than 50 kg;(B) 165 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 50 kg or more and less than 60 kg;(C) 195 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 60 kg or more and less than 70 kg;(D) 225 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 70 kg or more and less than 83 kg;(E) 270 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 83 kg or more and less than 100 kg;(F) 330 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 100 kg or more and less than 120 kg;(G) 390 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 120 kg or more and less than 140 kg; and / or(H) 450 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 140 kg or more and less than 165 kg.[8-1] The bispecific antibody of [8], wherein:(A) 135 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 41 kg or more and less than 50 kg;(B) 165 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 50 kg or more and less than 60 kg;(C) 195 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 60 kg or more and less than 70 kg;(D) 225 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 70 kg or more and less than 83 kg;(E) 270 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 83 kg or more and less than 100 kg;(F) 330 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 100 kg or more and less than 120 kg;(G) 390 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 120 kg or more and less than 140 kg; and(H) 450 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 140 kg or more and less than 165 kg.[8-2]A bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein:(A-1) 135 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 48 kg or more and less than 50 kg;(B-1) 195 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 66 kg or more and less than 70 kg;(C-1) 225 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 76 kg or more and less than 83 kg;(D-1) 270 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 99 kg or more and less than 100 kg;(E-1) 330 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 111 kg or more and less than 120 kg;(F-1) 390 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 131 kg or more and less than 140 kg; and / or(G-1) 450 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 151 kg or more and less than 165 kg.[8-3] A bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein:(A-2) 135 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(B-2) 165 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 50 kg or more and less than 55 kg, and more than 55 kg and less than 60 kg;(C-2) 195 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(D-2) 225 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 70 kg or more and less than 75kg, and more than 75 kg and less than 83 kg;(E-2) 270 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 83 kg or more and less than 90 kg and more than 90 kg and less than 100 kg;(F-2) 330 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 100 kg or more and less than 110 kg, and more than 110kg and less than 120 kg;(G-2) 390 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than 140 kg; and / or(H-2) 450 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than 165 kg.[9] A method of treating a disease and / or reducing an incidence of the disease in a subject, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the method comprises administering to the subject a pharmaceutical composition comprising a bispecific antibody,wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID Nos: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID Nos: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID Nos: 11, 12, and 13, respectively,wherein:(A) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 41 kg or more and less than 50 kg;(B) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 50 kg or more and less than 60 kg;(C) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 60 kg or more and less than 70 kg;(D) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 70 kg or more and less than 83 kg;(E) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 83 kg or more and less than 100 kg;(F) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 100 kg or more and less than 120 kg;(G) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 120 kg or more and less than 140 kg; and / or(H) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 140 kg or more and less than 165 kg.[9-1] The method of [9], wherein:(A) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 41 kg or more and less than 50 kg;(B) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 50 kg or more and less than 60 kg;(C) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 60 kg or more and less than 70 kg;(D) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 70 kg or more and less than 83 kg;(E) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 83 kg or more and less than 100 kg;(F) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 100 kg or more and less than 120 kg;(G) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 120 kg or more and less than 140 kg; and(H) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 140 kg or more and less than 165 kg.[9-2] A method of treating a disease and / or reducing an incidence of the disease in a subject, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the method comprises administering to the subject a pharmaceutical composition comprising a bispecific antibody,wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID Nos: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID Nos: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID Nos: 11, 12, and 13, respectively,wherein:(A-1) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 48 kg or more and less than 50 kg;(B-1) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 66 kg or more and less than 70 kg;(C-1) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 76 kg or more and less than 83 kg;(D-1) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 99 kg or more and less than 100 kg;(E-1) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 111 kg or more and less than 120 kg;(F-1) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 131 kg or more and less than 140 kg; and / or(G-1) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 151 kg or more and less than 165 kg.[9-3] A method of treating a disease and / or reducing an incidence of the disease in a subject, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the method comprises administering to the subject a pharmaceutical composition comprising a bispecific antibody,wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID Nos: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID Nos: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID Nos: 11, 12, and 13, respectively,wherein:(A-2) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(B-2) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 50 kg or more and less than 55 kg, and more than 55 kg and less than 60 kg;(C-2) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(D-2) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 70 kg or more and less than 75kg, and more than 75 kg and less than 83 kg;(E-2) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 83 kg or more and less than 90 kg and more than 90 kg and less than 100 kg;(F-2) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 100 kg or more and less than 110 kg, and more than 110kg and less than 120 kg;(G-2) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than140 kg; and / or(H-2) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a subject with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than165 kg.

[0010] Use of a bispecific antibody in the manufacture of a pharmaceutical composition for treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein:(A) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 41 kg or more and less than 50 kg;(B) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 50 kg or more and less than 60 kg;(C) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 60 kg or more and less than 70 kg;(D) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 70 kg or more and less than 83 kg;(E) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 83 kg or more and less than 100 kg;(F) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 100 kg or more and less than 120 kg;(G) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 120 kg or more and less than 140 kg; and / or(H) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 140 kg or more and less than 165 kg.[10-1] The use of

[0010] , wherein:(A) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 41 kg or more and less than 50 kg;(B) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 50 kg or more and less than 60 kg;(C) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 60 kg or more and less than 70 kg;(D) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 70 kg or more and less than 83 kg;(E) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 83 kg or more and less than 100 kg;(F) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 100 kg or more and less than 120 kg;(G) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 120 kg or more and less than 140 kg; and(H) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 140 kg or more and less than 165 kg.[10-2] Use of a bispecific antibody in the manufacture of a pharmaceutical composition for treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein:(A-1) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 48 kg or more and less than 50 kg;(B-1) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 66 kg or more and less than 70 kg;(C-1) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 76 kg or more and less than 83 kg;(D-1) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 99 kg or more and less than 100 kg;(E-1) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 111 kg or more and less than 120 kg;(F-1) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 131 kg or more and less than 140 kg; and / or(G-1) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 151 kg or more and less than 165 kg.[10-3] Use of a bispecific antibody in the manufacture of a pharmaceutical composition for treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein:(A-2) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(B-2) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 50 kg or more and less than 55 kg, and more than 55 kg and less than 60 kg;(C-2) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(D-2) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 70 kg or more and less than 75kg, and more than 75 kg and less than 83 kg;(E-2) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 83 kg or more and less than 90 kg and more than 90 kg and less than 100 kg;(F-2) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 100 kg or more and less than 110 kg, and more than 110kg and less than 120 kg;(G-2) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than140 kg; and / or(H-2) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than165 kg.

[0011] A pharmaceutical composition comprising a bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein:(I) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 21 kg or more and less than 25 kg;(J) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 25 kg or more and less than 30 kg;(K) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 30 kg or more and less than 35 kg;(L) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 35 kg or more and less than 41 kg;(M) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 41 kg or more and less than 50 kg;(N) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 50 kg or more and less than 60 kg;(O) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 60 kg or more and less than 70 kg;(P) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 70 kg or more and less than 83 kg;(Q) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 83 kg or more and less than 100 kg;(R) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 100 kg or more and less than 120 kg;(S) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 120 kg or more and less than 140 kg; and / or(T) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 140 kg or more and less than 165 kg.[11-1] The pharmaceutical composition of

[0011] , wherein:(I) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 21 kg or more and less than 25 kg;(J) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 25 kg or more and less than 30 kg;(K) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 30 kg or more and less than 35 kg;(L) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 35 kg or more and less than 41 kg;(M) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 41 kg or more and less than 50 kg;(N) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 50 kg or more and less than 60 kg;(O) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 60 kg or more and less than 70 kg;(P) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 70 kg or more and less than 83 kg;(Q) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 83 kg or more and less than 100 kg;(R) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 100 kg or more and less than 120 kg;(S) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 120 kg or more and less than 140 kg; and(T) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 140 kg or more and less than 165 kg.[11-2] A pharmaceutical composition comprising a bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein:(H-1) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 23 kg or more and less than 25 kg;(I-1) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 28 kg or more and less than 30 kg;(J-1) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 33 kg or more and less than 35 kg;(K-1) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 38 kg or more and less than 41 kg;(L-1) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 48 kg or more and less than 50 kg;(M-1) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 66 kg or more and less than 70 kg;(N-1) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 76 kg or more and less than 83 kg;(O-1) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 99 kg or more and less than 100 kg;(P-1) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 111 kg or more and less than 120 kg;(Q-1) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 131 kg or more and less than 140 kg; and / or(R-1) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 151 kg or more and less than 165 kg.[11-3] A pharmaceutical composition comprising a bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein:(I-2) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 21 kg or more and less than 22.5 kg, and more than 22.5 kg and less than 25 kg;(J-2) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 25 kg or more and less than 27.5 kg, and more than 27.5 kg and less than 30 kg;(K-2) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 30 kg or more and less than 32.5 kg, and more than 32.5 kg and less than 35 kg;(L-2) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 35 kg or more and less than 37.5 kg, and more than 37.5 kg and less than 41 kg;(M-2) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(N-2) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 50 kg or more and less than 55 kg, and more than 55 kg and less than 60 kg;(O-2) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(P-2) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(Q-2) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(R-2) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 100 kg or more and less than 110 kg, and more than 110 kg and less than 120 kg;(S-2) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than 140 kg; and / or(T-2) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 140 kg or more and less than 150kg, and more than 150 kg and less than165 kg.

[0012] A bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein:(I) 135 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 21 kg or more and less than 25 kg;(J) 165 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 25 kg or more and less than 30 kg;(K) 195 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 30 kg or more and less than 35 kg;(L) 225 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 35 kg or more and less than 41 kg;(M) 270 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 41 kg or more and less than 50 kg;(N) 330 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 50 kg or more and less than 60 kg;(O) 390 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 60 kg or more and less than 70 kg;(P) 450 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 70 kg or more and less than 83 kg;(Q) 540 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 83 kg or more and less than 100 kg;(R) 660 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 100 kg or more and less than 120 kg;(S) 780 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 120 kg or more and less than 140 kg; and / or(T) 900 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 140 kg or more and less than 165 kg.[12-1] The bispecific antibody of

[0012] , wherein:(I) 135 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 21 kg or more and less than 25 kg;(J) 165 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 25 kg or more and less than 30 kg;(K) 195 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 30 kg or more and less than 35 kg;(L) 225 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 35 kg or more and less than 41 kg;(M) 270 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 41 kg or more and less than 50 kg;(N) 330 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 50 kg or more and less than 60 kg;(O) 390 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 60 kg or more and less than 70 kg;(P) 450 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 70 kg or more and less than 83 kg;(Q) 540 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 83 kg or more and less than 100 kg;(R) 660 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 100 kg or more and less than 120 kg;(S) 780 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 120 kg or more and less than 140 kg; and(T) 900 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 140 kg or more and less than 165 kg.[12-2] A bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein:(H-1) 135 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 23 kg or more and less than 25 kg;(I-1) 165 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 28 kg or more and less than 30 kg;(J-1) 195 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 33 kg or more and less than 35 kg;(K-1) 225 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 38 kg or more and less than 41 kg;(L-1) 270 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 48 kg or more and less than 50 kg;(M-1) 390 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 66 kg or more and less than 70 kg;(N-1) 450 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 76 kg or more and less than 83 kg;(O-1) 540 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 99 kg or more and less than 100 kg;(P-1) 660 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 111 kg or more and less than 120 kg;(Q-1) 780 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 131 kg or more and less than 140 kg; and / or(R-1) 900 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 151 kg or more and less than 165 kg.[12-3] A bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein:(I-2) 135 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 21 kg or more and less than 22.5 kg, and more than 22.5 kg and less than 25 kg;(J-2) 165 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 25 kg or more and less than 27.5 kg, and more than 27.5 kg and less than 30 kg;(K-2) 195 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 30 kg or more and less than 32.5 kg, and more than 32.5 kg and less than 35 kg;(L-2) 225 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 35 kg or more and less than 37.5 kg, and more than 37.5 kg and less than 41 kg;(M-2) 270 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(N-2) 330 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 50 kg or more and less than 55 kg, and more than 55 kg and less than 60 kg;(O-2) 390 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(P-2) 450 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(Q-2) 540 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(R-2) 660 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 100 kg or more and less than 110 kg, and more than 110 kg and less than 120 kg;(S-2) 780 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than 140 kg; and / or(T-2) 900 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 140 kg or more and less than 150kg, and more than 150 kg and less than165 kg.

[0013] A method of treating a disease and / or reducing an incidence of the disease in a subject, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the method comprises administering to the subject a pharmaceutical composition comprising a bispecific antibody,wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein:(I) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 21 kg or more and less than 25 kg;(J) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 25 kg or more and less than 30 kg;(K) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 30 kg or more and less than 35 kg;(L) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 35 kg or more and less than 41 kg;(M) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 41 kg or more and less than 50 kg;(N) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 50 kg or more and less than 60 kg;(O) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 60 kg or more and less than 70 kg;(P) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 70 kg or more and less than 83 kg;(Q) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 83 kg or more and less than 100 kg;(R) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 100 kg or more and less than 120 kg;(S) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 120 kg or more and less than 140 kg; and / or(T) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 140 kg or more and less than 165 kg.[13-1] The method of

[0013] , wherein:(I) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 21 kg or more and less than 25 kg;(J) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 25 kg or more and less than 30 kg;(K) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 30 kg or more and less than 35 kg;(L) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 35 kg or more and less than 41 kg;(M) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 41 kg or more and less than 50 kg;(N) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 50 kg or more and less than 60 kg;(O) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 60 kg or more and less than 70 kg;(P) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 70 kg or more and less than 83 kg;(Q) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 83 kg or more and less than 100 kg;(R) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 100 kg or more and less than 120 kg;(S) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 120 kg or more and less than 140 kg; and(T) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 140 kg or more and less than 165 kg.[13-2] A method of treating a disease and / or reducing an incidence of the disease in a subject, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the method comprises administering to the subject a pharmaceutical composition comprising a bispecific antibody,wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein:(H-1) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 23 kg or more and less than 25 kg;(I-1) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 28 kg or more and less than 30 kg;(J-1) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 33 kg or more and less than 35 kg;(K-1) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 38 kg or more and less than 41 kg;(L-1) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 48 kg or more and less than 50 kg;(M-1) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 66 kg or more and less than 70 kg;(N-1) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 76 kg or more and less than 83 kg;(O-1) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 99 kg or more and less than 100 kg;(P-1) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 111 kg or more and less than 120 kg;(Q-1) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 131 kg or more and less than 140 kg; and / or(R-1) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 151 kg or more and less than 165 kg.[13-3] A method of treating a disease and / or reducing an incidence of the disease in a subject, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the method comprises administering to the subject a pharmaceutical composition comprising a bispecific antibody,wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein:(I-2) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 21 kg or more and less than 22.5 kg, and more than 22.5 kg and less than 25 kg;(J-2) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 25 kg or more and less than 27.5 kg, and more than 27.5 kg and less than 30 kg;(K-2) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 30 kg or more and less than 32.5 kg, and more than 32.5 kg and less than 35 kg;(L-2) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 35 kg or more and less than 37.5 kg, and more than 37.5 kg and less than 41 kg;(M-2) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(N-2) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 50 kg or more and less than 55 kg, and more than 55 kg and less than 60 kg;(O-2) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(P-2) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(Q-2) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(R-2) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 100 kg or more and less than 110 kg, and more than 110 kg and less than 120 kg;(S-2) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than 140 kg; and / or(T-2) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a subject with a body weight of 140 kg or more and less than 150kg, and more than 150 kg and less than165 kg.

[0014] Use of a bispecific antibody in the manufacture of a pharmaceutical composition for treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein:(I) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 21 kg or more and less than 25 kg;(J) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 25 kg or more and less than 30 kg;(K) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 30 kg or more and less than 35 kg;(L) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 35 kg or more and less than 41 kg;(M) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 41 kg or more and less than 50 kg;(N) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 50 kg or more and less than 60 kg;(O) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 60 kg or more and less than 70 kg;(P) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 70 kg or more and less than 83 kg;(Q) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 83 kg or more and less than 100 kg;(R) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 100 kg or more and less than 120 kg;(S) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 120 kg or more and less than 140 kg; and / or(T) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 140 kg or more and less than 165 kg.[14-1] The use of

[0014] , wherein:(I) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 21 kg or more and less than 25 kg;(J) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 25 kg or more and less than 30 kg;(K) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 30 kg or more and less than 35 kg;(L) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 35 kg or more and less than 41 kg;(M) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 41 kg or more and less than 50 kg;(N) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 50 kg or more and less than 60 kg;(O) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 60 kg or more and less than 70 kg;(P) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 70 kg or more and less than 83 kg;(Q) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 83 kg or more and less than 100 kg;(R) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 100 kg or more and less than 120 kg;(S) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 120 kg or more and less than 140 kg; and(T) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 140 kg or more and less than 165 kg.[14-2] Use of a bispecific antibody in the manufacture of a pharmaceutical composition for treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein:(H-1) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 23 kg or more and less than 25 kg;(I-1) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 28 kg or more and less than 30 kg;(J-1) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 33 kg or more and less than 35 kg;(K-1) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 38 kg or more and less than 41 kg;(L-1) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 48 kg or more and less than 50 kg;(M-1) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 66 kg or more and less than 70 kg;(N-1) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 76 kg or more and less than 83 kg;(O-1) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 99 kg or more and less than 100 kg;(P-1) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 111 kg or more and less than 120 kg;(Q-1) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 131 kg or more and less than 140 kg; and / or(R-1) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 151 kg or more and less than 165 kg.[14-3] Use of a bispecific antibody in the manufacture of a pharmaceutical composition for treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa),wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively;a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively,wherein:(I-2) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 21 kg or more and less than 22.5 kg, and more than 22.5 kg and less than 25 kg;(J-2) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 25 kg or more and less than 27.5 kg, and more than 27.5 kg and less than 30 kg;(K-2) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 30 kg or more and less than 32.5 kg, and more than 32.5 kg and less than 35 kg;(L-2) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 35 kg or more and less than 37.5 kg, and more than 37.5 kg and less than 41 kg;(M-2) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(N-2) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 50 kg or more and less than 55 kg, and more than 55 kg and less than 60 kg;(O-2) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(P-2) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(Q-2) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(R-2) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 100 kg or more and less than 110 kg, and more than 110 kg and less than 120 kg;(S-2) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than 140 kg; and / or(T-2) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 140 kg or more and less than 150kg, and more than 150 kg and less than165 kg.

[0015] The pharmaceutical composition, method or use of any one of [7-1], [9-1], [10-1], [11-1], [13-1] and [14-1], wherein:(A) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient (a subject) with a body weight of 41 kg or more and less than 50 kg;(B) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient (a subject) with a body weight of 50 kg or more and less than 60 kg;(C) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient (a subject) with a body weight of 60 kg or more and less than 70 kg;(D) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient (a subject) with a body weight of 70 kg or more and less than 83 kg;(E) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient (a subject) with a body weight of 83 kg or more and less than 100 kg;(F) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient (a subject) with a body weight of 100 kg or more and less than 120 kg;(G) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient (a subject) with a body weight of 120 kg or more and less than 140 kg;(H) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient (a subject) with a body weight of 140 kg or more and less than 165 kg;(I) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient (a subject) with a body weight of 21 kg or more and less than 25 kg;(J) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient (a subject) with a body weight of 25 kg or more and less than 30 kg;(K) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient (a subject) with a body weight of 30 kg or more and less than 35 kg;(L) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient (a subject) with a body weight of 35 kg or more and less than 41 kg;(M) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient (a subject) with a body weight of 41 kg or more and less than 50 kg;(N) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient (a subject) with a body weight of 50 kg or more and less than 60 kg;(O) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient (a subject) with a body weight of 60 kg or more and less than 70 kg;(P) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient (a subject) with a body weight of 70 kg or more and less than 83 kg;(Q) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient (a subject) with a body weight of 83 kg or more and less than 100 kg;(R) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient (a subject) with a body weight of 100 kg or more and less than 120 kg;(S) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient (a subject) with a body weight of 120 kg or more and less than 140 kg; and(T) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient (a subject) with a body weight of 140 kg or more and less than 165 kg.[15-1] The bispecific antibody of [8-1] or [12-1], wherein:(A) 135 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 41 kg or more and less than 50 kg;(B) 165 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 50 kg or more and less than 60 kg;(C) 195 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 60 kg or more and less than 70 kg;(D) 225 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 70 kg or more and less than 83 kg;(E) 270 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 83 kg or more and less than 100 kg;(F) 330 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 100 kg or more and less than 120 kg;(G) 390 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 120 kg or more and less than 140 kg;(H) 450 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 140 kg or more and less than 165 kg;(I) 135 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 21 kg or more and less than 25 kg;(J) 165 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 25 kg or more and less than 30 kg;(K) 195 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 30 kg or more and less than 35 kg;(L) 225 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 35 kg or more and less than 41 kg;(M) 270 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 41 kg or more and less than 50 kg;(N) 330 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 50 kg or more and less than 60 kg;(O) 390 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 60 kg or more and less than 70 kg;(P) 450 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 70 kg or more and less than 83 kg;(Q) 540 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 83 kg or more and less than 100 kg;(R) 660 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 100 kg or more and less than 120 kg;(S) 780 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 120 kg or more and less than 140 kg; and(T) 900 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 140 kg or more and less than 165 kg.

[0016] The pharmaceutical composition, bispecific antibody, method, use, or kit of any one of [1]-[15-1], wherein:the bispecific antibody is administered at a loading dose of at 3 mg / kg to a patient, four times at an interval of a week (once every week for four weeks); andafter completing administration of the loading dose, from the fifth administration, the bispecific antibody, for example, the bispecific antibody as comprised in the pharmaceutical composition is administered to the patient every two weeks at a maintenance dose selected from the group consisting of said (a)-(h), (a-1)-(g-1), (a-2)-(h-2), (C1)-(C8), (A)-(H), (A-1)-(G-1), and (A-2)-(H-2), or the bispecific antibody, for example, the bispecific antibody as comprised in the pharmaceutical composition is administered to the patient every four weeks at a maintenance dose selected from the group consisting of said (i)-(t), (h-1)-(r-1), (i-2)-(t-2), (C9)-(C20), (I)-(T), (H-1)-(R-1) and (I-2)-(T-2),wherein:(a)-(h) is defined in [1], [2], [3], [4], or [5];(a-1)-(g-1) is defined in [1-1], [2-1], [3-1], [4-1], or [5-1];(a-2)-(h-2) is defined in [1-2], [2-2], [3-2], [4-2], or [5-2];(C1)-(C8) is defined in [6];(A)-(H) is defined in [7], [7-1], [8], [8-1], [9], [9-1],

[0010] , [10-1],

[0015] , or [15-1];(A-1)-(G-1) is defined in [7-2], [8-2], [9-2], or [10-2];(A-2)-(H-2) is defined in [7-3], [8-3], [9-3], or [10-3];(i)-(t) is defined in [1], [2], [3], [4], or [5];(h-1)-(r-1) is defined in [1-1], [2-1], [3-1], [4-1], or [5-1];(i-2)-(t-2) is defined in [1-2], [2-2], [3-2], [4-2], or [5-2];(C9)-(C20) is defined in [6];(I)-(T) is defined in

[0011] , [11-1],

[0012] , [12-1],

[0013] , [13-1],

[0014] , [14-1],

[0015] , or [15-1];(H-1)-(R-1) is defined in [11-2], [12-2], [13-2], or [14-2];(I-2)-(T-2) is defined in [11-3], [12-3], [13-3], or [14-3].[16-1] The pharmaceutical composition, bispecific antibody, method, use, or kit of

[0016] ,wherein the maintenance dose of the bispecific antibody, for example the maintenance dose of the bispecific antibody as comprised in the pharmaceutical composition, is administered to the patient one week after the last administration of the loading dose.

[0017] The pharmaceutical composition, bispecific antibody, method, use, or kit of any one of [1]-[15-1], wherein:the bispecific antibody is administered to a patient at a loading dose of at 3 mg / kg, four times at an interval of a week (once every week for four weeks); andafter completing administration of the loading dose, the bispecific antibody is administered to the patientonce or separately multiple times at a maintenance dose of 6 mg / kg per four weeks; and thenthe bispecific antibody, for example, the bispecific antibody as comprised in the pharmaceutical composition, is administered to the patient every two weeks at a maintenance dose selected from the group consisting of said (a)-(h), (a-1)-(g-1), (a-2)-(h-2), (C1)-(C8),(A)-(H), (A-1)-(G-1) and (A-2)-(H-2), or the bispecific antibody, for example, the bispecific antibody as comprised in the pharmaceutical composition, is administered to the patient every four weeks at a maintenance dose selected from the group consisting of said (i)-(t), (h-1)-(r-1), (i-2)-(t-2), (C9)-(C20), (I)-(T), (H-1)-(R-1) and (I-2)-(T-2),wherein:(a)-(h) is defined in [1], [2], [3], [4], or [5];(a-1)-(g-1) is defined in [1-1], [2-1], [3-1], [4-1], or [5-1];(a-2)-(h-2) is defined in [1-2], [2-2], [3-2], [4-2], or [5-2];(C1)-(C8) is defined in [6];(A)-(H) is defined in [7], [7-1], [8], [8-1], [9], [9-1],

[0010] , [10-1],

[0015] , or [15-1];(A-1)-(G-1) is defined in [7-2], [8-2], [9-2], or [10-2];(A-2)-(H-2) is defined in [7-3], [8-3], [9-3], or [10-3];(i)-(t) is defined in [1], [2], [3], [4], or [5];(h-1)-(r-1) is defined in [1-1], [2-1], [3-1], [4-1], or [5-1];(i-2)-(t-2) is defined in [1-2], [2-2], [3-2], [4-2], or [5-2];(C9)-(C20) is defined in [6];(I)-(T) is defined in

[0011] , [11-1],

[0012] , [12-1],

[0013] , [13-1],

[0014] , [14-1],

[0015] , or [15-1];(H-1)-(R-1) is defined in [11-2], [12-2], [13-2], or [14-2];(I-2)-(T-2) is defined in [11-3], [12-3], [13-3], or [14-3].For clarity, when referring to the bispecific antibody being administered to the patient "once or separately multiple times at a maintenance dose of 6 mg / kg per four weeks", it is meant that the amount of the bispecific antibody in each maintenance dose totals 6 mg / kg over the course of a four week period, wherein each maintenance dose is given as one single administration once every four week period, or is evenly divided into two or more administrations evenly spaced out over each four week period. For example, each 6 mg / kg maintenance dose can be (i) administered once every four weeks, or (ii) divided into two biweekly administrations of 3 mg / kg each, or (iii) divided into four weekly administrations of 1.5 mg / kg each.[17-1] The pharmaceutical composition, bispecific antibody, method, use or kit of any one of [1]-[15-1], wherein:the bispecific antibody is administered to a patient at a loading dose of 3mg / kg, four times at an interval of a week (once every week for four weeks); andafter completing administration of the loading dose, then one or more maintenance doses of the bispecific antibody is administered to the patient, wherein the amount of antibody in each maintenance dose totals 6 mg / kg over the course of a four week period, wherein each maintenance dose is administered once every four week period or is divided into two or more administrations spaced out over each four week period,thenthe bispecific antibody, for example, the bispecific antibody as comprised in the pharmaceutical composition, is administered to the patient every two weeks at a maintenance dose selected from the group consisting of said (a)-(h), (a-1)-(g-1), (a-2)-(h-2), (C1)-(C8), (A)-(H), (A-1)-(G-1) and (A-2)-(H-2), or the bispecific antibody, for example, the bispecific antibody as comprised in the pharmaceutical composition is administered to the patient every four weeks at a maintenance dose selected from the group consisting of said (i)-(t), (h-1)-(r-1), (i-2)-(t-2), (C9)-(C20), (I)-(T), (H-1)-(R-1) and (I-2)-(T-2),wherein:(a)-(h) is defined in [1], [2], [3], [4], or [5];(a-1)-(g-1) is defined in [1-1], [2-1], [3-1], [4-1], or [5-1];(a-2)-(h-2) is defined in [1-2], [2-2], [3-2], [4-2], or [5-2];(C1)-(C8) is defined in [6];(A)-(H) is defined in [7], [7-1], [8], [8-1], [9], [9-1],

[0010] , [10-1],

[0015] , or [15-1];(A-1)-(G-1) is defined in [7-2], [8-2], [9-2], or [10-2];(A-2)-(H-2) is defined in [7-3], [8-3], [9-3], or [10-3];(i)-(t) is defined in [1], [2], [3], [4], or [5];(h-1)-(r-1) is defined in [1-1], [2-1], [3-1], [4-1], or [5-1];(i-2)-(t-2) is defined in [1-2], [2-2], [3-2], [4-2], or [5-2];(C9)-(C20) is defined in [6];(I)-(T) is defined in

[0011] , [11-1],

[0012] , [12-1],

[0013] , [13-1],

[0014] , [14-1],

[0015] , or [15-1];(H-1)-(R-1) is defined in [11-2], [12-2], [13-2], or [14-2];(I-2)-(T-2) is defined in [11-3], [12-3], [13-3], or [14-3].[17-2] The pharmaceutical composition, bispecific antibody, method, use, or kit of

[0017] or [17-1], wherein the administration of the maintenance dose of the bispecific antibody at 6mg / kg per four weeks is selected from the group consisting of (m1) to (m3) below:(m1) the maintenance dose is administered in one single dose of the bispecific antibody at 6 mg / kg, wherein the one single dose of the maintenance dose of the bispecific antibody at 6 mg / kg is administered once every four weeks,(m2) the maintenance dose is administered in two single doses of the bispecific antibody each at 3 mg / kg, wherein each single dose of the maintenance dose of the bispecific antibody at 3 mg / kg is administered once every two weeks, or(m3) the maintenance dose is administered in four single doses of the bispecific antibody each at 1.5 mg / kg, wherein each single dose of the maintenance dose of the bispecific antibody at 1.5mg / kg is administered once every week.[17-3] The pharmaceutical composition, bispecific antibody, method, use, or kit of any one of [17-2],wherein the first maintenance dose of the bispecific antibody selected from the group consisting of (m1) to (m3) is administered one week after the last administration of the loading dose.[17-4] The pharmaceutical composition, bispecific antibody, method, use, or kit of any one of

[0016] ,

[0017] and [17-1], wherein the bispecific antibody which is administered at a loading dose of 3mg / kg is comprised in the pharmaceutical composition which is contained in a vial.

[0018] The pharmaceutical composition, bispecific antibody, method, or use of any one of [1], [2], [3] and [4],wherein:a loading dose of the bispecific antibody selected from the group consisting of (aa)-(hh) which is comprised in a pharmaceutical composition as a single dose is administered to the patient (the subject) once every week for four weeks;and thereafter the maintenance dose of the bispecific antibody selected from the group consisting of (a)-(h) defined in [1], [2], [3] or [4] which is comprised in the pharmaceutical composition as a single dose is administered to the patient (the subject) every two weeks;wherein (aa)-(hh) and (a)-(h) are as below:(aa) a loading dose of 135 mg for the patient (the subject) with a body weight of 41 kg or more and less than 50 kg;(bb) a loading dose of 165 mg for the patient (the subject) with a body weight of 50 kg or more and less than 60 kg;(cc) a loading dose of 195 mg for the patient (the subject) with a body weight of 60 kg or more and less than 70 kg;(dd) a loading dose of 225 mg for the patient (the subject) with a body weight of 70 kg or more and less than 83 kg;(ee) a loading dose of 270 mg for the patient (the subject) with a body weight of 83 kg or more and less than 100 kg;(ff) a loading dose of 330 mg for the patient (the subject) with a body weight of 100 kg or more and less than 120 kg;(gg) a loading dose of 390 mg for the patient (the subject) with a body weight of 120 kg or more and less than 140 kg;(hh) a loading dose of 450 mg for the patient (the subject) with a body weight of 140 kg or more and less than 165 kg;(a) a maintenance dose of 135 mg for the patient (the subject) with a body weight of 41 kg or more and less than 50 kg;(b) a maintenance dose of 165 mg for the patient (the subject) with a body weight of 50 kg or more and less than 60 kg;(c) a maintenance dose of 195 mg for the patient (the subject) with a body weight of 60 kg or more and less than 70 kg;(d) a maintenance dose of 225 mg for the patient (the subject) with a body weight of 70 kg or more and less than 83 kg;(e) a maintenance dose of 270 mg for the patient (the subject) with a body weight of 83 kg or more and less than 100 kg;(f) a maintenance dose of 330 mg for the patient (the subject) with a body weight of 100 kg or more and less than 120 kg;(g) a maintenance dose of 390 mg for the patient (the subject) with a body weight of 120 kg or more and less than 140 kg;(h) a maintenance dose of 450 mg for the patient (the subject) with a body weight of 140 kg or more and less than 165 kg.[18-1] The pharmaceutical composition, bispecific antibody, method, or use of any one of [1-1], [2-1], [3-1] and [4-1],wherein:a loading dose of the bispecific antibody selected from the group consisting of (aa-1)-(gg-1) which is comprised in a pharmaceutical composition as a single dose is administered to the patient (the subject) once every week for four weeks;and thereafter the maintenance dose of the bispecific antibody selected from the group consisting of (a-1)-(g-1) defined in [1-1], [2-1], [3-1] or [4-1] which is comprised in the pharmaceutical composition as a single dose is administered to the patient (the subject) every two weeks;wherein (aa-1)-(gg-1) and (a-1)-(g-1) are as below:(aa-1) a loading dose of 135 mg for the patient (the subject) with a body weight of 48 kg or more and less than 50 kg;(bb-1) a loading dose of 195 mg for the patient (the subject) with a body weight of 66 kg or more and less than 70 kg;(cc-1) a loading dose of 225 mg for the patient (the subject) with a body weight of 76 kg or more and less than 83 kg;(dd-1) a loading dose of 270 mg for the patient (the subject) with a body weight of 99 kg or more and less than 100 kg;(ee-1) a loading dose of 330 mg for the patient (the subject) with a body weight of 111 kg or more and less than 120 kg;(ff-1) a loading dose of 390 mg for the patient (the subject) with a body weight of 131 kg or more and less than 140 kg;(gg-1) a loading dose of 450 mg for the patient (the subject) with a body weight of 151 kg or more and less than 165 kg;(a-1) a maintenance dose of 135 mg for the patient (the subject) with a body weight of 48 kg or more and less than 50 kg;(b-1) a maintenance dose of 195 mg for the patient (the subject) with a body weight of 66 kg or more and less than 70 kg;(c-1) a maintenance dose of 225 mg for the patient (the subject) with a body weight of 76 kg or more and less than 83 kg;(d-1) a maintenance dose of 270 mg for the patient (the subject) with a body weight of 99 kg or more and less than 100 kg;(e-1) a maintenance dose of 330 mg for the patient (the subject) with a body weight of 111 kg or more and less than 120 kg;(f-1) a maintenance dose of 390 mg for the patient (the subject) with a body weight of 131 kg or more and less than 140 kg;(g-1) a maintenance dose of 450 mg for the patient (the subject) with a body weight of 151 kg or more and less than 165 kg.[18-2] The pharmaceutical composition, bispecific antibody, method, or use of any one of [1-2], [2-2], [3-2] and [4-2],wherein:a loading dose of the bispecific antibody selected from the group consisting of (aa-2)-(hh-2) which is comprised in a pharmaceutical composition as a single dose is administered to the patient (the subject) once every week for four weeks;and thereafter the maintenance dose of the bispecific antibody selected from the group consisting of (a-2)-(h-2) defined in [1-2], [2-2], [3-2] or [4-2] which is comprised in the pharmaceutical composition as a single dose is administered to the patient (the subject) every two weeks;wherein (aa-2)-(hh-2) and (a-2)-(h-2) are as below:(aa-2) a loading dose of 135 mg for the patient (the subject) with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(bb-2) a loading dose of 165 mg for the patient (the subject) with a body weight of 50 kg or more and less than 55 kg, and more than 55 kg and less than 60 kg;(cc-2) a loading dose of 195 mg for the patient (the subject) with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(dd-2) a loading dose of 225 mg for the patient (the subject) with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(ee-2) a loading dose of 270 mg for the patient (the subject) with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(ff-2) a loading dose of 330 mg for the patient (the subject) with a body weight of 100 kg or more and less than 110 kg, and more than 110 kg and less than 120 kg;(gg-2) a loading dose of 390 mg for the patient (the subject) with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than 140 kg;(hh-2) a loading dose of 450 mg for the patient (the subject) with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than 165 kg;(a-2) a maintenance dose of 135 mg for the patient (the subject) with a body weight of 41 kg or more and less than 45 kg, and more than 45kg and less than 50kg;(b-2) a maintenance dose of 165 mg for the patient (the subject) with a body weight of 50 kg or more and less than 55kg, and more than 55kg and less than 60 kg;(c-2) a maintenance dose of 195 mg for the patient (the subject) with a body weight of 60 kg or more and less than 65kg, and more than 65kg and less than 70 kg;(d-2) a maintenance dose of 225 mg for the patient (the subject) with a body weight of 70 kg or more and less than 75kg, and more than 75kg and less than 83 kg;(e-2) a maintenance dose of 270 mg for the patient (the subject) with a body weight of 83 kg or more and less than 90kg, and more than 90kg and less than 100 kg;(f-2) a maintenance dose of 330 mg for the patient (the subject) with a body weight of 100 kg or more and less than 110kg, and more than 110kg and less than 120 kg;(g-2) a maintenance dose of 390 mg for the patient (the subject) with a body weight of 120 kg or more and less than 130kg, and more than 130kg and less than 140 kg;(h-2) a maintenance dose of 450 mg for the patient (the subject) with a body weight of 140 kg or more and less than 150kg, and more than 150kg and less than 165 kg.[18-3] The pharmaceutical composition, bispecific antibody, method, or use of any one of [1], [2], [3] and [4],whereina loading dose of the bispecific antibody selected from the group consisting of (aa)-(hh) which is comprised in a pharmaceutical composition as a single dose is administered to the patient (the subject) once every week for four weeks;and thereafter the maintenance dose of the bispecific antibody selected from the group consisting of (m)-(t) defined in [1], [2], [3] or [4] is administered to the patient (the subject) every four weeks; ;wherein (aa)-(hh) and (m)-(t) are as below:(aa) a loading dose of 135 mg for the patient (the subject) with a body weight of 41 kg or more and less than 50 kg;(bb) a loading dose of 165 mg for the patient (the subject) with a body weight of 50 kg or more and less than 60 kg;(cc) a loading dose of 195 mg for the patient (the subject) with a body weight of 60 kg or more and less than 70 kg;(dd) a loading dose of 225 mg for the patient (the subject) with a body weight of 70 kg or more and less than 83 kg;(ee) a loading dose of 270 mg for the patient (the subject) with a body weight of 83 kg or more and less than 100 kg;(ff) a loading dose of 330 mg for the patient (the subject) with a body weight of 100 kg or more and less than 120 kg;(gg) a loading dose of 390 mg for the patient (the subject) with a body weight of 120 kg or more and less than 140 kg;(hh) a loading dose of 450 mg for the patient (the subject) with a body weight of 140 kg or more and less than 165 kg;(m) a maintenance dose of 270 mg for the patient (the subject) with a body weight of 41 kg or more and less than 50 kg;(n) a maintenance dose of 330 mg for the patient (the subject) with a body weight of 50 kg or more and less than 60 kg;(o) a maintenance dose of 390 mg for the patient (the subject) with a body weight of 60 kg or more and less than 70 kg;(p) a maintenance dose of 450 mg for the patient (the subject) with a body weight of 70 kg or more and less than 83 kg;(q) a maintenance dose of 540 mg for the patient (the subject) with a body weight of 83 kg or more and less than 100 kg;(r) a maintenance dose of 660 mg for the patient (the subject) with a body weight of 100 kg or more and less than 120 kg;(s) a maintenance dose of 780 mg for the patient (the subject) with a body weight of 120 kg or more and less than 140 kg;(t) a maintenance dose of 900 mg for the patient (the subject) with a body weight of 140 kg or more and less than 165 kg.[18-4] The pharmaceutical composition, bispecific antibody, method, or use of any one of [1-1], [2-1], [3-1] and [4-1],whereina loading dose of the bispecific antibody selected from the group consisting of (aa-1)-(gg-1) which is comprised in a pharmaceutical composition as a single dose is administered to the patient (the subject) once every week for four weeks;and thereafter the maintenance dose of the bispecific antibody selected from the group consisting of (l-1)-(r-1) defined in [1-1], [2-1], [3-1] or [4-1] is administered to the patient (the subject) every four weeks;wherein (aa-1)-(gg-1) and (l-1)-(r-1) are as below:(aa-1) a loading dose of 135 mg for the patient (the subject) with a body weight of 48 kg or more and less than 50 kg;(bb-1) a loading dose of 195 mg for the patient (the subject) with a body weight of 66 kg or more and less than 70 kg;(cc-1) a loading dose of 225 mg for the patient (the subject) with a body weight of 76 kg or more and less than 83 kg;(dd-1) a loading dose of 270 mg for the patient (the subject) with a body weight of 99 kg or more and less than 100 kg;(ee-1) a loading dose of 330 mg for the patient (the subject) with a body weight of 111 kg or more and less than 120 kg;(ff-1) a loading dose of 390 mg for the patient (the subject) with a body weight of 131 kg or more and less than 140 kg;(gg-1) a loading dose of 450 mg for the patient (the subject) with a body weight of 151 kg or more and less than 165 kg;(l-1) a maintenance dose of 270 mg for the patient (the subject) with a body weight of 48 kg or more and less than 50 kg;(m-1) a maintenance dose of 390 mg for the patient (the subject) with a body weight of 66 kg or more and less than 70 kg;(n-1) a maintenance dose of 450 mg for the patient (the subject) with a body weight of 76 kg or more and less than 83 kg;(o-1) a maintenance dose of 540 mg for the patient (the subject) with a body weight of 99 kg or more and less than 100 kg;(p-1) a maintenance dose of 660 mg for the patient (the subject) with a body weight of 111 kg or more and less than 120 kg;(q-1) a maintenance dose of 780 mg for the patient (the subject) with a body weight of 131 kg or more and less than 140 kg; and(r-1) a maintenance dose of 900 mg for the patient (the subject) with a body weight of 151 kg or more and less than 165 kg.[18-5] The pharmaceutical composition, bispecific antibody, method, or use of any one of [1-2], [2-2], [3-2] and [4-2],whereina loading dose of the bispecific antibody selected from the group consisting of (aa-2)-(hh-2) which is comprised in a pharmaceutical composition as a single dose is administered to the patient (the subject) once every week for four weeks;and thereafter the maintenance dose of the bispecific antibody selected from the group consisting of (m-2)-(t-2) defined in [1-2], [2-2], [3-2] or [4-2] is administered to the patient (the subject) every four weeks;wherein (aa-2)-(hh-2) and (m-2)-(t-2) are as below:(aa-2) a loading dose of 135 mg for the patient (the subject) with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(bb-2) a loading dose of 165 mg for the patient (the subject) with a body weight of 50 kg or more and less than 55 kg, and more than 55 kg and less than 60 kg;(cc-2) a loading dose of 195 mg for the patient (the subject) with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(dd-2) a loading dose of 225 mg for the patient (the subject) with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(ee-2) a loading dose of 270 mg for the patient (the subject) with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(ff-2) a loading dose of 330 mg for the patient (the subject) with a body weight of 100 kg or more and less than 110 kg, and more than 110 kg and less than 120 kg;(gg-2) a loading dose of 390 mg for the patient (the subject) with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than 140 kg;(hh-2) a loading dose of 450 mg for the patient (the subject) with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than 165 kg;(m-2) a maintenance dose of 270 mg for the patient (the subject) with a body weight of 41 kg or more and less than 45 kg, and more than 45kg and less than 50 kg;(n-2) a maintenance dose of 330 mg for the patient (the subject) with a body weight of 50 kg or more and less than 55 kg, and more than 55kg and less than 60 kg;(o-2) a maintenance dose of 390 mg for the patient (the subject) with a body weight of 60 kg or more and less than 65 kg, and more than 65kg and less than 70 kg;(p-2) a maintenance dose of 450 mg for the patient (the subject) with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(q-2) a maintenance dose of 540 mg for the patient (the subject) with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(r-2) a maintenance dose of 660 mg for the patient (the subject) with a body weight of 100 kg or more and less than 110 kg, and more than 110 kg and less than 120 kg;(s-2) a maintenance dose of 780 mg for the patient (the subject) with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than 140 kg; and(t-2) a maintenance dose of 900 mg for the patient (the subject) with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than 165 kg.[18-6] The kit of [5],wherein the instruction document further instructs thatthe bispecific antibody is administered to the patient once every week for four weeks, as a single dose, at a loading dose of the bispecific antibody selected from the group consisting of (aa)-(hh);and thereafter the maintenance dose of the bispecific antibody selected from the group consisting of (a)-(h) defined in [5] is administered to the patient every two weeks;wherein (aa)-(hh) and (a)-(h) are as below:(aa) a loading dose of 135 mg for the patient with a body weight of 41 kg or more and less than 50 kg;(bb) a loading dose of 165 mg for the patient with a body weight of 50 kg or more and less than 60 kg;(cc) a loading dose of 195 mg for the patient with a body weight of 60 kg or more and less than 70 kg;(dd) a loading dose of 225 mg for the patient with a body weight of 70 kg or more and less than 83 kg;(ee) a loading dose of 270 mg for the patient with a body weight of 83 kg or more and less than 100 kg;(ff) a loading dose of 330 mg for the patient with a body weight of 100 kg or more and less than 120 kg;(gg) a loading dose of 390 mg for the patient with a body weight of 120 kg or more and less than 140 kg;(hh) a loading dose of 450 mg for the patient with a body weight of 140 kg or more and less than 165 kg;(a) a maintenance dose of 135 mg for the patient with a body weight of 41 kg or more and less than 50 kg;(b) a maintenance dose of 165 mg for the patient with a body weight of 50 kg or more and less than 60 kg;(c) a maintenance dose of 195 mg for the patient with a body weight of 60 kg or more and less than 70 kg;(d) a maintenance dose of 225 mg for the patient with a body weight of 70 kg or more and less than 83 kg;(e) a maintenance dose of 270 mg for the patient with a body weight of 83 kg or more and less than 100 kg;(f) a maintenance dose of 330 mg for the patient with a body weight of 100 kg or more and less than 120 kg;(g) a maintenance dose of 390 mg for the patient with a body weight of 120 kg or more and less than 140 kg;(h) a maintenance dose of 450 mg for the patient with a body weight of 140 kg or more and less than 165 kg.[18-7] The kit of [5-1],wherein the instruction document further instructs thatthe bispecific antibody is administered to the patient once every week for four weeks, as a single dose, at a loading dose of the bispecific antibody selected from the group consisting of (aa-1)-(gg-1);and thereafter the maintenance dose of the bispecific antibody selected from the group consisting of (a-1)-(g-1) defined in [5] is administered to the patient every two weeks;wherein (aa-1)-(gg-1) and (a-1)-(g-1) are as below:(aa-1) a loading dose of 135 mg for the patient with a body weight of 48 kg or more and less than 50 kg;(bb-1) a loading dose of 195 mg for the patient with a body weight of 66 kg or more and less than 70 kg;(cc-1) a loading dose of 225 mg for the patient with a body weight of 76 kg or more and less than 83 kg;(dd-1) a loading dose of 270 mg for the patient with a body weight of 99 kg or more and less than 100 kg;(ee-1) a loading dose of 330 mg for the patient with a body weight of 111 kg or more and less than 120 kg;(ff-1) a loading dose of 390 mg for the patient with a body weight of 131 kg or more and less than 140 kg;(gg-1) a loading dose of 450 mg for the patient with a body weight of 151 kg or more and less than 165 kg;(a-1) a maintenance dose of 135 mg for the patient with a body weight of 48 kg or more and less than 50 kg;(b-1) a maintenance dose of 195 mg for the patient with a body weight of 66 kg or more and less than 70 kg;(c-1) a maintenance dose of 225 mg for the patient with a body weight of 76 kg or more and less than 83 kg;(d-1) a maintenance dose of 270 mg for the patient with a body weight of 99 kg or more and less than 100 kg;(e-1) a maintenance dose of 330 mg for the patient with a body weight of 111 kg or more and less than 120 kg;(f-1) a maintenance dose of 390 mg for the patient with a body weight of 131 kg or more and less than 140 kg;(g-1) a maintenance dose of 450 mg for the patient with a body weight of 151 kg or more and less than 165 kg.[18-8] The kit of [5-2],wherein the instruction document further instructs thatthe bispecific antibody is administered to the patient once every week for four weeks, as a single dose, at a loading dose of the bispecific antibody selected from the group consisting of (aa-2)-(hh-2);and thereafter the maintenance dose of the bispecific antibody selected from the group consisting of (a-2)-(h-2) defined in [5-2] is administered to the patient every two weeks;wherein (aa-2)-(hh-2) and (a-2)-(h-2) are as below:(aa-2) a loading dose of 135 mg for the patient with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(bb-2) a loading dose of 165 mg for the patient with a body weight of 50 kg or more and less than 55 kg, and more than 55 kg and less than 60 kg;(cc-2) a loading dose of 195 mg for the patient with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(dd-2) a loading dose of 225 mg for the patient with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(ee-2) a loading dose of 270 mg for the patient with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(ff-2) a loading dose of 330 mg for the patient with a body weight of 100 kg or more and less than 110 kg, and more than 110 kg and less than 120 kg;(gg-2) a loading dose of 390 mg for the patient with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than 140 kg;(hh-2) a loading dose of 450 mg for the patient with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than 165 kg;(a-2) a maintenance dose of 135 mg for the patient with a body weight of 41 kg or more and less than 45 kg, and more than 45kg and less than 50kg;(b-2) a maintenance dose of 165 mg for the patient with a body weight of 50 kg or more and less than 55kg, and more than 55kg and less than 60 kg;(c-2) a maintenance dose of 195 mg for the patient with a body weight of 60 kg or more and less than 65kg, and more than 65kg and less than 70 kg;(d-2) a maintenance dose of 225 mg for the patient with a body weight of 70 kg or more and less than 75kg, and more than 75kg and less than 83 kg;(e-2) a maintenance dose of 270 mg for the patient with a body weight of 83 kg or more and less than 90kg, and more than 90kg and less than 100 kg;(f-2) a maintenance dose of 330 mg for the patient with a body weight of 100 kg or more and less than 110kg, and more than 110kg and less than 120 kg;(g-2) a maintenance dose of 390 mg for the patient with a body weight of 120 kg or more and less than 130kg, and more than 130kg and less than 140 kg;(h-2) a maintenance dose of 450 mg for the patient with a body weight of 140 kg or more and less than 150kg, and more than 150kg and less than 165 kg.[18-9] The kit of [5],wherein the instruction document further instructs thatthe bispecific antibody is administered to the patient once every week for four weeks, as a single dose, at a loading dose of the bispecific antibody selected from the group consisting of (aa)-(hh);and thereafter the maintenance dose of the bispecific antibody selected from the group consisting of (m)-(t) defined in [5] is administered to the patient every four weeks;wherein (aa)-(hh) and (m)-(t) are as below:(aa) a loading dose of 135 mg for the patient with a body weight of 41 kg or more and less than 50 kg;(bb) a loading dose of 165 mg for the patient with a body weight of 50 kg or more and less than 60 kg;(cc) a loading dose of 195 mg for the patient with a body weight of 60 kg or more and less than 70 kg;(dd) a loading dose of 225 mg for the patient with a body weight of 70 kg or more and less than 83 kg;(ee) a loading dose of 270 mg for the patient with a body weight of 83 kg or more and less than 100 kg;(ff) a loading dose of 330 mg for the patient with a body weight of 100 kg or more and less than 120 kg;(gg) a loading dose of 390 mg for the patient with a body weight of 120 kg or more and less than 140 kg;(hh) a loading dose of 450 mg for the patient with a body weight of 140 kg or more and less than 165 kg;(m) a maintenance dose of 270 mg for the patient with a body weight of 41 kg or more and less than 50 kg;(n) a maintenance dose of 330 mg for the patient with a body weight of 50 kg or more and less than 60 kg;(o) a maintenance dose of 390 mg for the patient with a body weight of 60 kg or more and less than 70 kg;(p) a maintenance dose of 450 mg for the patient with a body weight of 70 kg or more and less than 83 kg;(q) a maintenance dose of 540 mg for the patient with a body weight of 83 kg or more and less than 100 kg;(r) a maintenance dose of 660 mg for the patient with a body weight of 100 kg or more and less than 120 kg;(s) a maintenance dose of 780 mg for the patient with a body weight of 120 kg or more and less than 140 kg;(t) a maintenance dose of 900 mg for the patient with a body weight of 140 kg or more and less than 165 kg.[18-10] The kit of [5-1],wherein the instruction document further instructs thatthe bispecific antibody is administered to the patient once every week for four weeks, as a single dose, at a loading dose of the bispecific antibody selected from the group consisting of (aa-1)-(gg-1);and thereafter the maintenance dose of the bispecific antibody selected from the group consisting of (l-1)-(r-1) defined in [5-1] is administered to the patient every four weeks;wherein (aa-1)-(gg-1) and (l-1)-(r-1) are as below:(aa-1) a loading dose of 135 mg for the patient with a body weight of 48 kg or more and less than 50 kg;(bb-1) a loading dose of 195 mg for the patient with a body weight of 66 kg or more and less than 70 kg;(cc-1) a loading dose of 225 mg for the patient with a body weight of 76 kg or more and less than 83 kg;(dd-1) a loading dose of 270 mg for the patient with a body weight of 99 kg or more and less than 100 kg;(ee-1) a loading dose of 330 mg for the patient with a body weight of 111 kg or more and less than 120 kg;(ff-1) a loading dose of 390 mg for the patient with a body weight of 131 kg or more and less than 140 kg;(gg-1) a loading dose of 450 mg for the patient with a body weight of 151 kg or more and less than 165 kg;(l-1) a maintenance dose of 270 mg for the patient with a body weight of 48 kg or more and less than 50 kg;(m-1) a maintenance dose of 390 mg for the patient with a body weight of 66 kg or more and less than 70 kg;(n-1) a maintenance dose of 450 mg for the patient with a body weight of 76 kg or more and less than 83 kg;(o-1) a maintenance dose of 540 mg for the patient with a body weight of 99 kg or more and less than 100 kg;(p-1) a maintenance dose of 660 mg for the patient with a body weight of 111 kg or more and less than 120 kg;(q-1) a maintenance dose of 780 mg for the patient with a body weight of 131 kg or more and less than 140 kg; and(r-1) a maintenance dose of 900 mg for the patient with a body weight of 151 kg or more and less than 165 kg.[18-11] The kit of [5-2],wherein the instruction document further instructs thatthe bispecific antibody is administered to the patient once every week for four weeks, as a single dose, at a loading dose of the bispecific antibody selected from the group consisting of (aa-2)-(hh-2);and thereafter the maintenance dose of the bispecific antibody selected from the group consisting of (m-2)-(t-2) defined in [5-2] is administered to the patient every four weeks;wherein (aa-2)-(hh-2) and (m-2)-(t-2) are as below:(aa-2) a loading dose of 135 mg for the patient with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(bb-2) a loading dose of 165 mg for the patient with a body weight of 50 kg or more and less than 55 kg, and more than 55 kg and less than 60 kg;(cc-2) a loading dose of 195 mg for the patient with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(dd-2) a loading dose of 225 mg for the patient with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(ee-2) a loading dose of 270 mg for the patient with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(ff-2) a loading dose of 330 mg for the patient with a body weight of 100 kg or more and less than 110 kg, and more than 110 kg and less than 120 kg;(gg-2) a loading dose of 390 mg for the patient with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than 140 kg;(hh-2) a loading dose of 450 mg for the patient with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than 165 kg;(m-2) a maintenance dose of 270 mg for the patient with a body weight of 41 kg or more and less than 45 kg, and more than 45kg and less than 50 kg;(n-2) a maintenance dose of 330 mg for the patient with a body weight of 50 kg or more and less than 55 kg, and more than 55kg and less than 60 kg;(o-2) a maintenance dose of 390 mg for the patient with a body weight of 60 kg or more and less than 65 kg, and more than 65kg and less than 70 kg;(p-2) a maintenance dose of 450 mg for the patient with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(q-2) a maintenance dose of 540 mg for the patient with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(r-2) a maintenance dose of 660 mg for the patient with a body weight of 100 kg or more and less than 110 kg, and more than 110kg and less than 120 kg;(s-2) a maintenance dose of 780 mg for the patient with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than 140 kg; and(t-2) a maintenance dose of 900 mg for the patient with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than 165 kg.[18-12] The pharmaceutical composition of [6],which is selected from the group consisting of (CC1) to (CC8) below:(CC1) a pharmaceutical composition comprising 135 mg of the bispecific antibody as a single dose for use in administering once every week for four weeks to the congenital hemophilia A patient whose body weight is 41 kg or more and less than 50 kg and thereafter administering once every two weeks to the patient;(CC2) a pharmaceutical composition comprising 165 mg of the bispecific antibody as a single dose for use in administering once every week for four weeks to the congenital hemophilia A patient whose body weight is 50 kg or more and less than 60 kg and thereafter administering once every two weeks to the patient;(CC3) a pharmaceutical composition comprising 195 mg of the bispecific antibody as a single dose for use in administering once every week for four weeks to the congenital hemophilia A patient whose body weight is 60 kg or more and less than 70 kg and thereafter administering once every two weeks to the patient;(CC4) a pharmaceutical composition comprising 225 mg of the bispecific antibody as a single dose for use in administering once every week for four weeks to the congenital hemophilia A patient whose body weight is 70 kg or more and less than 83 kg and thereafter administering once every two weeks to the patient;(CC5) a pharmaceutical composition comprising 270 mg of the bispecific antibody as a single dose for use in administering once every week for four weeks to the congenital hemophilia A patient whose body weight is 83 kg or more and less than 100 kg and thereafter administering once every two weeks to the patient;(CC6) a pharmaceutical composition comprising 330 mg of the bispecific antibody as a single dose for use in administering once every week for four weeks to the congenital hemophilia A patient whose body weight is 100 kg or more and less than 120 kg and thereafter administering once every two weeks to the patient;(CC7) a pharmaceutical composition comprising 390 mg of the bispecific antibody as a single dose for use in administering once every week for four weeks to the congenital hemophilia A patient whose body weight is 120 kg or more and less than 140 kg and thereafter administering once every two weeks to the patient;(CC8) a pharmaceutical composition comprising 450 mg of the bispecific antibody as a single dose for use in administering once every week for four weeks to the congenital hemophilia A patient whose body weight is 140 kg or more and less than 165 kg and thereafter administering once every two weeks to the patient.[18-13] The pharmaceutical composition or the method of any one of [7] and [9],wherein:(AA) 135 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 41 kg or more and less than 50 kg;(BB) 165 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 50 kg or more and less than 60 kg;(CC) 195 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 60 kg or more and less than 70 kg;(DD) 225 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 70 kg or more and less than 83 kg;(EE) 270 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 83 kg or more and less than 100 kg;(FF) 330 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 100 kg or more and less than 120 kg;(GG) 390 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 120 kg or more and less than 140 kg; and / or(HH) 450 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 140 kg or more and less than 165 kg;and thereafter(A) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient (the subject) with a body weight of 41 kg or more and less than 50 kg;(B) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient (the subject) with a body weight of 50 kg or more and less than 60 kg;(C) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient (the subject) with a body weight of 60 kg or more and less than 70 kg;(D) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient (the subject) with a body weight of 70 kg or more and less than 83 kg;(E) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient (the subject) with a body weight of 83 kg or more and less than 100 kg;(F) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient (the subject) with a body weight of 100 kg or more and less than 120 kg;(G) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient (the subject) with a body weight of 120 kg or more and less than 140 kg; and / or(H) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient (the subject) with a body weight of 140 kg or more and less than 165 kg.[18-14] The pharmaceutical composition or the method of any one of [7-2] and [9-2],wherein:(AA-1) 135 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the subject with a body weight of 48 kg or more and less than 50 kg;(BB-1) 195 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the subject with a body weight of 66 kg or more and less than 70 kg;(CC-1) 225 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the subject with a body weight of 76 kg or more and less than 83 kg;(DD-1) 270 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the subject with a body weight of 99 kg or more and less than 100 kg;(EE-1) 330 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the subject with a body weight of 111 kg or more and less than 120 kg;(FF-1) 390 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the subject with a body weight of 131 kg or more and less than 140 kg; and / or(GG-1) 450 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the subject with a body weight of 151 kg or more and less than 165 kg;and thereafter(A-1) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the subject with a body weight of 48 kg or more and less than 50 kg;(B-1) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the subject with a body weight of 66 kg or more and less than 70 kg;(C-1) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the subject with a body weight of 76 kg or more and less than 83 kg;(D-1) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the subject with a body weight of 99 kg or more and less than 100 kg;(E-1) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the subject with a body weight of 111 kg or more and less than 120 kg;(F-1) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the subject with a body weight of 131 kg or more and less than 140 kg; and / or(G-1) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the subject with a body weight of 151 kg or more and less than 165 kg.[18-15] The pharmaceutical composition or the method of any one of [7-3] and [9-3],wherein:(AA-2) 135 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(BB-2) 165 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 50 kg or more and less than 55kg, and more than 55 kg and less than 60 kg;(CC-2) 195 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(DD-2) 225 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(EE-2) 270 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(FF-2) 330 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 100 kg or more and less than 110 kg, and more than 110 kg and less than 120 kg;(GG-2) 390 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than140 kg; and / or(HH-2) 450 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than165 kg;and thereafter(A-2) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient (the subject) with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(B-2) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient (the subject) with a body weight of 50 kg or more and less than 55 kg, and more than 55 kg and less than 60 kg;(C-2) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient (the subject) with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(D-2) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient (the subject) with a body weight of 70 kg or more and less than 75kg, and more than 75 kg and less than 83 kg;(E-2) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient (the subject) with a body weight of 83 kg or more and less than 90 kg and more than 90 kg and less than 100 kg;(F-2) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient (the subject) with a body weight of 100 kg or more and less than 110 kg, and more than 110kg and less than 120 kg;(G-2) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient (the subject) with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than140 kg; and / or(H-2) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient (the subject) with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than165 kg.[18-16] The pharmaceutical composition or the method of any one of

[0011] and

[0013] ,wherein:(AA) 135 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 41 kg or more and less than 50 kg;(BB) 165 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 50 kg or more and less than 60 kg;(CC) 195 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 60 kg or more and less than 70 kg;(DD) 225 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 70 kg or more and less than 83 kg;(EE) 270 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 83 kg or more and less than 100 kg;(FF) 330 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 100 kg or more and less than 120 kg;(GG) 390 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 120 kg or more and less than 140 kg; and / or(HH) 450 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 140 kg or more and less than 165 kg;and thereafter(M) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 41 kg or more and less than 50 kg;(N) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 50 kg or more and less than 60 kg;(O) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 60 kg or more and less than 70 kg;(P) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 70 kg or more and less than 83 kg;(Q) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 83 kg or more and less than 100 kg;(R) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 100 kg or more and less than 120 kg;(S) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 120 kg or more and less than 140 kg;(T) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 140 kg or more and less than 165 kg.[18-17] The pharmaceutical composition or the method of any one of [11-2] and [13-2],wherein:(AA-1) 135 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 48 kg or more and less than 50 kg;(BB-1) 195 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 66 kg or more and less than 70 kg;(CC-1) 225 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 76 kg or more and less than 83 kg;(DD-1) 270 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 99 kg or more and less than 100 kg;(EE-1) 330 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 111 kg or more and less than 120 kg;(FF-1) 390 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 131 kg or more and less than 140 kg; and / or(GG-1) 450 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 151 kg or more and less than 165 kg;and thereafter(L-1) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 48 kg or more and less than 50 kg;(M-1) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 66 kg or more and less than 70 kg;(N-1) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 76 kg or more and less than 83 kg;(O-1) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 99 kg or more and less than 100 kg;(P-1) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 111 kg or more and less than 120 kg;(Q-1) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 131 kg or more and less than 140 kg; and / or(R-1) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 151 kg or more and less than 165 kg.[18-18] The pharmaceutical composition or the method of any one of [11-3] and [13-3],(AA-2) 135 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(BB-2) 165 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 50 kg or more and less than 55kg, and more than 55 kg and less than 60 kg;(CC-2) 195 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(DD-2) 225 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(EE-2) 270 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(FF-2) 330 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 100 kg or more and less than 110 kg, and more than 110 kg and less than 120 kg;(GG-2) 390 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than140 kg; and / or(HH-2) 450 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient (the subject) with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than165 kg;and thereafter(M-2) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(N-2) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 50 kg or more and less than 55 kg, and more than 55 kg and less than 60 kg;(O-2) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(P-2) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(Q-2) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(R-2) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 100 kg or more and less than 110 kg, and more than 110 kg and less than 120 kg;(S-2) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than 140 kg; and / or(T-2) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient (the subject) with a body weight of 140 kg or more and less than 150kg, and more than 150 kg and less than165 kg.[18-19] The bispecific antibody of [8],wherein:(AA) 135 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 41 kg or more and less than 50 kg;(BB) 165 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 50 kg or more and less than 60 kg;(CC) 195 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 60 kg or more and less than 70 kg;(DD) 225 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 70 kg or more and less than 83 kg;(EE) 270 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 83 kg or more and less than 100 kg;(FF) 330 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 100 kg or more and less than 120 kg;(GG) 390 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 120 kg or more and less than 140 kg; and / or(HH) 450 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 140 kg or more and less than 165 kg;and thereafter(A) 135 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 41 kg or more and less than 50 kg;(B) 165 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 50 kg or more and less than 60 kg;(C) 195 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 60 kg or more and less than 70 kg;(D) 225 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 70 kg or more and less than 83 kg;(E) 270 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 83 kg or more and less than 100 kg;(F) 330 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 100 kg or more and less than 120 kg;(G) 390 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 120 kg or more and less than 140 kg; and / or(H) 450 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 140 kg or more and less than 165 kg.[18-20] The bispecific antibody of [8-2],wherein:(AA-1) 135 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 48 kg or more and less than 50 kg;(BB-1) 195 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 66 kg or more and less than 70 kg;(CC-1) 225 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 76 kg or more and less than 83 kg;(DD-1) 270 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 99 kg or more and less than 100 kg;(EE-1) 330 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 111 kg or more and less than 120 kg;(FF-1) 390 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 131 kg or more and less than 140 kg; and / or(GG-1) 450 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 151 kg or more and less than 165 kg;and thereafter(A-1) 135 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 48 kg or more and less than 50 kg;(B-1) 195 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 66 kg or more and less than 70 kg;(C-1) 225 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 76 kg or more and less than 83 kg;(D-1) 270 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 99 kg or more and less than 100 kg;(E-1) 330 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 111 kg or more and less than 120 kg;(F-1) 390 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 131 kg or more and less than 140 kg; and / or(G-1) 450 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 151 kg or more and less than 165 kg.[18-21] The bispecific antibody of [8-3],wherein:(AA-2) 135 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(BB-2) 165 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 50 kg or more and less than 55kg, and more than 55 kg and less than 60 kg;(CC-2) 195 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(DD-2) 225 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(EE-2) 270 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(FF-2) 330 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 100 kg or more and less than 110 kg, and more than 110 kg and less than 120 kg;(GG-2) 390 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than140 kg; and / or(HH-2) 450 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than165 kg;and thereafter(A-2) 135 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(B-2) 165 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 50 kg or more and less than 55 kg, and more than 55 kg and less than 60 kg;(C-2) 195 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(D-2) 225 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 70 kg or more and less than 75kg, and more than 75 kg and less than 83 kg;(E-2) 270 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 83 kg or more and less than 90 kg and more than 90 kg and less than 100 kg;(F-2) 330 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 100 kg or more and less than 110 kg, and more than 110kg and less than 120 kg;(G-2) 390 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than140 kg; and / or(H-2) 450 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for the patient with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than165 kg.[18-22] The bispecific antibody of

[0012] ,wherein:(AA) 135 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 41 kg or more and less than 50 kg;(BB) 165 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 50 kg or more and less than 60 kg;(CC) 195 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 60 kg or more and less than 70 kg;(DD) 225 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 70 kg or more and less than 83 kg;(EE) 270 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 83 kg or more and less than 100 kg;(FF) 330 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 100 kg or more and less than 120 kg;(GG) 390 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 120 kg or more and less than 140 kg; and / or(HH) 450 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 140 kg or more and less than 165 kg;and thereafter(M) 270 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 41 kg or more and less than 50 kg;(N) 330 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 50 kg or more and less than 60 kg;(O) 390 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 60 kg or more and less than 70 kg;(P) 450 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 70 kg or more and less than 83 kg;(Q) 540 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 83 kg or more and less than 100 kg;(R) 660 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 100 kg or more and less than 120 kg;(S) 780 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 120 kg or more and less than 140 kg; and / or(T) 900 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 140 kg or more and less than 165 kg.[18-23] The bispecific antibody of [12-2],wherein:(AA-1) 135 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 48 kg or more and less than 50 kg;(BB-1) 195 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 66 kg or more and less than 70 kg;(CC-1) 225 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 76 kg or more and less than 83 kg;(DD-1) 270 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 99 kg or more and less than 100 kg;(EE-1) 330 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 111 kg or more and less than 120 kg;(FF-1) 390 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 131 kg or more and less than 140 kg; and / or(GG-1) 450 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 151 kg or more and less than 165 kg;and thereafter(L-1) 270 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 48 kg or more and less than 50 kg;(M-1) 390 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 66 kg or more and less than 70 kg;(N-1) 450 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 76 kg or more and less than 83 kg;(O-1) 540 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 99 kg or more and less than 100 kg;(P-1) 660 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 111 kg or more and less than 120 kg;(Q-1) 780 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 131 kg or more and less than 140 kg; and / or(R-1) 900 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 151 kg or more and less than 165 kg.[18-24] The bispecific antibody of [12-3],wherein:(AA-2) 135 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(BB-2) 165 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 50 kg or more and less than 55kg, and more than 55 kg and less than 60 kg;(CC-2) 195 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(DD-2) 225 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(EE-2) 270 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(FF-2) 330 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 100 kg or more and less than 110 kg, and more than 110 kg and less than 120 kg;(GG-2) 390 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than140 kg; and / or(HH-2) 450 mg of the bispecific antibody is administered, as a single loading dose in a pharmaceutical composition, once every week for four weeks to the patient with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than165 kg;and thereafter(M-2) 270 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(N-2) 330 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 50 kg or more and less than 55 kg, and more than 55 kg and less than 60 kg;(O-2) 390 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(P-2) 450 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(Q-2) 540 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(R-2) 660 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 100 kg or more and less than 110 kg, and more than 110 kg and less than 120 kg;(S-2) 780 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than 140 kg; and / or(T-2) 900 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for the patient with a body weight of 140 kg or more and less than 150kg, and more than 150 kg and less than165 kg.[18-25] The use of

[0010] ,wherein:(AA) 135 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 41 kg or more and less than 50 kg;(BB) 165 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 50 kg or more and less than 60 kg;(CC) 195 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 60 kg or more and less than 70 kg;(DD) 225 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 70 kg or more and less than 83 kg;(EE) 270 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 83 kg or more and less than 100 kg;(FF) 330 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 100 kg or more and less than 120 kg;(GG) 390 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 120 kg or more and less than 140 kg; and / or(HH) 450 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 140 kg or more and less than 165 kg;and thereafter(A) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 41 kg or more and less than 50 kg;(B) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 50 kg or more and less than 60 kg;(C) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 60 kg or more and less than 70 kg;(D) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 70 kg or more and less than 83 kg;(E) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 83 kg or more and less than 100 kg;(F) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 100 kg or more and less than 120 kg;(G) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 120 kg or more and less than 140 kg; and / or(H) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 140 kg or more and less than 165 kg.[18-26] The use of [10-2],wherein:(AA-1) 135 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 48 kg or more and less than 50 kg;(BB-1) 195 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 66 kg or more and less than 70 kg;(CC-1) 225 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 76 kg or more and less than 83 kg;(DD-1) 270 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 99 kg or more and less than 100 kg;(EE-1) 330 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 111 kg or more and less than 120 kg;(FF-1) 390 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 131 kg or more and less than 140 kg; and / or(GG-1) 450 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 151 kg or more and less than 165 kg;and thereafter(A-1) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 48 kg or more and less than 50 kg;(B-1) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 66 kg or more and less than 70 kg;(C-1) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 76 kg or more and less than 83 kg;(D-1) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 99 kg or more and less than 100 kg;(E-1) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 111 kg or more and less than 120 kg;(F-1) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 131 kg or more and less than 140 kg; and / or(G-1) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 151 kg or more and less than 165 kg.[18-27] The use of [10-3],wherein:(AA-2) 135 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(BB-2) 165 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 50 kg or more and less than 55kg, and more than 55 kg and less than 60 kg;(CC-2) 195 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(DD-2) 225 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(EE-2) 270 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(FF-2) 330 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 100 kg or more and less than 110 kg, and more than 110 kg and less than 120 kg;(GG-2) 390 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than140 kg; and / or(HH-2) 450 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than165 kg;and thereafter(A-2) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(B-2) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 50 kg or more and less than 55 kg, and more than 55 kg and less than 60 kg;(C-2) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(D-2) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 70 kg or more and less than 75kg, and more than 75 kg and less than 83 kg;(E-2) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 83 kg or more and less than 90 kg and more than 90 kg and less than 100 kg;(F-2) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 100 kg or more and less than 110 kg, and more than 110kg and less than 120 kg;(G-2) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than140 kg; and / or(H-2) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than165 kg.[18-28] The use of

[0014] ,wherein:(AA) 135 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 41 kg or more and less than 50 kg;(BB) 165 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 50 kg or more and less than 60 kg;(CC) 195 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 60 kg or more and less than 70 kg;(DD) 225 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 70 kg or more and less than 83 kg;(EE) 270 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 83 kg or more and less than 100 kg;(FF) 330 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 100 kg or more and less than 120 kg;(GG) 390 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 120 kg or more and less than 140 kg; and / or(HH) 450 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 140 kg or more and less than 165 kg;and thereafter(M) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 41 kg or more and less than 50 kg;(N) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 50 kg or more and less than 60 kg;(O) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 60 kg or more and less than 70 kg;(P) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 70 kg or more and less than 83 kg;(Q) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 83 kg or more and less than 100 kg;(R) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 100 kg or more and less than 120 kg;(S) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 120 kg or more and less than 140 kg; and / or(T) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 140 kg or more and less than 165 kg.[18-29] The use of [14-2],wherein:(AA-1) 135 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 48 kg or more and less than 50 kg;(BB-1) 195 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 66 kg or more and less than 70 kg;(CC-1) 225 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 76 kg or more and less than 83 kg;(DD-1) 270 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 99 kg or more and less than 100 kg;(EE-1) 330 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 111 kg or more and less than 120 kg;(FF-1) 390 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 131 kg or more and less than 140 kg; and / or(GG-1) 450 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 151 kg or more and less than 165 kg;and thereafter(L-1) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 48 kg or more and less than 50 kg;(M-1) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 66 kg or more and less than 70 kg;(N-1) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 76 kg or more and less than 83 kg;(O-1) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 99 kg or more and less than 100 kg;(P-1) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 111 kg or more and less than 120 kg;(Q-1) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 131 kg or more and less than 140 kg; and / or(R-1) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 151 kg or more and less than 165 kg.[18-30] The use of [14-3],wherein:(AA-2) 135 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(BB-2) 165 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 50 kg or more and less than 55kg, and more than 55 kg and less than 60 kg;(CC-2) 195 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(DD-2) 225 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(EE-2) 270 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(FF-2) 330 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 100 kg or more and less than 110 kg, and more than 110 kg and less than 120 kg;(GG-2) 390 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than140 kg; and / or(HH-2) 450 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to the patient with a body weight of 140 kg or more and less than 150 kg, and more than 150 kg and less than165 kg;and thereafter(M-2) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 41 kg or more and less than 45 kg, and more than 45 kg and less than 50 kg;(N-2) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 50 kg or more and less than 55 kg, and more than 55 kg and less than 60 kg;(O-2) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 60 kg or more and less than 65 kg, and more than 65 kg and less than 70 kg;(P-2) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 70 kg or more and less than 75 kg, and more than 75 kg and less than 83 kg;(Q-2) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 83 kg or more and less than 90 kg, and more than 90 kg and less than 100 kg;(R-2) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 100 kg or more and less than 110 kg, and more than 110 kg and less than 120 kg;(S-2) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 120 kg or more and less than 130 kg, and more than 130 kg and less than 140 kg; and / or(T-2) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 140 kg or more and less than 150kg, and more than 150 kg and less than165 kg.[18-31]The pharmaceutical composition, bispecific antibody, method, use, kit of any one of

[0018] -[18-11], [18-13]-[18-30], wherein the maintenance dose of the bispecific antibody, for example the maintenance dose of the bispecific antibody as comprised in the pharmaceutical composition, is administered to the patient one week after the last administration of the loading dose.[18-32] The pharmaceutical composition, bispecific antibody, method, use, kit of any one of [1]-[18-31],wherein the body weight range into which the patient's body weight (the subject's body weight) falls is determined before the administration of the pharmaceutical composition or the bispecific antibody selected from the group consisting of said (aa)-(hh), (aa-1)-(gg-1), (aa-2)-(hh-2), (AA)-(HH), (AA-1)-(GG-1), (AA-2)-(HH-2), (a)-(t), (a-1)-(r-1), (a-2)-(t-2), (C1)-(C20), (CC1)-(CC8), (A)-(T), (A-1)-(R-1) and (A-2)-(T-2).

[0019] A product for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa), wherein the product comprises:(1) one or more containers;(2) a pharmaceutical composition comprising 135 mg, 165 mg, 195 mg, 225 mg, 270 mg, 330 mg, 390 mg, 450 mg, 540 mg, 660 mg, 780 mg, or 900 mg of a bispecific antibody, wherein the bispecific antibody comprises: a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively; a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; and a third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively;wherein the bispecific antibody is administered to a patient in accordance with an instruction document which is optionally comprised in the kit, or preferably comprised in the product; andwherein the instruction document instructs that the bispecific antibody is administered, as a single dose:every two weeks at a maintenance dose of 135 mg for a patient with a body weight of 41 kg or more and less than 50 kg, 165 mg for a patient with a body weight of 50 kg or more and less than 60 kg, 195 mg for a patient with a body weight of 60 kg or more and less than 70 kg, 225 mg for a patient with a body weight of 70 kg or more and less than 83 kg, 270 mg for a patient with a body weight of 83 kg or more and less than 100 kg, 330 mg for a patient with a body weight of 100 kg or more and less than 120 kg, 390 mg for a patient with a body weight of 120 kg or more and less than 140 kg, and / or 450 mg for a patient with a body weight of 140 kg or more and less than 165 kg; and / orevery four weeks at a maintenance dose of 135 mg for a patient with a body weight of 21 kg or more and less than 25 kg, 165 mg for a patient with a body weight of 25 kg or more and less than 30 kg, 195 mg for a patient with a body weight of 30 kg or more and less than 35 kg, 225 mg for a patient with a body weight of 35 kg or more and less than 41 kg, 270 mg for a patient with a body weight of 41 kg or more and less than 50 kg, 330 mg for a patient with a body weight of 50 kg or more and less than 60 kg, 390 mg for a patient with a body weight of 60 kg or more and less than 70 kg, 450 mg for a patient with a body weight of 70 kg or more and less than 83 kg, 540 mg for a patient with a body weight of 83 kg or more and less than 100 kg, 660 mg for a patient with a body weight of 100 kg or more and less than 120 kg, 780 mg for a patient with a body weight of 120 kg or more and less than 140 kg, and / or 900 mg for a patient with a body weight of 140 kg or more and less than 165 kg.[19-1] The product of

[0019] , wherein the instruction document instructs that the bispecific antibody is administered, as a single dose:every two weeks at a maintenance dose of 135 mg for a patient with a body weight of 41 kg or more and less than 50 kg, 165 mg for a patient with a body weight of 50 kg or more and less than 60 kg, 195 mg for a patient with a body weight of 60 kg or more and less than 70 kg, 225 mg for a patient with a body weight of 70 kg or more and less than 83 kg, 270 mg for a patient with a body weight of 83 kg or more and less than 100 kg, 330 mg for a patient with a body weight of 100 kg or more and less than 120 kg, 390 mg for a patient with a body weight of 120 kg or more and less than 140 kg, and 450 mg for a patient with a body weight of 140 kg or more and less than 165 kg; and / orevery four weeks at a maintenance dose of 135 mg for a patient with a body weight of 21 kg or more and less than 25 kg, 165 mg for a patient with a body weight of 25 kg or more and less than 30 kg, 195 mg for a patient with a body weight of 30 kg or more and less than 35 kg, 225 mg for a patient with a body weight of 35 kg or more and less than 41 kg, 270 mg for a patient with a body weight of 41 kg or more and less than 50 kg, 330 mg for a patient with a body weight of 50 kg or more and less than 60 kg, 390 mg for a patient with a body weight of 60 kg or more and less than 70 kg, 450 mg for a patient with a body weight of 70 kg or more and less than 83 kg, 540 mg for a patient with a body weight of 83 kg or more and less than 100 kg, 660 mg for a patient with a body weight of 100 kg or more and less than 120 kg, 780 mg for a patient with a body weight of 120 kg or more and less than 140 kg, and 900 mg for a patient with a body weight of 140 kg or more and less than 165 kg.

[0020] The product of

[0019] or [19-1], wherein the instruction document further instructs that the bispecific antibody is administered to a patient four times at a loading dose of 3 mg / kg at an interval of a week (once every week for four times); and after completing administration of the loading dose, preferably one week after the last administration of the loading dose, said maintenance dose is administered.[20-1] The product of

[0020] , wherein the bispecific antibody administered as the loading dose and the bispecific antibody administered as the maintenance dose as comprised in the pharmaceutical composition are contained in different containers, preferably, wherein the product does not comprise a container which contains the loading dose.[20-2] The product of

[0019] or [19-1], wherein the instruction document further instructs thatthe bispecific antibody is administered to the patient four times at an interval of a week (once every week for four weeks), as a single dose, at a loading dose of the bispecific antibody selected from the group consisting of (aa)-(hh); and after completing administration of the loading dose, preferably one week after the last administration of the loading dose, the maintenance dose defined in

[0019] or [19-1] is administered to the patient:(aa) a loading dose of 135 mg for the patient with a body weight of 41 kg or more and less than 50 kg;(bb) a loading dose of 165 mg for the patient with a body weight of 50 kg or more and less than 60 kg;(cc) a loading dose of 195 mg for the patient with a body weight of 60 kg or more and less than 70 kg;(dd) a loading dose of 225 mg for the patient with a body weight of 70 kg or more and less than 83 kg;(ee) a loading dose of 270 mg for the patient with a body weight of 83 kg or more and less than 100 kg;(ff) a loading dose of 330 mg for the patient with a body weight of 100 kg or more and less than 120 kg;(gg) a loading dose of 390 mg for the patient with a body weight of 120 kg or more and less than 140 kg;(hh) a loading dose of 450 mg for the patient with a body weight of 140 kg or more and less than 165 kg.

[0021] The pharmaceutical composition, bispecific antibody, method, or use, of any one of [1]-[1-2], [2]-[2-2], [3]-[3-2], [4]-[4-2], [6], [7]-[7-3], [8]-[8-3], [9]-[9-3],

[0010] -[10-3],

[0011] -[11-3],

[0012] -[12-3],

[0013] -[13-3],

[0014] -[14-3],

[0015] , [15-1],

[0016] , [16-1],

[0017] -[17-4],

[0018] -[18-5], and [18-12]-[18-32], wherein the pharmaceutical composition is contained in one or more containers.[21-1] The kit or product of any one of [5]-[5-2],

[0016] , [16-1],

[0017] -[17-3], [18-6]-[18-11], [18-31], [18-32],

[0019] , [19-1],

[0020] - [20-2], wherein the pharmaceutical composition is contained in said one or more containers.[21-2] The pharmaceutical composition, bispecific antibody, method, or use, of any one of [1] -[1-2], [2]-[2-2], [3]-[3-2], [4]-[4-2], [6], [7]-[7-3], [8]-[8-3], [9]-[9-3],

[0010] -[10-3],

[0011] -[11-3],

[0012] -[12-3],

[0013] -[13-3],

[0014] -[14-3],

[0015] , [15-1],

[0016] , [16-1],

[0017] -[17-4],

[0018] -[18-5], and [18-12]-[18-32], wherein the pharmaceutical composition which comprises a loading dose of the bispecific antibody selected from the group consisting of said (aa)-(hh), (aa-1)-(gg-1), (aa-2)-(hh-2), (AA)-(HH), (AA-1)-(GG-1), and (AA-2)-(HH-2), the pharmaceutical composition which comprises a maintenance dose of the bispecific antibody selected from the group consisting of said (a)-(t), (a-1)-(r-1), (a-2)-(t-2), (A)-(T), (A-1)-(R-1) and (A-2)-(T-2), and / or the pharmaceutical composition selected from the group consisting of said (C1)-(C20) and (CC1)-(CC8) is (are) contained in one or more containers.[21-3] The kit or product of any one of [5]-[5-2],

[0016] , [16-1],

[0017] -[17-4], [18-6]-[18-11], [18-31], [18-32], and

[0019] , [19-1],

[0020] -[20-2], wherein the pharmaceutical composition which comprises a loading dose of the bispecific antibody selected from the group consisting of said (aa)-(hh), (aa-1)-(gg-1), and (aa-2)-(hh-2), the pharmaceutical composition which comprises a maintenance dose of the bispecific antibody selected from the group consisting of said (a)-(t), (a-1)-(r-1), (a-2)-(t-2), and / or the pharmaceutical composition which comprises the 135 mg, 165 mg, 195 mg, 225 mg, 270 mg, 330 mg, 390 mg, 450 mg, 540 mg, 660 mg, 780 mg, or 900 mg of the bispecific antibody is (are) contained in said one or more containers.

[0022] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of

[0021] or [21-1], wherein a strength of the bispecific antibody comprised in the pharmaceutical composition is selected from the group consisting of 135 mg, 165 mg, 195 mg, 225 mg, and 270 mg.[22-1] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of [21-2] or [21-3], wherein a strength of the bispecific antibody comprised in the pharmaceutical composition is selected from the group consisting of 135 mg, 165 mg, 195 mg, 225 mg, and 270 mg.

[0023] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of

[0021] , [21-1], or

[0022] , wherein the one or more containers containing a pharmaceutical composition which comprises the bispecific antibody at a strength selected from the group consisting of 135mg, 165mg, 195mg, 225mg, and 270mg, are used per administration.[23-1] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of [21-2] , [21-3], or [22-1], wherein the one or more containers containing a pharmaceutical composition which comprises the bispecific antibody at a strength selected from the group consisting of 135mg, 165mg, 195mg, 225mg, and 270mg, is(are) used per administration.

[0024] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of

[0021] , [21-1],

[0022] and

[0023] , wherein two or more containers containing a pharmaceutical composition which comprises the bispecific antibody at the same strength or different strengths selected from the group consisting of 135mg, 165mg, 195mg, 225mg, and 270mg, are used per administration.[24-1] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of [21-2], [21-3], [22-1] and [23-1], wherein two or more containers containing a pharmaceutical composition which comprises the bispecific antibody at the same strength or different strengths selected from the group consisting of 135mg, 165mg, 195mg, 225mg, and 270mg, are used per administration.

[0025] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of

[0021] , [21-1] or

[0022] , wherein:(1-1) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 41 kg or more and less than 50 kg, one container comprising a pharmaceutical composition comprising 135 mg of the bispecific antibody is used per administration;(1-2) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 50 kg or more and less than 60 kg, one container comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody is used per administration;(1-3) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 60 kg or more and less than 70 kg, one container comprising a pharmaceutical composition comprising 190 mg, or preferably comprising 195mg, of the bispecific antibody is used per administration;(1-4) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 70 kg or more and less than 83 kg, one container comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody is used per administration;(1-5) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 83 kg or more and less than 100 kg, one container comprising a pharmaceutical composition comprising 270 mg of the bispecific antibody is used per administration;(1-6) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 100 kg or more and less than 120 kg, two containers each comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody are used per administration;(1-7) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 120 kg or more and less than 140 kg, two containers each comprising a pharmaceutical composition comprising 195 mg of the bispecific antibody are used per administration;(1-8) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 140 kg or more and less than 165 kg, two containers each comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody are used per administration;(2-1) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 21 kg or more and less than 25 kg, one container comprising a pharmaceutical composition comprising 135 mg of the bispecific antibody is used per administration;(2-2) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 25 kg or more and less than 30 kg, one container comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody is used per administration;(2-3) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 30 kg or more and less than 35 kg, one container comprising a pharmaceutical composition comprising 195 mg of the bispecific antibody is used per administration;(2-4) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 35 kg or more and less than 41 kg, one container comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody is used per administration;(2-5) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 41 kg or more and less than 50 kg, one container comprising a pharmaceutical composition comprising 270 mg of the bispecific antibody is used per administration;(2-6) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 50 kg or more and less than 60 kg, two containers each comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody are used per administration;(2-7) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 60 kg or more and less than 70 kg, two containers each comprising a pharmaceutical composition comprising 195 mg of the bispecific antibody are used per administration;(2-8) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 70 kg or more and less than 83 kg, two containers each comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody are used per administration;(2-9) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 83 kg or more and less than 100 kg, two containers each comprising a pharmaceutical composition comprising 270 mg of the bispecific antibody are used per administration;(2-10) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 100 kg or more and less than 120 kg, four containers each comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody are used per administration;(2-11) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 120 kg or more and less than 140 kg, four containers each comprising a pharmaceutical composition comprising 195 mg of the bispecific antibody are used per administration; and / or(2-12) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 140 kg or more and less than 165 kg, four containers each comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody are used per administration.[25-1] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of

[0021] , [21-1], [21-2], [21-3],

[0022] or [22-1],wherein:(1-1) if the bispecific antibody is administered every two weeks at a maintenance dose to the patient (the subject) with a body weight of 41 kg or more and less than 50 kg, one container comprising a pharmaceutical composition comprising 135 mg of the bispecific antibody is used per administration;(1-2) if the bispecific antibody is administered every two weeks at a maintenance dose to the patient (the subject) with a body weight of 50 kg or more and less than 60 kg, one container comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody is used per administration;(1-3) if the bispecific antibody is administered every two weeks at a maintenance dose to the patient (the subject) with a body weight of 60 kg or more and less than 70 kg, one container comprising a pharmaceutical composition comprising 195 mg of the bispecific antibody is used per administration;(1-4) if the bispecific antibody is administered every two weeks at a maintenance dose to thepatient (the subject) with a body weight of 70 kg or more and less than 83 kg, one container comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody is used per administration;(1-5) if the bispecific antibody is administered every two weeks at a maintenance dose to the patient (the subject) with a body weight of 83 kg or more and less than 100 kg, one container comprising a pharmaceutical composition comprising 270 mg of the bispecific antibody is used per administration;(1-6) if the bispecific antibody is administered every two weeks at a maintenance dose to the patient (the subject) with a body weight of 100 kg or more and less than 120 kg, two containers each comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody are used per administration;(1-7) if the bispecific antibody is administered every two weeks at a maintenance dose to the patient (the subject) with a body weight of 120 kg or more and less than 140 kg, two containers each comprising a pharmaceutical composition comprising 195 mg of the bispecific antibody are used per administration;(1-8) if the bispecific antibody is administered every two weeks at a maintenance dose to the patient (the subject) with a body weight of 140 kg or more and less than 165 kg, two containers each comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody are used per administration;(2-1) if the bispecific antibody is administered every four weeks at a maintenance dose to the patient (the subject) with a body weight of 21 kg or more and less than 25 kg, one container comprising a pharmaceutical composition comprising 135 mg of the bispecific antibody is used per administration;(2-2) if the bispecific antibody is administered every four weeks at a maintenance dose to the patient (the subject) with a body weight of 25 kg or more and less than 30 kg, one container comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody is used per administration;(2-3) if the bispecific antibody is administered every four weeks at a maintenance dose to the patient (the subject) with a body weight of 30 kg or more and less than 35 kg, one container comprising a pharmaceutical composition comprising 195 mg of the bispecific antibody is used per administration;(2-4) if the bispecific antibody is administered every four weeks at a maintenance dose to the patient (the subject) with a body weight of 35 kg or more and less than 41 kg, one container comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody is used per administration;(2-5) if the bispecific antibody is administered every four weeks at a maintenance dose to the patient (the subject) with a body weight of 41 kg or more and less than 50 kg, one container comprising a pharmaceutical composition comprising 270 mg of the bispecific antibody is used per administration;(2-6) if the bispecific antibody is administered every four weeks at a maintenance dose to the patient (the subject) with a body weight of 50 kg or more and less than 60 kg, two containers each comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody are used per administration;(2-7) if the bispecific antibody is administered every four weeks at a maintenance dose to the patient (the subject) with a body weight of 60 kg or more and less than 70 kg, two containers each comprising a pharmaceutical composition comprising 195 mg of the bispecific antibody are used per administration;(2-8) if the bispecific antibody is administered every four weeks at a maintenance dose to the patient (the subject) with a body weight of 70 kg or more and less than 83 kg, two containers each comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody are used per administration;(2-9) if the bispecific antibody is administered every four weeks at a maintenance dose to the patient (the subject) with a body weight of 83 kg or more and less than 100 kg, two containers each comprising a pharmaceutical composition comprising 270 mg of the bispecific antibody are used per administration;(2-10) if the bispecific antibody is administered every four weeks at a maintenance dose to the patient (the subject) with a body weight of 100 kg or more and less than 120 kg, four containers each comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody are used per administration;(2-11) if the bispecific antibody is administered every four weeks at a maintenance dose to the patient (the subject) with a body weight of 120 kg or more and less than 140 kg, four containers each comprising a pharmaceutical composition comprising 195 mg of the bispecific antibody are used per administration;(2-12) if the bispecific antibody is administered every four weeks at a maintenance dose to the patient (the subject) with a body weight of 140 kg or more and less than 165 kg, four containers each comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody are used per administration;(3-1) if the bispecific antibody is administered once every week at a loading dose to the patient (the subject) with a body weight of 41 kg or more and less than 50 kg, one container comprising a pharmaceutical composition comprising 135 mg of the bispecific antibody is used per administration;(3-2) if the bispecific antibody is administered once every week at a loading dose to the patient (the subject) with a body weight of 50 kg or more and less than 60 kg, one container comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody is used per administration;(3-3) if the bispecific antibody is administered once every week at a loading dose to the patient (the subject) with a body weight of 60 kg or more and less than 70 kg, one container comprising a pharmaceutical composition comprising 195 mg of the bispecific antibody is used per administration;(3-4) if the bispecific antibody is administered once every week at a loading dose to the patient (the subject) with a body weight of 70 kg or more and less than 83 kg, one container comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody is used per administration;(3-5) if the bispecific antibody is administered once every week at a loading dose to the patient (the subject) with a body weight of 83 kg or more and less than 100 kg, one container comprising a pharmaceutical composition comprising 270 mg of the bispecific antibody is used per administration;(3-6) if the bispecific antibody is administered once every week at a loading dose to the patient (the subject) with a body weight of 100 kg or more and less than 120 kg, two containers each comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody are used per administration;(3-7) if the bispecific antibody is administered once every week at a loading dose to the patient (the subject) with a body weight of 120 kg or more and less than 140 kg, two containers each comprising a pharmaceutical composition comprising 195 mg of the bispecific antibody are used per administration; and / or(3-8) if the bispecific antibody is administered once every week at a loading dose to the patient (the subject) with a body weight of 140 kg or more and less than 165 kg, two containers each comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody are used per administration;

[0026] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of

[0019] , [19-1],

[0020] -[20-2],

[0021] -[21-3],

[0022] , [22-1],

[0023] , [23-1],

[0024] , [24-1],

[0025] , and [25-1], wherein the container is an autoinjector, vial, syringe, electric device, needle safety device, or pen-type device.

[0027] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of

[0019] , [19-1],

[0020] -[20-2],

[0021] , [21-1]-[21-3],

[0022] , [22-1],

[0023] , [23-1],

[0024] , [24-1],

[0025] , [25-1], wherein the container is an injectable device.[27-1] The product of any one of [20-1] and the product of [20-1] in [21-1], [21-3],

[0022] , [22-1],

[0023] , [23-1],

[0024] , [24-1],

[0025] and [25-1], wherein the container which contains bispecific antibody administered as the loading dose is a vial and the container which contains the pharmaceutical composition comprising bispecific antibody administered as the maintenance dose is an injectable device.[27-2] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of

[0027] or [27-1], wherein the injectable device is a durable injection device or disposable injection device.

[0028] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of

[0027] or [27-1], wherein the injectable device is selected from an autoinjector, syringe, electric device, needle safety device, or pen-type device.[28-1] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of

[0027] or [27-1], wherein the injectable device is an autoinjector or syringe, .[28-2] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of

[0027] [27-1] or [28-1], wherein the injectable device is a pre-filled syringe, or a pre-filled syringe used together with an autoinjector as described herein.[28-3] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of

[0021] , [21-1]-[21-3],

[0022] , [22-1],

[0023] , [23-1],

[0024] , [24-1],

[0025] , [25-1],

[0026] ,

[0027] -[27-2],

[0028] , [28-1], and [28-2] wherein 0.2mL - 2.1mL of the pharmaceutical composition is contained in the container or injectable device.[28-4] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of [28-3], wherein 0.3mL - 2.0mL of the pharmaceutical composition is contained in the container or injectable device.[28-5] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of [28-4], wherein 0.4mL - 2.0mL of the pharmaceutical composition is contained in the container or injectable device.[28-6] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of [28-5], wherein 0.9mL - 1.8mL of the pharmaceutical composition is contained in the container or injectable device.[28-7] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of

[0021] , [21-1]-[21-3],

[0022] , [22-1],

[0023] , [23-1],

[0024] , [24-1],

[0025] , [25-1],

[0026] ,

[0027] -[27-2],

[0028] , [28-1]-[28-5], wherein 0.9mL of the pharmaceutical composition is contained in the container or injectable device for the pharmaceutical composition which comprises 135mg of the bispecific antibody or emicizumab, 1.1mL of the pharmaceutical composition is contained in the container or injectable device for the pharmaceutical composition which comprises 165mg of the bispecific antibody or emicizumab, 1.3mL of the pharmaceutical composition is contained in the container or injectable device for the pharmaceutical composition which comprises 195mg of the bispecific antibody or emicizumab, 1.5mL of the pharmaceutical composition is contained in the container or injectable device for the pharmaceutical composition which comprises 195mg, or preferably 225mg, of the bispecific antibody or emicizumab, and / or 1.8mL of the pharmaceutical composition is contained in the container or injectable device for the pharmaceutical composition which comprises 195mg, or preferably 270mg, of the bispecific antibody or emicizumab.

[0029] The pharmaceutical composition, bispecific antibody, method, use, kit or product of any one of [1]-[28-7], wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising an H chain variable region amino acid sequence of SEQ ID NO: 4;a second polypeptide which is an H chain comprising an H chain variable region amino acid sequence of SEQ ID NO: 9; anda third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region amino acid sequence of SEQ ID NO: 14.

[0030] The pharmaceutical composition, bispecific antibody, method, use, kit or product of any one of [1]-[28-7], wherein the bispecific antibody comprises:a first polypeptide which is an H chain comprising the amino acid sequence of SEQ ID NO: 5;a second polypeptide which is an H chain comprising the amino acid sequence of SEQ ID NO: 10; anda third and fourth polypeptide which are a commonly shared L chain comprising the amino acid sequence of SEQ ID NO: 15.

[0031] The pharmaceutical composition, bispecific antibody, method, use, kit or product of any one of [1]-[28-7], wherein the bispecific antibody is emicizumab.

[0032] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of [1]-

[0031] , wherein the pharmaceutical composition further comprises a histidine-aspartic acid buffer, arginine, and surfactant.[32-1] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of [1]-

[0031] , wherein the pharmaceutical composition further comprises a histidine-hydrochloride buffer, arginine, and surfactant.[32-2] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of

[0032] or [32-1], wherein the surfactant is PX188, PS20 or PS80.

[0033] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of [1]-

[0032] , wherein the pharmaceutical composition comprises 10 mM to 40 mM of histidine-aspartic acid buffer, 100 mM to 300 mM of arginine, and 0.2 mg / ml to 1 mg / ml of Poloxamer 188, and is at a pH of 4.5 to 6.5.

[0034] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of

[0033] , wherein the concentration of histidine in the histidine-aspartic acid buffer is 10mM to 40mM.[34-1] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of

[0033] , wherein the pharmaceutical composition comprises 14 mM to 26 mM of histidine-aspartic acid buffer, 100 mM to 200 mM of arginine, and 0.25 mg / ml to 0.75 mg / ml of Poloxamer 188, and is at a pH of 5.5 to 6.5, wherein the concentration of histidine in the histidine-aspartic acid buffer is 14 mM to 26 mM.[34-2] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of [1]-

[0034] , wherein pH of the pharmaceutical composition is 5.5 to 6.5.

[0035] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of

[0033] , wherein the pharmaceutical composition comprises 20 mM of histidine-aspartic acid buffer, 150 mM of arginine, and 0.5 mg / ml Poloxamer 188, and is at a pH of 6.

[0036] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of

[0035] , wherein the concentration of histidine in the histidine-aspartic acid buffer is 20mM.

[0037] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of [1]-

[0036] , wherein a concentration of the bispecific antibody or emicizumab comprised in the pharmaceutical composition is 20 mg / mL to 180 mg / mL.[37-1] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of [1]-

[0036] , wherein a concentration of the bispecific antibody or emicizumab comprised in the pharmaceutical composition is 135mg / mL to 165mg / mL.

[0038] The pharmaceutical composition, bispecific antibody, method, use, kit or product of

[0037] , wherein a concentration of the bispecific antibody or emicizumab comprised in the pharmaceutical composition is 150mg / mL.

[0039] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of

[0032] -

[0038] , wherein the aspartate or the hydrochloric acid is the counterion species for the buffer.[39-1] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of

[0032] -

[0039] , wherein the aspartic acid or the hydrochloric acid is comprised in an amount sufficient to adjust pH of the pharmaceutical composition.

[0040] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of

[0032] -

[0039] , wherein the arginine is L-arginine, aspartic acid is L-aspartic acid and histidine is L-histidine.

[0041] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of [1]-

[0031] , wherein a concentration of the bispecific antibody (emicizumab) is 150mg / mL and the pharmaceutical composition further comprises 3.1mg / ml L-histidine, 26.1mg / ml L-arginine, L-aspartic acid QS for pH 6.0 adjustment and 0.5mg / mL poloxamer 188 in aqueous solution.

[0042] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of [1]-

[0040] , wherein the pharmaceutical composition consists essentially of the bispecific antibody (emicizumab), histidine-aspartic acid buffer, arginine, and surfactant.

[0043] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of

[0041] , wherein the pharmaceutical composition consists essentially of the bispecific antibody (emicizumab), L-histidine, L-arginine, L-aspartic acid, poloxamer 188 and water.

[0044] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of [1]-[5], [7]-[18-11], [18-13]-

[0043] , wherein the disease which develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa) is hemophilia A, hemophilia A with emergence of an inhibitor against FVIII / FVIIIa, acquired hemophilia A, or von Willebrand disease.

[0045] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of [1]-[5], [7]-[18-11], [18-13]-

[0043] , wherein the disease which develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa) is congenital hemophilia A or von Willebrand disease.

[0046] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of [1]-[5], [7]-[18-11], [18-13]-

[0043] , wherein the disease which develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa) is congenital hemophilia A.

[0047] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of [6], [18-12],

[0045] , or

[0046] , wherein congenital hemophilia A is congenital hemophilia A with emergence of an inhibitor against FVIII / FVIIIa and congenital hemophilia A without emergence of an inhibitor against FVIII / FVIIIa.[47-1] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of

[0044] -

[0047] , wherein treating the disease and / or reducing an incidence of the disease is preventing or reducing the frequency of bleeding episodes in the patient.[47-2] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of

[0044] -

[0047] , wherein treating the disease and / or reducing an incidence of the disease is routine prophylaxis to prevent or reduce the frequency of bleeding episodes in the patient.

[0048] The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of [1]-

[0047] , wherein the bispecific antibody or emicizumab is administered to a human patient (subject).

[0049] The pharmaceutical composition, bispecific antibody, method, use, kit or product of any one of [1]-

[0048] , wherein the bispecific antibody or emicizumab is administered subcutaneously, p...

Claims

1. A pharmaceutical composition comprising a bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa), wherein the bispecific antibody comprises: a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively; a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; and a third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively, wherein the pharmaceutical composition comprises, as a single dose, a maintenance dose of the bispecific antibody selected from the group consisting of (a)-(h) below, and is administered to a patient every two weeks; or comprises, as a single dose, a maintenance dose of the bispecific antibody selected from the group consisting of (i)-(t) below, and is administered to a patient every four weeks: (a) a maintenance dose of 135 mg for a patient with a body weight of 41 kg or more and less than 50 kg; (b) a maintenance dose of 165 mg for a patient with a body weight of 50 kg or more and less than 60 kg; (c) a maintenance dose of 195 mg for a patient with a body weight of 60 kg or more and less than 70 kg; (d) a maintenance dose of 225 mg for a patient with a body weight of 70 kg or more and less than 83 kg; (e) a maintenance dose of 270 mg for a patient with a body weight of 83 kg or more and less than 100 kg; (f) a maintenance dose of 330 mg for a patient with a body weight of 100 kg or more and less than 120 kg; (g) a maintenance dose of 390 mg for a patient with a body weight of 120 kg or more and less than 140 kg; (h) a maintenance dose of 450 mg for a patient with a body weight of 140 kg or more and less than 165 kg; (i) a maintenance dose of 135 mg for a patient with a body weight of 21 kg or more and less than 25 kg; (j) a maintenance dose of 165 mg for a patient with a body weight of 25 kg or more and less than 30 kg; (k) a maintenance dose of 195 mg for a patient with a body weight of 30 kg or more and less than 35 kg; (l) a maintenance dose of 225 mg for a patient with a body weight of 35 kg or more and less than 41 kg; (m) a maintenance dose of 270 mg for a patient with a body weight of 41 kg or more and less than 50 kg; (n) a maintenance dose of 330 mg for a patient with a body weight of 50 kg or more and less than 60 kg; (o) a maintenance dose of 390 mg for a patient with a body weight of 60 kg or more and less than 70 kg; (p) a maintenance dose of 450 mg for a patient with a body weight of 70 kg or more and less than 83 kg; (q) a maintenance dose of 540 mg for a patient with a body weight of 83 kg or more and less than 100 kg; (r) a maintenance dose of 660 mg for a patient with a body weight of 100 kg or more and less than 120 kg; (s) a maintenance dose of 780 mg for a patient with a body weight of 120 kg or more and less than 140 kg; and (t) a maintenance dose of 900 mg for a patient with a body weight of 140 kg or more and less than 165 kg.

2. A bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa), wherein the bispecific antibody comprises: a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively; a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; and a third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively, wherein the bispecific antibody is administered to a patient every two weeks, as a single dose in a pharmaceutical composition, at a maintenance dose of the bispecific antibody selected from the group consisting of (a)-(h) below; or is administered to a patient every four weeks, as a single dose in a pharmaceutical composition, at a maintenance dose of the bispecific antibody selected from the group consisting of (i)-(t) below: (a) a maintenance dose of 135 mg for a patient with a body weight of 41 kg or more and less than 50 kg; (b) a maintenance dose of 165 mg for a patient with a body weight of 50 kg or more and less than 60 kg; (c) a maintenance dose of 195 mg for a patient with a body weight of 60 kg or more and less than 70 kg; (d) a maintenance dose of 225 mg for a patient with a body weight of 70 kg or more and less than 83 kg; (e) a maintenance dose of 270 mg for a patient with a body weight of 83 kg or more and less than 100 kg; (f) a maintenance dose of 330 mg for a patient with a body weight of 100 kg or more and less than 120 kg; (g) a maintenance dose of 390 mg for a patient with a body weight of 120 kg or more and less than 140 kg; (h) a maintenance dose of 450 mg for a patient with a body weight of 140 kg or more and less than 165 kg; (i) a maintenance dose of 135 mg for a patient with a body weight of 21 kg or more and less than 25 kg; (j) a maintenance dose of 165 mg for a patient with a body weight of 25 kg or more and less than 30 kg; (k) a maintenance dose of 195 mg for a patient with a body weight of 30 kg or more and less than 35 kg; (l) a maintenance dose of 225 mg for a patient with a body weight of 35 kg or more and less than 41 kg; (m) a maintenance dose of 270 mg for a patient with a body weight of 41 kg or more and less than 50 kg; (n) a maintenance dose of 330 mg for a patient with a body weight of 50 kg or more and less than 60 kg; (o) a maintenance dose of 390 mg for a patient with a body weight of 60 kg or more and less than 70 kg; (p) a maintenance dose of 450 mg for a patient with a body weight of 70 kg or more and less than 83 kg; (q) a maintenance dose of 540 mg for a patient with a body weight of 83 kg or more and less than 100 kg; (r) a maintenance dose of 660 mg for a patient with a body weight of 100 kg or more and less than 120 kg; (s) a maintenance dose of 780 mg for a patient with a body weight of 120 kg or more and less than 140 kg; and (t) a maintenance dose of 900 mg for a patient with a body weight of 140 kg or more and less than 165 kg.

3. A kit for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa), wherein the kit comprises: (1) a container; (2) a pharmaceutical composition comprising a maintenance dose of a bispecific antibody selected from the group consisting of (a)-(h) below, or a maintenance dose the bispecific antibody selected from the group consisting of (i)-(t) below, wherein the bispecific antibody is administered to a patient in accordance with an instruction document which is optionally comprised in the kit; and wherein the instruction document instructs that the bispecific antibody is administered every two weeks, as a single dose, at a maintenance dose of the bispecific antibody selected from the group consisting of (a)-(h) below, or is administered every four weeks, as a single dose, at a maintenance dose of the bispecific antibody selected from the group consisting of (i)-(t) below, wherein the bispecific antibody comprises: a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively; a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; and a third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively: (a) a maintenance dose of 135 mg for a patient with a body weight of 41 kg or more and less than 50 kg; (b) a maintenance dose of 165 mg for a patient with a body weight of 50 kg or more and less than 60 kg; (c) a maintenance dose of 195 mg for a patient with a body weight of 60 kg or more and less than 70 kg; (d) a maintenance dose of 225 mg for a patient with a body weight of 70 kg or more and less than 83 kg; (e) a maintenance dose of 270 mg for a patient with a body weight of 83 kg or more and less than 100 kg; (f) a maintenance dose of 330 mg for a patient with a body weight of 100 kg or more and less than 120 kg; (g) a maintenance dose of 390 mg for a patient with a body weight of 120 kg or more and less than 140 kg; (h) a maintenance dose of 450 mg for a patient with a body weight of 140 kg or more and less than 165 kg; (i) a maintenance dose of 135 mg for a patient with a body weight of 21 kg or more and less than 25 kg; (j) a maintenance dose of 165 mg for a patient with a body weight of 25 kg or more and less than 30 kg; (k) a maintenance dose of 195 mg for a patient with a body weight of 30 kg or more and less than 35 kg; (l) a maintenance dose of 225 mg for a patient with a body weight of 35 kg or more and less than 41 kg; (m) a maintenance dose of 270 mg for a patient with a body weight of 41 kg or more and less than 50 kg; (n) a maintenance dose of 330 mg for a patient with a body weight of 50 kg or more and less than 60 kg; (o) a maintenance dose of 390 mg for a patient with a body weight of 60 kg or more and less than 70 kg; (p) a maintenance dose of 450 mg for a patient with a body weight of 70 kg or more and less than 83 kg; (q) a maintenance dose of 540 mg for a patient with a body weight of 83 kg or more and less than 100 kg; (r) a maintenance dose of 660 mg for a patient with a body weight of 100 kg or more and less than 120 kg; (s) a maintenance dose of 780 mg for a patient with a body weight of 120 kg or more and less than 140 kg; and (t) a maintenance dose of 900 mg for a patient with a body weight of 140 kg or more and less than 165 kg.

4. A pharmaceutical composition comprising a bispecific antibody, wherein the bispecific antibody comprises: a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively; a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; and a third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively. which is selected from the group consisting of (C1) to (C20) below: (C1) a pharmaceutical composition comprising 135 mg of the bispecific antibody for use in administering once every two weeks to a congenital hemophilia A patient whose body weight is 41 kg or more and less than 50 kg; (C2) a pharmaceutical composition comprising 165 mg of the bispecific antibody for use in administering once every two weeks to a congenital hemophilia A patient whose body weight is 50 kg or more and less than 60 kg; (C3) a pharmaceutical composition comprising 195 mg of the bispecific antibody for use in administering once every two weeks to a congenital hemophilia A patient whose body weight is 60 kg or more and less than 70 kg; (C4) a pharmaceutical composition comprising 225 mg of the bispecific antibody for use in administering once every two weeks to a congenital hemophilia A patient whose body weight is 70 kg or more and less than 83 kg; (C5) a pharmaceutical composition comprising 270 mg of the bispecific antibody for use in administering once every two weeks to a congenital hemophilia A patient whose body weight is 83 kg or more and less than 100 kg; (C6) a pharmaceutical composition comprising 330 mg of the bispecific antibody for use in administering once every two weeks to a congenital hemophilia A patient whose body weight is 100 kg or more and less than 120 kg; (C7) a pharmaceutical composition comprising 390 mg of the bispecific antibody for use in administering once every two weeks to a congenital hemophilia A patient whose body weight is 120 kg or more and less than 140 kg; (C8) a pharmaceutical composition comprising 450 mg of the bispecific antibody for use in administering once every two weeks to a congenital hemophilia A patient whose body weight is 140 kg or more and less than 165 kg; (C9) a pharmaceutical composition comprising 135 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 21 kg or more and less than 25 kg; (C10) a pharmaceutical composition comprising 165 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 25 kg or more and less than 30 kg; (C11) a pharmaceutical composition comprising 195 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 30 kg or more and less than 35 kg; (C12) a pharmaceutical composition comprising 225 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 35 kg or more and less than 41 kg; (C13) a pharmaceutical composition comprising 270 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 41 kg or more and less than 50 kg; (C14) a pharmaceutical composition comprising 330 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 50 kg or more and less than 60 kg; (C15) a pharmaceutical composition comprising 390 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 60 kg or more and less than 70 kg; (C16) a pharmaceutical composition comprising 450 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 70 kg or more and less than 83 kg; (C17) a pharmaceutical composition comprising 540 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 83 kg or more and less than 100 kg; (C18) a pharmaceutical composition comprising 660 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 100 kg or more and less than 120 kg; (C19) a pharmaceutical composition comprising 780 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 120 kg or more and less than 140 kg; and (C20) a pharmaceutical composition comprising 900 mg of the bispecific antibody for use in administering once every four weeks to a congenital hemophilia A patient whose body weight is 140 kg or more and less than 165 kg.

5. A pharmaceutical composition comprising a bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa), wherein the bispecific antibody comprises: a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively; a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; and a third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively, wherein: (A) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 41 kg or more and less than 50 kg; (B) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 50 kg or more and less than 60 kg; (C) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 60 kg or more and less than 70 kg; (D) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 70 kg or more and less than 83 kg; (E) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 83 kg or more and less than 100 kg; (F) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 100 kg or more and less than 120 kg; (G) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 120 kg or more and less than 140 kg; and (H) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 140 kg or more and less than 165 kg.

6. A bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa), wherein the bispecific antibody comprises: a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively; a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; and a third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively, wherein: (A) 135 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 41 kg or more and less than 50 kg; (B) 165 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 50 kg or more and less than 60 kg; (C) 195 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 60 kg or more and less than 70 kg; (D) 225 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 70 kg or more and less than 83 kg; (E) 270 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 83 kg or more and less than 100 kg; (F) 330 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 100 kg or more and less than 120 kg; (G) 390 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 120 kg or more and less than 140 kg; and (H) 450 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 140 kg or more and less than 165 kg.

7. A pharmaceutical composition comprising a bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa), wherein the bispecific antibody comprises: a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively; a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; and a third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively, wherein: (I) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 21 kg or more and less than 25 kg; (J) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 25 kg or more and less than 30 kg; (K) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 30 kg or more and less than 35 kg; (L) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 35 kg or more and less than 41 kg; (M) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 41 kg or more and less than 50 kg; (N) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 50 kg or more and less than 60 kg; (O) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 60 kg or more and less than 70 kg; (P) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 70 kg or more and less than 83 kg; (Q) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 83 kg or more and less than 100 kg; (R) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 100 kg or more and less than 120 kg; (S) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 120 kg or more and less than 140 kg; and (T) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 140 kg or more and less than 165 kg.

8. A bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa), wherein the bispecific antibody comprises: a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively; a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; and a third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively, wherein: (I) 135 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 21 kg or more and less than 25 kg; (J) 165 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 25 kg or more and less than 30 kg; (K) 195 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 30 kg or more and less than 35 kg; (L) 225 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 35 kg or more and less than 41 kg; (M) 270 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 41 kg or more and less than 50 kg; (N) 330 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 50 kg or more and less than 60 kg; (O) 390 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 60 kg or more and less than 70 kg; (P) 450 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 70 kg or more and less than 83 kg; (Q) 540 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 83 kg or more and less than 100 kg; (R) 660 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 100 kg or more and less than 120 kg; (S) 780 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 120 kg or more and less than 140 kg; and (T) 900 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 140 kg or more and less than 165 kg.

9. The pharmaceutical composition of claim 5 or 7, wherein: (A) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 41 kg or more and less than 50 kg; (B) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 50 kg or more and less than 60 kg; (C) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 60 kg or more and less than 70 kg; (D) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 70 kg or more and less than 83 kg; (E) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 83 kg or more and less than 100 kg; (F) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 100 kg or more and less than 120 kg; (G) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 120 kg or more and less than 140 kg; (H) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for a patient with a body weight of 140 kg or more and less than 165 kg; (I) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 21 kg or more and less than 25 kg; (J) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 25 kg or more and less than 30 kg; (K) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 30 kg or more and less than 35 kg; (L) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 35 kg or more and less than 41 kg; (M) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 41 kg or more and less than 50 kg; (N) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 50 kg or more and less than 60 kg; (O) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 60 kg or more and less than 70 kg; (P) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 70 kg or more and less than 83 kg; (Q) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 83 kg or more and less than 100 kg; (R) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 100 kg or more and less than 120 kg; (S) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 120 kg or more and less than 140 kg; and (T) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for a patient with a body weight of 140 kg or more and less than 165 kg.

10. The bispecific antibody of claim 6 or 8, wherein: (A) 135 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 41 kg or more and less than 50 kg; (B) 165 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 50 kg or more and less than 60 kg; (C) 195 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 60 kg or more and less than 70 kg; (D) 225 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 70 kg or more and less than 83 kg; (E) 270 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 83 kg or more and less than 100 kg; (F) 330 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 100 kg or more and less than 120 kg; (G) 390 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 120 kg or more and less than 140 kg; (H) 450 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every two weeks for a patient with a body weight of 140 kg or more and less than 165 kg; (I) 135 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 21 kg or more and less than 25 kg; (J) 165 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 25 kg or more and less than 30 kg; (K) 195 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 30 kg or more and less than 35 kg; (L) 225 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 35 kg or more and less than 41 kg; (M) 270 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 41 kg or more and less than 50 kg; (N) 330 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 50 kg or more and less than 60 kg; (O) 390 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 60 kg or more and less than 70 kg; (P) 450 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 70 kg or more and less than 83 kg; (Q) 540 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 83 kg or more and less than 100 kg; (R) 660 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 100 kg or more and less than 120 kg; (S) 780 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 120 kg or more and less than 140 kg; and (T) 900 mg of the bispecific antibody is administered, as a single maintenance dose in a pharmaceutical composition, once every four weeks for a patient with a body weight of 140 kg or more and less than 165 kg.

11. The pharmaceutical composition, bispecific antibody, or kit of any one of claim 1 to 10, wherein: the bispecific antibody is administered at a loading dose of at 3 mg / kg to a patient, four times at an interval of a week (once every week for four weeks); and after completing administration of the loading dose, from the fifth administration, the bispecific antibody is administered to the patient every two weeks at a maintenance dose selected from the group consisting of (a)-(h), (C1)-(C8), and (A)-(H), or the bispecific antibody is administered to the patient every four weeks at a maintenance dose selected from the group consisting of(i)-(t), (C9)-(C20) and (I)-(T), wherein: (a)-(h) is defined in claim 1, 2 or 3; (C1)-(C8) is defined in claim 4; (A)-(H) is defined in claim 5, 6, 9 or 10; (i)-(t) is defined in claim 1, 2 or 3; (C9)-(C20) is defined in claim 4; (I)-(T) is defined in claim 7, 8, 9 or 10.

12. The pharmaceutical composition or bispecific antibody of any one of claim 1 and 2, wherein: a loading dose of the bispecific antibody selected from the group consisting of (aa)-(hh) which is comprised in the pharmaceutical composition as a single dose is administered to the patient once every week for four weeks; and thereafter the maintenance dose of the bispecific antibody selected from the group consisting of (a)-(h) defined in claim 1 or 2 which is comprised in the pharmaceutical composition as a single dose is administered to the patient every two weeks; wherein (aa)-(hh) and (a)-(h) are as below: (aa) a loading dose of 135 mg for the patient with a body weight of 41 kg or more and less than 50 kg; (bb) a loading dose of 165 mg for the patient with a body weight of 50 kg or more and less than 60 kg; (cc) a loading dose of 195 mg for the patient with a body weight of 60 kg or more and less than 70 kg; (dd) a loading dose of 225 mg for the patient with a body weight of 70 kg or more and less than 83 kg; (ee) a loading dose of 270 mg for the patient with a body weight of 83 kg or more and less than 100 kg; (ff) a loading dose of 330 mg for the patient with a body weight of 100 kg or more and less than 120 kg; (gg) a loading dose of 390 mg for the patient with a body weight of 120 kg or more and less than 140 kg; (hh) a loading dose of 450 mg for the patient with a body weight of 140 kg or more and less than 165 kg; (a) a maintenance dose of 135 mg for the patient with a body weight of 41 kg or more and less than 50 kg; (b) a maintenance dose of 165 mg for the patient with a body weight of 50 kg or more and less than 60 kg; (c) a maintenance dose of 195 mg for the patient with a body weight of 60 kg or more and less than 70 kg; (d) a maintenance dose of 225 mg for the patient with a body weight of 70 kg or more and less than 83 kg; (e) a maintenance dose of 270 mg for the patient with a body weight of 83 kg or more and less than 100 kg; (f) a maintenance dose of 330 mg for the patient with a body weight of 100 kg or more and less than 120 kg; (g) a maintenance dose of 390 mg for the patient with a body weight of 120 kg or more and less than 140 kg; (h) a maintenance dose of 450 mg for the patient with a body weight of 140 kg or more and less than 165 kg.

13. The pharmaceutical composition or bispecific antibody of any one of claim 1 and 2, wherein a loading dose of the bispecific antibody selected from the group consisting of (aa)-(hh) which is comprised in the pharmaceutical composition as a single dose is administered to the patient once every week for four weeks; and thereafter the maintenance dose of the bispecific antibody selected from the group consisting of (m)-(t) defined in claim 1 or 2 is administered to the patient every four weeks; ; wherein (aa)-(hh) and (m)-(t) are as below: (aa) a loading dose of 135 mg for the patient with a body weight of 41 kg or more and less than 50 kg; (bb) a loading dose of 165 mg for the patient with a body weight of 50 kg or more and less than 60 kg; (cc) a loading dose of 195 mg for the patient with a body weight of 60 kg or more and less than 70 kg; (dd) a loading dose of 225 mg for the patient with a body weight of 70 kg or more and less than 83 kg; (ee) a loading dose of 270 mg for the patient with a body weight of 83 kg or more and less than 100 kg; (ff) a loading dose of 330 mg for the patient with a body weight of 100 kg or more and less than 120 kg; (gg) a loading dose of 390 mg for the patient with a body weight of 120 kg or more and less than 140 kg; (hh) a loading dose of 450 mg for the patient with a body weight of 140 kg or more and less than 165 kg; (m) a maintenance dose of 270 mg for the patient with a body weight of 41 kg or more and less than 50 kg; (n) a maintenance dose of 330 mg for the patient with a body weight of 50 kg or more and less than 60 kg; (o) a maintenance dose of 390 mg for the patient with a body weight of 60 kg or more and less than 70 kg; (p) a maintenance dose of 450 mg for the patient with a body weight of 70 kg or more and less than 83 kg; (q) a maintenance dose of 540 mg for the patient with a body weight of 83 kg or more and less than 100 kg; (r) a maintenance dose of 660 mg for the patient with a body weight of 100 kg or more and less than 120 kg; (s) a maintenance dose of 780 mg for the patient with a body weight of 120 kg or more and less than 140 kg; (t) a maintenance dose of 900 mg for the patient with a body weight of 140 kg or more and less than 165 kg.

14. The kit of claim 5, wherein the instruction document further instructs that the bispecific antibody is administered to the patient once every week for four weeks, as a single dose, at a loading dose of the bispecific antibody selected from the group consisting of (aa)-(hh); and thereafter the maintenance dose of the bispecific antibody selected from the group consisting of (a)-(h) defined in claim 5 is administered to the patient every two weeks; wherein (aa)-(hh) and (a)-(h) are as below: (aa) a loading dose of 135 mg for the patient with a body weight of 41 kg or more and less than 50 kg; (bb) a loading dose of 165 mg for the patient with a body weight of 50 kg or more and less than 60 kg; (cc) a loading dose of 195 mg for the patient with a body weight of 60 kg or more and less than 70 kg; (dd) a loading dose of 225 mg for the patient with a body weight of 70 kg or more and less than 83 kg; (ee) a loading dose of 270 mg for the patient with a body weight of 83 kg or more and less than 100 kg; (ff) a loading dose of 330 mg for the patient with a body weight of 100 kg or more and less than 120 kg; (gg) a loading dose of 390 mg for the patient with a body weight of 120 kg or more and less than 140 kg; (hh) a loading dose of 450 mg for the patient with a body weight of 140 kg or more and less than 165 kg; (a) a maintenance dose of 135 mg for the patient with a body weight of 41 kg or more and less than 50 kg; (b) a maintenance dose of 165 mg for the patient with a body weight of 50 kg or more and less than 60 kg; (c) a maintenance dose of 195 mg for the patient with a body weight of 60 kg or more and less than 70 kg; (d) a maintenance dose of 225 mg for the patient with a body weight of 70 kg or more and less than 83 kg; (e) a maintenance dose of 270 mg for the patient with a body weight of 83 kg or more and less than 100 kg; (f) a maintenance dose of 330 mg for the patient with a body weight of 100 kg or more and less than 120 kg; (g) a maintenance dose of 390 mg for the patient with a body weight of 120 kg or more and less than 140 kg; (h) a maintenance dose of 450 mg for the patient with a body weight of 140 kg or more and less than 165 kg.

15. The kit of claim 5, wherein the instruction document further instructs that the bispecific antibody is administered to the patient once every week for four weeks, as a single dose, at a loading dose of the bispecific antibody selected from the group consisting of (aa)-(hh); and thereafter the maintenance dose of the bispecific antibody selected from the group consisting of (m)-(t) defined in claim 5 is administered to the patient every four weeks; wherein (aa)-(hh) and (m)-(t) are as below: (aa) a loading dose of 135 mg for the patient with a body weight of 41 kg or more and less than 50 kg; (bb) a loading dose of 165 mg for the patient with a body weight of 50 kg or more and less than 60 kg; (cc) a loading dose of 195 mg for the patient with a body weight of 60 kg or more and less than 70 kg; (dd) a loading dose of 225 mg for the patient with a body weight of 70 kg or more and less than 83 kg; (ee) a loading dose of 270 mg for the patient with a body weight of 83 kg or more and less than 100 kg; (ff) a loading dose of 330 mg for the patient with a body weight of 100 kg or more and less than 120 kg; (gg) a loading dose of 390 mg for the patient with a body weight of 120 kg or more and less than 140 kg; (hh) a loading dose of 450 mg for the patient with a body weight of 140 kg or more and less than 165 kg; (m) a maintenance dose of 270 mg for the patient with a body weight of 41 kg or more and less than 50 kg; (n) a maintenance dose of 330 mg for the patient with a body weight of 50 kg or more and less than 60 kg; (o) a maintenance dose of 390 mg for the patient with a body weight of 60 kg or more and less than 70 kg; (p) a maintenance dose of 450 mg for the patient with a body weight of 70 kg or more and less than 83 kg; (q) a maintenance dose of 540 mg for the patient with a body weight of 83 kg or more and less than 100 kg; (r) a maintenance dose of 660 mg for the patient with a body weight of 100 kg or more and less than 120 kg; (s) a maintenance dose of 780 mg for the patient with a body weight of 120 kg or more and less than 140 kg; (t) a maintenance dose of 900 mg for the patient with a body weight of 140 kg or more and less than 165 kg.

16. A pharmaceutical composition comprising a bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa), wherein the bispecific antibody comprises: a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively; a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; and a third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively, wherein: (AA) 135 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to a patient with a body weight of 41 kg or more and less than 50 kg; (BB) 165 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to a patient with a body weight of 50 kg or more and less than 60 kg; (CC) 195 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to a patient with a body weight of 60 kg or more and less than 70 kg; (DD) 225 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to a patient with a body weight of 70 kg or more and less than 83 kg; (EE) 270 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to a patient with a body weight of 83 kg or more and less than 100 kg; (FF) 330 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to a patient with a body weight of 100 kg or more and less than 120 kg; (GG) 390 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to a patient with a body weight of 120 kg or more and less than 140 kg; and / or (HH) 450 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to a patient with a body weight of 140 kg or more and less than 165 kg; and thereafter (A) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 41 kg or more and less than 50 kg; (B) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 50 kg or more and less than 60 kg; (C) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 60 kg or more and less than 70 kg; (D) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 70 kg or more and less than 83 kg; (E) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 83 kg or more and less than 100 kg; (F) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 100 kg or more and less than 120 kg; (G) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 120 kg or more and less than 140 kg; and / or (H) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every two weeks for the patient with a body weight of 140 kg or more and less than 165 kg.

17. A pharmaceutical composition comprising a bispecific antibody for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa), wherein the bispecific antibody comprises: a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively; a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; and a third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively, wherein: (AA) 135 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to a patient with a body weight of 41 kg or more and less than 50 kg; (BB) 165 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to a patient with a body weight of 50 kg or more and less than 60 kg; (CC) 195 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to a patient with a body weight of 60 kg or more and less than 70 kg; (DD) 225 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to a patient with a body weight of 70 kg or more and less than 83 kg; (EE) 270 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to a patient with a body weight of 83 kg or more and less than 100 kg; (FF) 330 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to a patient with a body weight of 100 kg or more and less than 120 kg; (GG) 390 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to a patient with a body weight of 120 kg or more and less than 140 kg; and / or (HH) 450 mg of the bispecific antibody is administered, as a single loading dose, once every week for four weeks to a patient with a body weight of 140 kg or more and less than 165 kg; and thereafter (M) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 41 kg or more and less than 50 kg; (N) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 50 kg or more and less than 60 kg; (O) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 60 kg or more and less than 70 kg; (P) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 70 kg or more and less than 83 kg; (Q) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 83 kg or more and less than 100 kg; (R) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 100 kg or more and less than 120 kg; (S) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 120 kg or more and less than 140 kg; (T) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks for the patient with a body weight of 140 kg or more and less than 165 kg.

18. A product for use in treating a disease and / or reducing an incidence of the disease, wherein the disease develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa), wherein the product comprises: (1) one or more containers; (2) a pharmaceutical composition comprising 135 mg, 165 mg, 195 mg, 225 mg, 270 mg, 330 mg, 390 mg, 450 mg, 540 mg, 660 mg, 780 mg, or 900 mg of a bispecific antibody, wherein the bispecific antibody comprises: a first polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively; a second polypeptide which is an H chain comprising an H chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; and a third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region comprising CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively; wherein the bispecific antibody is administered to a patient in accordance with an instruction document which is optionally comprised in the kit, or preferably comprised in the product; and wherein the instruction document instructs that the bispecific antibody is administered, as a single dose: every two weeks at a maintenance dose of 135 mg for a patient with a body weight of 41 kg or more and less than 50 kg, 165 mg for a patient with a body weight of 50 kg or more and less than 60 kg, 195 mg for a patient with a body weight of 60 kg or more and less than 70 kg, 225 mg for a patient with a body weight of 70 kg or more and less than 83 kg, 270 mg for a patient with a body weight of 83 kg or more and less than 100 kg, 330 mg for a patient with a body weight of 100 kg or more and less than 120 kg, 390 mg for a patient with a body weight of 120 kg or more and less than 140 kg, and 450 mg for a patient with a body weight of 140 kg or more and less than 165 kg; and / or every four weeks at a maintenance dose of 135 mg for a patient with a body weight of 21 kg or more and less than 25 kg, 165 mg for a patient with a body weight of 25 kg or more and less than 30 kg, 195 mg for a patient with a body weight of 30 kg or more and less than 35 kg, 225 mg for a patient with a body weight of 35 kg or more and less than 41 kg, 270 mg for a patient with a body weight of 41 kg or more and less than 50 kg, 330 mg for a patient with a body weight of 50 kg or more and less than 60 kg, 390 mg for a patient with a body weight of 60 kg or more and less than 70 kg, 450 mg for a patient with a body weight of 70 kg or more and less than 83 kg, 540 mg for a patient with a body weight of 83 kg or more and less than 100 kg, 660 mg for a patient with a body weight of 100 kg or more and less than 120 kg, 780 mg for a patient with a body weight of 120 kg or more and less than 140 kg, and 900 mg for a patient with a body weight of 140 kg or more and less than 165 kg.

19. The pharmaceutical composition or bispecific antibody of any one of claims 1, 2, and 4-11, 12, 13, 16, and 17, wherein the pharmaceutical composition is contained in one or more containers.

20. The kit or product of claim 3, 11, 14, 15, or 18, wherein the pharmaceutical composition is contained in said one or more containers.

21. The pharmaceutical composition, bispecific antibody, kit, or product of claim 19 or 20, wherein a strength of the bispecific antibody comprised in the pharmaceutical composition is selected from the group consisting of 135 mg, 165 mg, 195 mg, 225 mg, and 270 mg.

22. The pharmaceutical composition, bispecific antibody, kit, or product of any one of claims 19-21-, wherein one or more containers containing a pharmaceutical composition which comprises the bispecific antibody at a strength selected from the group consisting of 135mg, 165mg, 195mg, 225mg, and 270mg, are used per administration.

23. The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of claims 19-21, wherein: (1-1) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 41 kg or more and less than 50 kg, one container comprising a pharmaceutical composition comprising 135 mg of the bispecific antibody is used per administration; (1-2) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 50 kg or more and less than 60 kg, one container comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody is used per administration; (1-3) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 60 kg or more and less than 70 kg, one container comprising a pharmaceutical composition comprising 190 mg, or preferably comprising 195 mg of the bispecific antibody is used per administration; (1-4) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 70 kg or more and less than 83 kg, one container comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody is used per administration; (1-5) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 83 kg or more and less than 100 kg, one container comprising a pharmaceutical composition comprising 270 mg of the bispecific antibody is used per administration; (1-6) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 100 kg or more and less than 120 kg, two containers each comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody are used per administration; (1-7) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 120 kg or more and less than 140 kg, two containers each comprising a pharmaceutical composition comprising 195 mg of the bispecific antibody are used per administration; (1-8) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 140 kg or more and less than 165 kg, two containers each comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody are used per administration; (2-1) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 21 kg or more and less than 25 kg, one container comprising a pharmaceutical composition comprising 135 mg of the bispecific antibody is used per administration; (2-2) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 25 kg or more and less than 30 kg, one container comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody is used per administration; (2-3) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 30 kg or more and less than 35 kg, one container comprising a pharmaceutical composition comprising 195 mg of the bispecific antibody is used per administration; (2-4) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 35 kg or more and less than 41 kg, one container comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody is used per administration; (2-5) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 41 kg or more and less than 50 kg, one container comprising a pharmaceutical composition comprising 270 mg of the bispecific antibody is used per administration; (2-6) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 50 kg or more and less than 60 kg, two containers each comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody are used per administration; (2-7) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 60 kg or more and less than 70 kg, two containers each comprising a pharmaceutical composition comprising 195 mg of the bispecific antibody are used per administration; (2-8) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 70 kg or more and less than 83 kg, two containers each comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody are used per administration; (2-9) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 83 kg or more and less than 100 kg, two containers each comprising a pharmaceutical composition comprising 270 mg of the bispecific antibody are used per administration; (2-10) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 100 kg or more and less than 120 kg, four containers each comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody are used per administration; (2-11) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 120 kg or more and less than 140 kg, four containers each comprising a pharmaceutical composition comprising 195 mg of the bispecific antibody are used per administration; and / or (2-12) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 140 kg or more and less than 165 kg, four containers each comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody are used per administration.

24. The pharmaceutical composition, bispecific antibody, method, use, kit, or product of any one of claims 19-21, wherein: (1-1) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 41 kg or more and less than 50 kg, one container comprising a pharmaceutical composition comprising 135 mg of the bispecific antibody is used per administration; (1-2) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 50 kg or more and less than 60 kg, one container comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody is used per administration; (1-3) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 60 kg or more and less than 70 kg, one container comprising a pharmaceutical composition comprising 195 mg of the bispecific antibody is used per administration; (1-4) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 70 kg or more and less than 83 kg, one container comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody is used per administration; (1-5) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 83 kg or more and less than 100 kg, one container comprising a pharmaceutical composition comprising 270 mg of the bispecific antibody is used per administration; (1-6) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 100 kg or more and less than 120 kg, two containers each comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody are used per administration; (1-7) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 120 kg or more and less than 140 kg, two containers each comprising a pharmaceutical composition comprising 195 mg of the bispecific antibody are used per administration; (1-8) if the bispecific antibody is administered every two weeks at a maintenance dose to a patient with a body weight of 140 kg or more and less than 165 kg, two containers each comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody are used per administration; (2-1) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 21 kg or more and less than 25 kg, one container comprising a pharmaceutical composition comprising 135 mg of the bispecific antibody is used per administration; (2-2) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 25 kg or more and less than 30 kg, one container comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody is used per administration; (2-3) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 30 kg or more and less than 35 kg, one container comprising a pharmaceutical composition comprising 195 mg of the bispecific antibody is used per administration; (2-4) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 35 kg or more and less than 41 kg, one container comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody is used per administration; (2-5) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 41 kg or more and less than 50 kg, one container comprising a pharmaceutical composition comprising 270 mg of the bispecific antibody is used per administration; (2-6) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 50 kg or more and less than 60 kg, two containers each comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody are used per administration; (2-7) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 60 kg or more and less than 70 kg, two containers each comprising a pharmaceutical composition comprising 195 mg of the bispecific antibody are used per administration; (2-8) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 70 kg or more and less than 83 kg, two containers each comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody are used per administration; (2-9) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 83 kg or more and less than 100 kg, two containers each comprising a pharmaceutical composition comprising 270 mg of the bispecific antibody are used per administration; (2-10) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 100 kg or more and less than 120 kg, four containers each comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody are used per administration; (2-11) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 120 kg or more and less than 140 kg, four containers each comprising a pharmaceutical composition comprising 195 mg of the bispecific antibody are used per administration; (2-12) if the bispecific antibody is administered every four weeks at a maintenance dose to a patient with a body weight of 140 kg or more and less than 165 kg, four containers each comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody are used per administration; (3-1) if the bispecific antibody is administered once every week at a loading dose to a patient with a body weight of 41 kg or more and less than 50 kg, one container comprising a pharmaceutical composition comprising 135 mg of the bispecific antibody is used per administration; (3-2) if the bispecific antibody is administered once every week at a loading dose to a patient with a body weight of 50 kg or more and less than 60 kg, one container comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody is used per administration; (3-3) if the bispecific antibody is administered once every week at a loading dose to a patient with a body weight of 60 kg or more and less than 70 kg, one container comprising a pharmaceutical composition comprising 195 mg of the bispecific antibody is used per administration; (3-4) if the bispecific antibody is administered once every week at a loading dose to a patient with a body weight of 70 kg or more and less than 83 kg, one container comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody is used per administration; (3-5) if the bispecific antibody is administered once every week at a loading dose to a patient with a body weight of 83 kg or more and less than 100 kg, one container comprising a pharmaceutical composition comprising 270 mg of the bispecific antibody is used per administration; (3-6) if the bispecific antibody is administered once every week at a loading dose to a patient with a body weight of 100 kg or more and less than 120 kg, two containers each comprising a pharmaceutical composition comprising 165 mg of the bispecific antibody are used per administration; (3-7) if the bispecific antibody is administered once every week at a loading dose to a patient with a body weight of 120 kg or more and less than 140 kg, two containers each comprising a pharmaceutical composition comprising 195 mg of the bispecific antibody are used per administration; and / or (3-8) if the bispecific antibody is administered once every week at a loading dose to a patient with a body weight of 140 kg or more and less than 165 kg, two containers each comprising a pharmaceutical composition comprising 225 mg of the bispecific antibody are used per administration.

25. The pharmaceutical composition, bispecific antibody, kit, or product of any one of claims 18-24, wherein the container is an autoinjector, vial, syringe, electric device, needle safety device, or pen-type device.

26. The pharmaceutical composition, bispecific antibody, kit, or product of any one of claims 18-24, wherein the container is an injectable device.

27. The pharmaceutical composition, bispecific antibody, kit, or product of claim 26, wherein the injectable device is an autoinjector or syringe,28. The pharmaceutical composition, bispecific antibody, method, use, kit, or product of claim 26 or 27, wherein the injectable device is a pre-filled syringe, or a pre-filled syringe used together with an autoinjector as described herein.

29. The pharmaceutical composition, bispecific antibody, kit, or product of any one of claims 19-28, wherein 0.2mL - 2.1mL of the pharmaceutical composition is contained in the container or injectable device.

30. The pharmaceutical composition, bispecific antibody, kit or product of any one of claims 1-29, wherein the bispecific antibody comprises: a first polypeptide which is an H chain comprising an H chain variable region amino acid sequence of SEQ ID NO: 4; a second polypeptide which is an H chain comprising an H chain variable region amino acid sequence of SEQ ID NO: 9; and a third and fourth polypeptide which are a commonly shared L chain comprising an L chain variable region amino acid sequence of SEQ ID NO: 14.

31. The pharmaceutical composition, bispecific antibody, kit or product of any one of claims 1-29, wherein the bispecific antibody comprises: a first polypeptide which is an H chain comprising the amino acid sequence of SEQ ID NO: 5; a second polypeptide which is an H chain comprising the amino acid sequence of SEQ ID NO: 10; and a third and fourth polypeptide which are a commonly shared L chain comprising the amino acid sequence of SEQ ID NO: 15.

32. The pharmaceutical composition, bispecific antibody, kit or product of any one of claims 1-30, wherein the bispecific antibody is emicizumab.

33. The pharmaceutical composition, bispecific antibody, kit, or product of any one of claims 1-32, wherein the pharmaceutical composition further comprises a histidine-aspartic acid buffer, arginine, and surfactant.

34. The pharmaceutical composition, bispecific antibody, kit, or product of any one of claims 1-33, wherein the pharmaceutical composition comprises 10 mM to 40 mM of histidine-aspartic acid buffer, 100 mM to 300 mM of arginine, and 0.2 mg / ml to 1 mg / ml of Poloxamer 188, and is at a pH of 4.5 to 6.5.

35. The pharmaceutical composition, bispecific antibody, kit, or product of claim 34, wherein the concentration of histidine in the histidine-aspartic acid buffer is 10mM to 40mM.

36. The pharmaceutical composition, bispecific antibody, kit, or product of any one of claims 1-35, wherein a concentration of the bispecific antibody or emicizumab comprised in the pharmaceutical composition is 135 mg / mL to 165 mg / mL.

37. The pharmaceutical composition, bispecific antibody, method, use, kit or product of claims 1-35, wherein a concentration of the bispecific antibody or emicizumab comprised in the pharmaceutical composition is 150mg / mL.

38. The pharmaceutical composition, bispecific antibody, kit, or product of any one of claims 1-3, 5-37, wherein the disease which develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa) is hemophilia A, hemophilia A with emergence of an inhibitor against FVIII / FVIIIa, acquired hemophilia A, or von Willebrand disease.

39. The pharmaceutical composition, bispecific antibody, kit, or product of any one of claims 1-3, 5-37, wherein the disease which develops and / or progresses due to a decrease or deficiency in an activity of blood coagulation factor VIII (FVIII) and / or activated blood coagulation factor VIII (FVIIIa) is congenital hemophilia A or von Willebrand disease.

40. The pharmaceutical composition, bispecific antibody, kit, or product of claim 4 or 40, wherein congenital hemophilia A is congenital hemophilia A with emergence of an inhibitor against FVIII / FVIIIa and congenital hemophilia A without emergence of an inhibitor against FVIII / FVIIIa.

41. The pharmaceutical composition, bispecific antibody, kit or product of any one of claims 1-40, wherein the bispecific antibody or emicizumab is administered subcutaneously.

42. A method of treating hemophilia A (congenital Factor VIII deficiency) with or without Factor VIII inhibitors comprising administering to a patient having hemophilia A (congenital Factor VIII deficiency) with or without Factor VIII inhibitors a pharmaceutical composition comprising emicizumab, wherein (A) 135 mg of emicizumab is administered, as a single maintenance dose, once every two weeks when the body weight of the patient is 41 kg or more and less than 50 kg; (B) 165 mg of the emicizumab is administered, as a single maintenance dose, once every two weeks when the body weight of the patient is 50 kg or more and less than 60 kg; (C) 195 mg of the emicizumab is administered, as a single maintenance dose, once every two weeks when the body weight of the patient is 60 kg or more and less than 70 kg; (D) 225 mg of the emicizumab is administered, as a single maintenance dose, once every two weeks when the body weight of the patient is 70 kg or more and less than 83 kg; (E) 270 mg of the emicizumab is administered, as a single maintenance dose, once every two weeks when the body weight of the patient is 83 kg or more and less than 100 kg; (F) 330 mg of the emicizumab is administered, as a single maintenance dose, once every two weeks when the body weight of the patient is 100 kg or more and less than 120 kg; (G) 390 mg of the emicizumab is administered, as a single maintenance dose, once every two weeks when the body weight of the patient is 120 kg or more and less than 140 kg; (H) 450 mg of the emicizumab is administered, as a single maintenance dose, once every two weeks when the body weight of the patient is 140 kg or more and less than 165 kg; (I) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 21 kg or more and less than 25 kg; (J) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 25 kg or more and less than 30 kg; (K) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 30 kg or more and less than 35 kg; (L) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 35 kg or more and less than 41 kg; (M) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 41 kg or more and less than 50 kg; (N) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 50 kg or more and less than 60 kg; (O) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 60 kg or more and less than 70 kg; (P) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 70 kg or more and less than 83 kg; (Q) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 83 kg or more and less than 100 kg; (R) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 100 kg or more and less than 120 kg; (S) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 120 kg or more and less than 140 kg; or (T) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 140 kg or more and less than 165 kg.

43. A method of routine prophylaxis to prevent or reduce the frequency of bleeding episodes in a patient having hemophilia A (congenital Factor VIII deficiency) with or without Factor VIII inhibitors comprising administering to the patient a pharmaceutical composition comprising emicizumab, wherein (A) 135 mg of emicizumab is administered, as a single maintenance dose, once every two weeks when the body weight of the patient is 41 kg or more and less than 50 kg; (B) 165 mg of the emicizumab is administered, as a single maintenance dose, once every two weeks when the body weight of the patient is 50 kg or more and less than 60 kg; (C) 195 mg of the emicizumab is administered, as a single maintenance dose, once every two weeks when the body weight of the patient is 60 kg or more and less than 70 kg; (D) 225 mg of the emicizumab is administered, as a single maintenance dose, once every two weeks when the body weight of the patient is 70 kg or more and less than 83 kg; (E) 270 mg of the emicizumab is administered, as a single maintenance dose, once every two weeks when the body weight of the patient is 83 kg or more and less than 100 kg; (F) 330 mg of the emicizumab is administered, as a single maintenance dose, once every two weeks when the body weight of the patient is 100 kg or more and less than 120 kg; (G) 390 mg of the emicizumab is administered, as a single maintenance dose, once every two weeks when the body weight of the patient is 120 kg or more and less than 140 kg; (H) 450 mg of the emicizumab is administered, as a single maintenance dose, once every two weeks when the body weight of the patient is 140 kg or more and less than 165 kg; (I) 135 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 21 kg or more and less than 25 kg; (J) 165 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 25 kg or more and less than 30 kg; (K) 195 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 30 kg or more and less than 35 kg; (L) 225 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 35 kg or more and less than 41 kg; (M) 270 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 41 kg or more and less than 50 kg; (N) 330 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 50 kg or more and less than 60 kg; (O) 390 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 60 kg or more and less than 70 kg; (P) 450 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 70 kg or more and less than 83 kg; (Q) 540 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 83 kg or more and less than 100 kg; (R) 660 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 100 kg or more and less than 120 kg; (S) 780 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 120 kg or more and less than 140 kg; or (T) 900 mg of the bispecific antibody is administered, as a single maintenance dose, once every four weeks when the body weight of the patient is 140 kg or more and less than 165 kg.

44. A method of routine prophylaxis to prevent or reduce the frequency of bleeding episodes in a patient having hemophilia A (congenital Factor VIII deficiency) with or without Factor VIII inhibitors comprising administering to the patient a pharmaceutical composition comprising emicizumab, wherein the method comprises the steps of: (a1) determining if the patient's body weight is 41 kg or more and less than 50 kg; and (b1) if the patient's body weight is 41 kg or more and less than 50 kg, administering to the patient 135 mg of the emicizumab as a single maintenance dose once every two weeks; or (a2) determining if the patient's body weight is 50 kg or more and less than 60 kg; and (b2) if the patient's body weight is 50 kg or more and less than 60 kg, administering to the patient 165 mg of the emicizumab as a single maintenance dose once every two weeks; or (a3) determining if the patient's body weight is 60 kg or more and less than 70 kg; and (b3) if the patient's body weight is 60 kg or more and less than 70 kg, administering to the patient 195 mg of the emicizumab as a single maintenance dose once every two weeks; or (a4) determining if the patient's body weight is 70 kg or more and less than 83 kg; and (b4) if the patient's body weight is 70 kg or more and less than 83 kg, administering to the patient 225 mg of the emicizumab as a single maintenance dose once every two weeks; or (a5) determining if the patient's body weight is 83 kg or more and less than 100 kg; and (b5) if the patient's body weight is 83 kg or more and less than 100 kg, administering to the patient 270 mg of the emicizumab as a single maintenance dose once every two weeks; or (a6) determining if the patient's body weight is 100 kg or more and less than 120 kg; and (b6) if the patient's body weight is 100 kg or more and less than 120 kg, administering to the patient 330 mg of the emicizumab as a single maintenance dose once every two weeks; or (a7) determining if the patient's body weight is 120 kg or more and less than 140 kg; and (b7) if the patient's body weight is 120 kg or more and less than 140 kg, administering to the patient 390 mg of the emicizumab as a single maintenance dose once every two weeks; or (a8) determining if the patient's body weight is 140 kg or more and less than 165 kg; and (b8) if the patient's body weight is 140 kg or more and less than 165 kg, administering to the patient 450 mg of the emicizumab as a single maintenance dose once every two weeks; or (a9) determining if the patient's body weight is 21 kg or more and less than 25 kg; and (b9) if the patient's body weight is 21 kg or more and less than 25 kg, administering to the patient 135 mg of the emicizumab as a single maintenance dose once every four weeks; or (a10) determining if the patient's body weight is 25 kg or more and less than 30 kg; and (b10) if the patient's body weight is 25 kg or more and less than 30 kg, administering to the patient 165 mg of the emicizumab as a single maintenance dose once every four weeks; or (a11) determining if the patient's body weight is 30 kg or more and less than 35 kg; and (b11) if the patient's body weight is 30 kg or more and less than 35 kg, administering to the patient 195 mg of the emicizumab as a single maintenance dose once every four weeks; or (a12) determining if the patient's body weight is 35 kg or more and less than 41 kg; and (b12) if the patient's body weight is 35 kg or more and less than 41 kg, administering to the patient 225 mg of the emicizumab as a single maintenance dose once every four weeks; or (a13) determining if the patient's body weight is 41 kg or more and less than 50 kg; and (b13) if the patient's body weight is 41 kg or more and less than 50 kg, administering to the patient 270 mg of the emicizumab as a single maintenance dose once every four weeks; or (a14) determining if the patient's body weight is 50 kg or more and less than 60 kg; and (b14) if the patient's body weight is 50 kg or more and less than 60 kg, administering to the patient 330 mg of the emicizumab as a single maintenance dose once every four weeks; or (a15) determining if the patient's body weight is 60 kg or more and less than 70 kg; and (b15) if the patient's body weight is 60 kg or more and less than 70 kg, administering to the patient 390 mg of the emicizumab as a single maintenance dose once every four weeks; or (a16) determining if the patient's body weight is 70 kg or more and less than 83 kg; and (b16) if the patient's body weight is 70 kg or more and less than 83 kg, administering to the patient 450 mg of the emicizumab as a single maintenance dose once every four weeks; or (a17) determining if the patient's body weight is 83 kg or more and less than 100 kg; and (b17) if the patient's body weight is 83 kg or more and less than 100 kg, administering to the patient 540 mg of the emicizumab as a single maintenance dose once every four weeks; or (a18) determining if the patient's body weight is 100 kg or more and less than 120 kg; and (b18) if the patient's body weight is 100 kg or more and less than 120 kg, administering to the patient 660 mg of the emicizumab as a single maintenance dose once every four weeks; or (a19) determining if the patient's body weight is 120 kg or more and less than 140kg; and (b19) if the patient's body weight is 120 kg or more and less than 140kg , administering to the patient 780 mg of the emicizumab as a single maintenance dose once every four weeks; or (a20) determining if the patient's body weight is 140 kg or more and less than 165 kg; and (b20) if the patient's body weight is 140 kg or more and less than 165 kg, administering to the patient 900 mg of the emicizumab as a single maintenance dose once every four weeks.

45. An article of manufacture comprising a subcutaneous administration device which contains and delivers to a patient 135 mg of emicizumab, wherein the device contains and delivers to the patient 0.9 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL.

46. An article of manufacture comprising a subcutaneous administration device which contains and delivers to a patient 165 mg of emicizumab, wherein the device contains and delivers to the patient 1.1 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL.

47. An article of manufacture comprising a subcutaneous administration device which contains and delivers to a patient 195 mg of emicizumab, wherein the device contains and delivers to the patient 1.3 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL.

48. An article of manufacture comprising a subcutaneous administration device which contains and delivers to a patient 225 mg of emicizumab, wherein the device contains and delivers to the patient 1.5 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL.

49. An article of manufacture comprising a subcutaneous administration device which contains and delivers to a patient 270 mg of emicizumab, wherein the device contains and delivers to the patient 1.8 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL.

50. The article of manufacture of any one of claims 37-41, wherein the subcutaneous administration device is a syringe.

51. The article of manufacture of claim 42, wherein the syringe is a prefilled syringe.

52. A method of routine prophylaxis to prevent or reduce the frequency of bleeding episodes in a patient having hemophilia A (congenital Factor VIII deficiency) with or without Factor VIII inhibitors comprising administering to the patient a pharmaceutical composition comprising emicizumab, wherein: A. 135 mg of the emicizumab is subcutaneously administered using one subcutaneous injection device which contains and delivers to a patient 135 mg of emicizumab, wherein the device contains and delivers to the patient 0.9 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL, as a single maintenance dose, once every two weeks when the body weight of the patient is 41 kg or more and less than 50 kg; B. 165 mg of the emicizumab is subcutaneously administered using one subcutaneous injection device which contains and delivers to a patient 165 mg of emicizumab, wherein the device contains and delivers to the patient 1.1 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL, as a single maintenance dose, once every two weeks when the body weight of the patient is 50 kg or more and less than 60 kg; C. 195 mg of the emicizumab is subcutaneously administered using one subcutaneous injection device which contains and delivers to a patient 195 mg of emicizumab, wherein the device contains and delivers to the patient 1.3 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL, as a single maintenance dose, once every two weeks when the body weight of the patient is 60 kg or more and less than 70 kg; D. 225 mg of the emicizumab is subcutaneously administered using one subcutaneous injection device which contains and delivers to a patient 225 mg of emicizumab, wherein the device contains and delivers to the patient 1.5 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL, as a single maintenance dose, once every two weeks when the body weight of the patient is 70 kg or more and less than 83 kg; E. 270 mg of the emicizumab is subcutaneously administered using one subcutaneous injection device which contains and delivers to a patient 270 mg of emicizumab, wherein the device contains and delivers to the patient 1.8 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL, as a single maintenance dose, once every two weeks when the body weight of the patient is 83 kg or more and less than 100 kg; F. 330 mg of the emicizumab is subcutaneously administered using two subcutaneous injection devices (eg, a prefilled syringes) which each contain and deliver to a patient 165 mg of emicizumab, wherein each device contains and delivers to the patient 1.1 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL, as a single maintenance dose, once every two weeks when the body weight of the patient is 100 kg or more and less than 120 kg; G. 390 mg of the emicizumab is subcutaneously administered using one subcutaneous injection devices (eg, a prefilled syringes) which contains and deliver to a patient 195 mg of emicizumab, wherein each device contains and delivers to the patient 1.3 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL, as a single maintenance dose, once every two weeks when the body weight of the patient is 120 kg or more and less than 140 kg; H. 450 mg of the emicizumab is subcutaneously administered using two subcutaneous injection devices (eg, a prefilled syringes) which each contain and deliver to a patient 225 mg of emicizumab, wherein each device contains and delivers to the patient 1.5 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL, as a single maintenance dose, once every two weeks when the body weight of the patient is 140 kg or more and less than 165 kg; I. 135 mg of the emicizumab is subcutaneously administered using one subcutaneous injection device which contains and delivers to a patient 135 mg of emicizumab, wherein the device contains and delivers to the patient 0.9 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL, as a single maintenance dose, once every four weeks when the body weight of the patient is 21 kg or more and less than 25 kg; J. 165 mg of the emicizumab is subcutaneously administered using one subcutaneous injection device which contains and delivers to a patient 165 mg of emicizumab, wherein the device contains and delivers to the patient 1.1 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL, as a single maintenance dose, once every four weeks when the body weight of the patient is 25 kg or more and less than 30 kg; K. 195 mg of the emicizumab is subcutaneously administered using one subcutaneous injection device which contains and delivers to a patient 195 mg of emicizumab, wherein the device contains and delivers to the patient 1.3 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL, as a single maintenance dose, once every four weeks when the body weight of the patient is 30 kg or more and less than 35 kg; L. 225 mg of the emicizumab is subcutaneously administered using one subcutaneous injection device which contains and delivers to a patient 135 mg of emicizumab, wherein the device contains and delivers to the patient 1.5 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL, as a single maintenance dose, once every four weeks when the body weight of the patient is 35 kg or more and less than 41 kg; M. 270 mg of the emicizumab is subcutaneously administered using one subcutaneous injection device which contains and delivers to a patient 270 mg of emicizumab, wherein the device contains and delivers to the patient 1.8 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL, as a single maintenance dose, once every four weeks when the body weight of the patient is 41 kg or more and less than 50 kg; N. 330 mg of the emicizumab is subcutaneously administered using two subcutaneous injection devices (eg, a prefilled syringes) which each contain and deliver to a patient 165 mg of emicizumab, wherein each device contains and delivers to the patient 1.1 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL, as a single maintenance dose, once every four weeks when the body weight of the patient is 50 kg or more and less than 60 kg; O. 390 mg of the emicizumab is subcutaneously administered using one subcutaneous injection devices (eg, a prefilled syringes) which contains and deliver to a patient 195 mg of emicizumab, wherein each device contains and delivers to the patient 1.3 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL, as a single maintenance dose, once every four weeks when the body weight of the patient is 60 kg or more and less than 70 kg; P. 450 mg of the emicizumab is subcutaneously administered using two subcutaneous injection devices (eg, a prefilled syringes) which each contain and deliver to a patient 225 mg of emicizumab, wherein each device contains and delivers to the patient 1.5 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL, as a single maintenance dose, once every two weeks when the body weight of the patient is 70 kg or more and less than 83 kg; Q. 540 mg of the emicizumab is subcutaneously administered using two subcutaneous injection devices (eg, a prefilled syringes) which each contain and deliver to a patient 270 mg of emicizumab, wherein each device contains and delivers to the patient 1.8 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL, as a single maintenance dose, once every two weeks when the body weight of the patient is 83 kg or more and less than 100 kg; R. 660 mg of the emicizumab is subcutaneously administered using four subcutaneous injection devices (eg, a prefilled syringes) which each contain and deliver to a patient 165 mg of emicizumab, wherein each device contains and delivers to the patient 1.1 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL, as a single maintenance dose, once every two weeks when the body weight of the patient is 100 kg or more and less than 120 kg; S. 780 mg of the emicizumab is subcutaneously administered using four subcutaneous injection devices (eg, a prefilled syringes) which each contain and deliver to a patient 195 mg of emicizumab, wherein each device contains and delivers to the patient 1.3 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL, as a single maintenance dose, once every two weeks when the body weight of the patient is 120 kg or more and less than 140 kg; or T. 900 mg of the emicizumab is subcutaneously administered using four subcutaneous injection devices (eg, a prefilled syringes) which each contain and deliver to a patient 225 mg of emicizumab, wherein each device contains and delivers to the patient 1.5 mL of a pharmaceutical composition with emicizumab at a concentration of 150 mg / mL, as a single maintenance dose, once every two weeks when the body weight of the patient is 140 kg or more and less than 165 kg.

53. The method of claim 44, wherein in (A)-(E), (G), (I)-(M), and (O), the subcutaneous injection device is a syringe, or wherein in (F), (H), (N), and (P)-(T), These are the subcutaneous injection devices are syringes.

54. The method of claim 45, wherein in (A)-(E), (G), (I)-(M), and (O), the syringe is a prefilled syringe, or wherein in (F), (H), (N), and (P)-(T), the syringes are prefilled syringes.

Images